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The Gram-positive group A streptococcus (GAS) is a strict human pathogen, 
which causes a wide variety of infections, ranging in severity from minor to life 
threatening.  In order to cause such a diverse array of diseases, GAS utilizes two-
component signal transduction systems (TCS) to coordinately regulate sets of virulence 
genes in response to changing host conditions.  The present study investigates the role of 
the TrxSR TCS in the regulation of virulence of the GAS.  Using an insertional 
inactivation mutation in TrxR in serotype M1 MGAS5005, transcriptome studies 
established that TrxR activates transcription of Mga-regulated virulence genes, a separate 
non-TCS regulatory pathway controlling factors important for immune evasion and 
colonization.  Transcriptional reporter fusions of Pmga to firefly luciferase revealed that 
the TrxR regulation occurs through the Pmga promoter.  Additionally, electrophoretic 
mobility shift assays using purified His-MBP tagged TrxR established specific binding of 
TrxR to Pmga, although the interaction appeared to be transient.  To determine the 
importance of signal transduction for TrxR-mediated regulation of the Mga regulon and 
virulence, an in vitro reconstitution assay was performed with purified TrxR and TrxS.  
Using both wild type and mutated forms of the TrxSR proteins, we demonstrated that 
TrxSR is a functional two-component phosphorelay system.  Interestingly, 
phosphorylation of TrxR did not appear to be critical for DNA binding and regulation, 
since a TrxR D55A mutation did not change the expression of TrxR regulated genes in 
GAS based on EMSA and qPCR.  In order to investigate whether there is a functional 
conservation of TrxR’s involvement in GAS virulence regulation, mutations were made 
in serotype M4 and M49 strains representing either throat only or generalist strains.  We 
have determined that TrxR regulates mga and Mga-regulated genes (emm, arp) in the M4 
and M49 backgrounds, suggesting conservation of TrxR’s role in virulence regulation.  
Overall, TrxSR represents a functional TCS that appears to directly regulate the Mga 
virulence regulon independent of phosphorelay.  Furthermore, the functional 
conservation of TrxR regulation of Mga in other serotypes suggests a conserved role for 
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 The Group A Streptococcus (GAS), or Streptococcus pyogenes, is a strict human 
pathogen of clinical importance worldwide.  GAS causes not only benign, self-limiting  
infections, such as pharyngitis and impetigo, but also severe, invasive infections like 
necrotizing fasciitis and streptococcal toxic shock syndrome.  Nonsuppurative infections 
such as acute post-streptococcal glomerulonephritis can also occur following GAS 
infection.  GAS has the ability to infect a broad range of tissues, evidenced by the 
numerous diseases it can cause.  Although typical portals of entry for infection include 
the throat and skin, the more severe diseases may develop following mild trauma or 
surgery.  GAS can also spread from normally sterile sites of colonization to deeper 
tissues, as well as throughout the bloodstream and lymphatics, to other organs.   Recent 
estimates of invasive GAS infections indicate that there are over 18 million cases 
worldwide, resulting in at least 500,000 deaths per year (36).  There is no current vaccine 
that exists to prevent GAS infections, making GAS among the more significant global 
human pathogens.   
 In order to rapidly adapt to changing in vivo environments encountered during 
infection, GAS must be able to coordinately regulate the transcription of its virulence 
genes in response to relevant host signals.  One method that GAS employs to accomplish 
this is through the use of two-component signal transduction systems (TCSs).  Several 
TCSs exist in GAS, with many of their roles previously elucidated.  This study addresses 
the role of the uncharacterized TCS, TrxSR, and its relation to virulence regulation in 
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GAS.  This work begins with a general characterization of the TrxSR TCS, including 
definition of its operon structure and its regulon.  An insertional inactivation mutation 
within trxR was made in a virulent M1 strain of GAS, and determination of its regulon 
was accomplished through microarray studies.  The transcriptome analysis identified that 
expression of the core Mga-regulated virulence genes is activated by TrxR, and this 
activation appears to be conserved within GAS, as an M4 and M49 strain shared the same 
effect.  Additionally, trxSR is shown to be co-transcribed with an upstream hypothetical 
membrane protein.  However, a potential role for this protein in the TrxSR TCS has not 
yet been established.   
 The second focus of this research was an in-depth investigation into the TrxS and 
TrxR proteins, in relation to their functions within the TCS.  TrxS was shown to both 
autophosphorylate and dimerize, two key functions required for an HK to pass a 
phosphate to the RR in response to receiving a signal.  TrxR was also shown to accept 
this phosphate, demonstrating that TrxSR form a cognate pair, as they participate in a 
functional phosphorelay.  Further studies of the TrxR protein demonstrate that it can bind 
directly to the promoter region of mga in order to regulate its gene transcription.  
Moreover, this regulation occurs in the absence of a phosphorylated TrxR, suggesting 
that TrxR may be active in the absence of interaction with TrxS.   
Overall, this work demonstrates that TrxSR represents a functional TCS, which 
directly regulates the Mga virulence regulon independent of phosphorelay.  Furthermore, 
the functional conservation of TrxR regulation of Mga in other serotypes suggests a 









 Throughout history, there have been countless epidemics of Group A 
Streptococcus (GAS, Streptococcus pyogenes) related diseases.  Evidence of GAS 
infection has been found in skulls dating back to 8000-6500 B.C. (233).  Perhaps the 
earliest described epidemic occurred in the times of Hippocrates, in roughly 430 B.C., 
when it is believed that many people fell victim to an outbreak of what we now recognize 
as scarlet fever (154).  Much later, in the 16th-18th centuries, signs of pharyngitis and its 
complications were reported in Europe.  Although numerous investigators recognized the 
potential cause of some of these diseases as spherical chain-growing organisms, it was 
until not 1874 that Billroth named these organisms streptococcus, for strepto, meaning 
twisted or chain and kokhos, meaning berry or seed (60).  After this, streptococci were 
frequently classified according to the disease that they caused (e.g. Streptococcus 
erysipelatis - erysipelas, Streptococcus scarlatinae - scarlet fever).  The classification of 
GAS began to show more order in 1903 when Schotmüller determined that streptococci 
could be differentiated based upon their ability to hemolyze red blood cells (60).  In 1933 
Lancefield developed a system for classifying the β-hemolytic streptococci (60).  Those 
hemolytic strains that belonged to the serotype A group in Lancefield’s classification 
included the majority of the pathogenic strains that infected humans; these collectively 
became known as Streptococcus pyogenes.   
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CLASSIFICATION OF GAS 
 
General characteristics 
 GAS is a non-motile, Gram-positive coccus that grows in chains of varying length 
or pairs.  GAS divides in one plane and individual cells range in size from 0.6-1.0 µm in 
diameter.  They are facultative anaerobes and non-spore forming.  Additionally, they are 
both catalase and oxidase-negative.  GAS are also β-hemolytic on blood agar plates, as 
they create a zone of clearance around themselves, caused by lysis of the red blood cells 
on the agar plate.   
 
Growth requirements 
 GAS has strict requirements for growth; they are members of the lactic acid 
bacteria that rely on fermentation of glucose for growth and energy production.  They 
grow in nutrient-rich media, first described by Todd and Hewitt in 1932, that includes 
neopeptone extracts, dextrose or glucose as the carbon source, and a complex mixture of 
nutrients from beef-heart infusion (254).  Additionally, 2% yeast extract is added to the 
Todd-Hewitt (THY) media to enhance GAS growth (262).  GAS cultures are grown at 
37°C with 5% CO2 or under ambient conditions.   
 
Lancefield grouping 
 In order to initially categorize the various hemolytic streptococci, Lancefield 
developed a test to serologically differentiate the various human, animal, and dairy 
product strains from one another.  This test, a precipitin reaction, utilized hot acid to 
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extract the carbohydrate from each strain.  After extraction, the carbohydrate was 
incubated with C-antigens (to the surface carbohydrate) from various streptococci to 
determine what it interacted with (131).  Lancefield classified the various strains into five 
groups, named A-E.  Those strains that had the group A antigen, correlated with strains 
isolated from human infection.  Lancefield’s nomenclature formed the basis for 
classification of all streptococci and gave the β-hemolytic strep from the human host its 
name, the Group A Streptococcus (GAS).   
 
M, T, and OF typing 
 In addition to categorizing streptococci by its surface carbohydrate, individual 
strains of GAS are characterized by their M protein.  This typing has led to the 
subdivision of GAS strains into more than 180 different recognized M-serotypes (181).  
Lancefield developed a method for determination of M-antigens in GAS strains which 
included acid extraction of the M protein followed by a capillary precipitin reaction with 
known streptococcal sera to determine the specific M-type based upon the presence or 
absence of precipitate formation (131, 247).  More recently, Beall and Facklam 
developed a method for identification of M-type by means of a PCR reaction in which a 
primer pair specific to the 5’ region of the emm gene is used to amplify the hyper-variable 
epitope (17).  This is later sequenced and compared to a database of emm genes to 
determine the GAS emm-type.   
 Along with classifying strains based upon their M-type, GAS strains are also 
classified according to their T antigen, which was originally defined by its resistance to 
trypsin (23).  While the function of the T protein is not well understood, a recent study 
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suggests that it may be a component of a pilus-like structure (175).  It exists in far fewer 
variants than the M protein.  Additionally, a single T antigen may be found in strains 
belonging to varying M serotypes.  Strains of the same M-type can also contain more 
than one T antigen.  A third typing scheme for GAS strains is based upon the presence of 
the serum opacity factor (sof) gene.  Opacity factor (OF) typing generally accompanies 
M-typing, as SOF production highly correlates with specific M types (18). 
 
Class determination 
 Serotypes of GAS are divided into two classes based upon the reactivity of their 
M protein with an antibody directed against the C repeat region and by the presence of 
serum opacity factor (SOF) (22).  Class I serotypes share an M protein that has a surface-
exposed C repeat region, whereas Class II serotypes have an M protein that lacks this 
repeat region.  Additionally, it is the Class II serotypes that contain the serum opacity 
factor gene, as Class I serotypes do not.   
 
 
GROUP A STREPTOCOCCAL DISEASE 
 
 GAS is able to cause a wide range of infections and diseases, ranging in severity 
from minor to life threatening.  Those infections that are minor and typically self-limiting 
include pharyngitis (infection of the throat) and impetigo and erysipelas (infections of the 
skin).  More serious GAS infections, those that constitute severe and invasive diseases, 
are puerperal fever, streptococcal toxic shock syndrome (STSS), bacteremia, and 
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necrotizing fasciitis.  Approximately 163,000 deaths occur each year from these invasive 
diseases (36).  Lastly, GAS is associated with several nonsuppurative sequelae, including 
acute rheumatic fever (ARF) and acute post streptococcal glomerulonephritis (APSGN).  
For each infection or disease, its symptoms, clinical manifestations, affected population, 





 Streptococcal pharyngitis, otherwise known as “strep throat”, is the most common 
bacterial infection caused by GAS.  Roughly 616 million new cases of pharyngitis occur 
each year (36).  It is more prevalent in school-aged children between the ages of 5 and 
12, although pharyngitis can affect all age groups (225). GAS colonization can also be 
asymptomatic (55), increasing carriage rates among the population.  Crowding is an 
important factor in the spread of GAS pharyngitis, as transmission of the bacteria 
primarily occurs by inhalation of aerosolized droplets or direct contact with respiratory 
secretions.  The usual incubation period for streptococcal pharyngitis is 2 to 4 days.  By 
the end of this period, a pronounced sore throat accompanied by fever, headache, and 
malaise can occur.  In more acute cases of pharyngitis, nausea and abdominal pain can 
arise.  To confirm a streptococcal pharyngeal infection, the current “gold standard” 
practice involves swabbing the throat and culturing the swab on blood agar plates.  
Following this procedure, it typically takes 24-48 hours to verify the presence of GAS 
through the presence of β-hemolytic colonies.  Rapid antigen diagnostic tests have also 
been used.  They produce quicker, more immediate results, although they generally lack 
 8 
sensitivity and can yield a false-positive (225).  Antibiotics, most notably penicillin and 
erythromycin, are used to treat a GAS-mediated pharyngeal infection.   Even in the 
absence of antibiotics, a pharyngeal infection is self-limiting; virtually all signs and 
symptoms of it disappear within a week.   
 
Scarlet Fever 
 Today, in developed countries, scarlet fever is generally a mild disease.  It is 
typically described as pharyngitis with a rash or benign scarlet fever.  While it was once a 
considerably more serious and, sometimes, even fatal childhood disease, the malignant 
toxic forms of scarlet fever have become less common and it is now easily treatable 
(233).  As benign scarlet fever is typically associated with pharyngitis, it is additionally 
characterized by a sandpaper-like rash that begins on the neck and chest and eventually 
spreads across the extremities.  Moreover, a “strawberry tongue” is observed in patients 
with benign scarlet fever, as the papillae of the tongue become red and swollen.  In more 
severe cases of the septic and toxic forms of scarlet fever, in addition to the 
aforementioned symptoms, markedly high fevers and delirium are observed.  These cases 
are typically confounded by more invasive symptoms (septic- local and hematogenous 
spread of GAS; toxic- exudation of numerous membranous tissues) caused by the 
streptococcal pyrogenic exotoxins (SPEs) and can lead to systemic toxicity and death 








 Streptococcal impetigo, also known as pyoderma, is a skin infection of the dermis 
and epidermis.  It is caused by both GAS and Staphylococcus aureus, and most 
commonly affects the lower extremities.  Impetigo is characterized by a pus-filled, 
bacteria-rich blister that forms on the skin, which, with time, oozes and develops a thick 
golden crust.   Typically prevalent in children aged 2-5 years old living in unhealthy 
conditions, impetigo also manifests in adults following previous respiratory tract 
infections or skin disorders.   Because GAS has been shown to colonize and persist on 
normal skin for a substantial period of time (6), it has the ability to enter and invade the 
skin quickly, once minor trauma appears, and cause infection.  Itching is the primary 
symptom associated with impetigo.  Although it is a contagious disease, impetigo can be 
easily treated with penicillin.   Moreover, importantly, impetigo is linked to one of the 
streptococcal secondary sequelae, acute glomerulonephritis, which will be discussed 
more in detail later, within this chapter.   
 
Cellulitis 
 GAS is the most common cause of cellulitis, although some cases are caused by S. 
aureus.  Cellulitis is a diffuse inflammation of the subcutaneous layers of the skin.  
Typical symptoms include a pinkish skin color, along with swelling and pain.  
Predisposing conditions for cellulitis generally include some form of skin irritation, such 
as a burn, animal bite, rash, or dry skin (233).  Additionally, individuals who have poor 
blood circulation or a weakened immune system, like diabetics or the elderly, are more at 
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risk for developing cellulitis.  Penicillin is generally used to treat cellulitis.  However, 
when is S. aureus suspected, nafcillin or oxacillin are used (233).  
 
Erysipelas 
 Erysipelas is an acute infection of the superficial layer of the skin, characterized 
by red, raised, well-demarcated lesions. The erythematous lesion is typically 
accompanied by intense pain and fever.  Although the great majority of cases are caused 
by GAS, erysipelas can also be caused by streptococci of groups G, C, and B and rarely 
by staphylococci (27).  Erysipelas, although relatively uncommon today, affects mainly 
the elderly.  The most common site for infection today is on the lower extremities, 
including the legs and feet.  Historically, however, it was the face (27).  The portal of 
entry for the bacteria is generally the skin, where local trauma or an abrasion occurs.  
More rarely, when erysipelas occurs on the face, the oropharynx serves as the origin for 
the bacteria.  The erysipelas infection is typically treated with penicillin and resolves 





 Puerperal fever (childbed fever) was one of the most deadly diseases of the 19th 
century.  However, now the disease is seen only sporadically and in isolated instances.  
Puerperal fever can be contracted during pregnancy, miscarriage, or abortion and is 
marked by infection of the genital tract and endometrial lining.  This acute endometritis is 
commonly masked by abdominal pain and is thus usually not recognized immediately 
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following child delivery.  Following entry into the women’s endometrial lining, GAS can 
quickly spread to the surrounding structures and into the bloodstream (233).  Once sepsis 
occurs, fever, leukocytosis, and increasingly severe pain typically alert doctors that a 
more severe infection is present.  If left untreated, this infection could result in death.  
Since the advent of aseptic techniques (pioneered by Semmelweis) and the use of 
antibiotics, the number of cases of puerperal fever has drastically declined (60).  Today it 
is rarely fatal.   
 
Streptococcal Toxic Shock Syndrome 
 Streptococcal toxic shock syndrome (STSS) consists of a streptococcal infection 
followed by rapid onset of shock and organ failure.  The latter portion of the infection, in 
which severe symptoms of shock and failure occur, is generally associated with 
production of GAS pyrogenic exotoxins (SPEs).  These superantigens can over stimulate 
the immune system to produce numerous inflammatory cytokines, leading to shock and 
overall tissue damage (122, 235).  Unlike the staphylococcal form of toxic shock 
syndrome that has historically been linked to tampon use, streptococcal TSS is more 
common following a streptococcal infection of the skin, as it serves as the portal of entry 
in roughly 25% of streptococcal TSS cases (235).  Characterized by rapid onset of fever, 
high blood pressure, chills, nausea, confusion, and pain, STSS is also commonly present 
with a deep-seated systemic infection such as bacteremia or necrotizing fasciitis.  
Because progression of streptococcal TSS is so fast, within 24-48 hours of onset, multiple 
organ failure and death can occur.  In order to treat STSS, numerous measures are taken 
not only to address the individual symptoms associated with the infection (e.g. 
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hypotension, renal dysfunction), but also to treat the more aggressive infections (e.g. 
surgical debridement for necrotizing fasciitis).   
 
Bacteremia 
 Although GAS infections typically localize in the skin or throat, in more severe 
cases, when the bacteria enter the bloodstream, bacteremia occurs.   Historically, 
streptococcal bacteremia occurred most commonly in children and the elderly.  Today, 
however, sepsis cases have been increasing in individuals 14-40 years of age.  
Bacteremia in children typically results from streptococcal pharyngeal infections, 
whereas cases of the elderly emanate from infections of the skin (234).  Bacteremia has 
also been found in intravenous drug users.  This may account for the increase in sepsis 
cases in the 14-40 year old age group.  Typical clinical characteristics of GAS bacteremia 
include fever, chills, and shock.  Mortality rates have been reported as relatively low 
within the last forty years (234), as antibiotic therapy has been used to widely treat 
bacteremia.    
 
Necrotizing Fasciitis 
 Necrotizing fasciitis, also known as the ‘flesh-eating disease’, is an infection of 
the subcutaneous tissue that results in the highly progressive destruction of fascia and fat.   
Within a matter of days, the infection can progress from an apparent benign skin lesion to 
a highly lethal disease.  Although GAS is widely known as the most common causative 
agent of necrotizing fasciitis, other Gram-positive bacteria such as S. aureus and 
Clostridium perfringens and C. septicum can elicit similar disease pathology (234).  
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Characteristically, beginning at the site of a trivial or minor wound, the infection 
becomes painful.  As it swells, it also becomes red and produces heat.  Within 24 hours, 
the infection spreads and migrates outward from the site of the initial infection.  During 
the next 24-48 hours, the redness transitions to purple and eventually to blue, as it forms 
fluid-filled blisters and bullae.  At this point, severe tissue destruction and gangrene, have 
occurred, accompanied by the extensive necrosis of the subcutaneous tissue, occur, and 
the patient becomes very weak, as fever and delirium set in.  Additional systemic sepsis 
and toxic shock can also occur.    In order to treat necrotizing fasciitis, early detection and 
treatment are vital.  Typically, antibiotic therapy, surgical debridement, and even 
amputation are used to slow the disease progression and rid the body of the damaged 
tissue.  Although previous mortality rates have been reported as low as 20%, today’s 
mortality rates have risen to >50% (235), most likely due to the emergence of more 




Acute Rheumatic Fever 
 Acute rheumatic fever (ARF) is a nonsuppurative systemic inflammatory disease 
that can affect the heart, joints, skin, and central nervous system following an upper 
respiratory infection with GAS.  Roughly, 233,000 deaths occur each year as a result of 
rheumatic fever (36).  Furthermore, it is the leading cause of childhood heart disease 
globally and thus, most commonly, appears in children between the ages of 5 and 15 
(150).  Rheumatic fever is believed to be caused by an autoimmune attack, in which host 
immune cells create antibodies against GAS that also appear to cross-react with self-
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epitopes against the myocardium and joints.  Due to the numerous clinical manifestations 
of ARF, diagnosing the disease is accomplished following the criteria set forth by Jones, 
who outlined specific major and minor clinical signs to identify the disease (159).  ARF 
can also lead to more severe manifestations including congestive heart failure and 
Sydenham's chorea.  Treatment of ARF includes antimicrobial therapy to rid the body of 
GAS and anti-inflammatory agents and analgesics to control joint pain.  For long-term 
management of ARF, patients are given continuous prophylactic antibiotic treatment to 
prevent recurrent attacks, as they represent the major cause of deaths and disabilities from 
rheumatic heart disease.   
 
Acute Post Streptococcal Glomerulonephritis 
 Acute post streptococcal glomerulonephritis (ASPGN) is an acute inflammatory 
disease, involving the renal glomeruli that filter waste products from the blood. ASPGN 
can result after both pharyngeal and GAS skin infections.  The latent period between a 
streptococcal pharyngeal infection and nephritis is roughly 1 to 3 weeks.  After a skin 
infection, it is more prolonged, 3-6 weeks (102).  ASPGN occurs primarily in children, 
young adults, and individuals over 40 years of age, with males affected twice as often as 
females (55). ASPGN is thought to develop after immune complexes consisting of 
streptococcal antigens (such as the M protein) complexed with host antibody deposit in 
the kidney glomeruli, causing the tubules to become inflamed, and impairing the kidney’s 
ability to filter and eliminate waste.  Symptoms of ASPGN often include high blood 
pressure, kidney edema, and presence of blood in the urine.  Diagnosis of ASPGN 
requires urinalysis testing and treatment is generally aimed towards lowering the blood 
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pressure and reducing edema.  Mortality due to ASPGN is very low; less than 0.5% of 




 As the number of incidents of invasive GAS disease rise, the need for a vaccine to 
protect against these diseases intensifies.  With the target group for vaccination children 
5-15 years old, the ideal vaccine would contain an epitope that is conserved in all GAS 
strains, is highly immunogenic, induces both IgG and IgA, and most importantly, does 
not exhibit cross-reactivity with human tissue (232).  GAS vaccine development has 
historically focused on the N-terminal region of the M protein, as Lancefield originally 
showed that antibodies against this region are not only protective, but bactericidal as well 
(132).  Several potential candidates have since used this region to develop multivalent N-
terminal type-specific vaccines.  However, even with the latest vaccine (26-valent) 
incorporating 26 of the most common M-types (107), because of the vast number and 
flux of M-types in developing countries, this vaccine would have limited effectiveness in 
the worldwide fight against invasive GAS disease.   Additionally, because some 
antibodies to the M protein are cross-reactive with human myosin (56), a characteristic 
that is central to the pathogenesis of ARF, the use of the M protein in a vaccine remains 
problematic.  As an alternative, numerous groups have tried to use well-characterized 
virulence factors for vaccine candidates, including ScpA (48, 110), the GAS carbohydrate 
(214), the fibronectin-binding protein Sfb1 (87, 164), and various exotoxins (259).  In 
spite of this, none of these candidates has reached human clinical trials.  Nevertheless, 
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there is renewed hope that future developments will lead to a potential vaccine, and in 





 In order to cause such a wide range of diseases, GAS utilize numerous virulence 
factors that enable them to colonize the host, invade the surrounding tissue, evade the 
host immune system, and disseminate throughout the body, causing further infection.  
Many of these virulence factors are surface-associated, as they are attached to the 
streptococcal cell, and others are released and secreted into the extracellular environment 










FIGURE 1.  Group A streptococcal virulence factors.  Schematic illustrates many cell-
surface associated virulence factors, including the M and M-like proteins, fibronectin-
binding proteins (SfbI/II, FBP54, F2, PFBP), capsule, C5a peptidase (SclA), and GRAB. 
Also shows some of the secreted factors of GAS: streptolysin O (SLO), streptolysin S 
(SLS), secreted inhibitor of complement (Sic), DNases, Mac/IdeS, and superantigenic 




M and M-like proteins 
 The major surface protein of GAS involved in both adherence and immune 
evasion is the M protein, encoded by emm.  The M protein is an alpha-helical coiled-coil 
dimer that consists of four different repeat regions (A, B, C, D); one of these repeats, the 
A region, is hypervariable and confers serotype specificity to the strain (196).  Currently, 
there are over 200 different recognized M-serotypes (171).  It has been observed that the 
size of the M protein can vary, depending on the number of the repeat units in the A and 
B portions of the protein (100).  While the M protein has historically been used for 
serotyping and classification of GAS, it also plays an important and very significant role 
in the streptococcal cell.  
 One of the major functions of the M protein is to protect the GAS cell from 
phagocytosis by the host.  It does this by binding to the complement regulatory protein H 
to inhibit and interfere with opsonization of the cell (104).  Additionally, the M protein 
can prevent the deposition of the complement factor C3b on the surface of the GAS cell, 
inhibiting the alternative complement pathway (104).  A second key function of the M 
protein lies in its ability to adhere to different molecules.  Many of the A repeats from 
different M proteins have been shown to bind to plasminogen, IgA, IgG (2), human C4b-
binding protein (5), and factor H (165, 181).  The B repeats, which are semi-
hypervariable, bind to fibrinogen (105) and human serum albumin (2).  Lastly, it is 
believed that the M protein can be released by the cell, in a soluble form (190), to act as a 
superantigen that contributes to T-cell activation and inflammatory responses during 
invasive streptococcal infections.   
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 In addition to the M protein, there exist within this gene superfamily many other 
structurally similar proteins.  More than 20 genes have been identified within the emm 
superfamily (e.g. mrp, arp, emmL, fcrA, sir, enn, and sph) and have been appropriately 
named M-like or M-related proteins, due to their highly conserved domain structure 
within the cell-wall associated region of the proteins (101).  These proteins, because of 
their similar domains, have variable immunoglobulin binding capabilities (29) like that of 
the M protein. 
 
Lipotechoic acid 
 Lipotechoic acid (LTA) is the fundamental component of the GAS cell wall, 
made up of techoic acid molecules attached to the wall via lipid anchors.   LTA has been 
shown to adhere to oral epithelial cells through fibronectin binding (227) and it is 
believed to be an initial mediator of adhesion, before specific high-affinity receptor 
adhesins, as it is capable of recognizing a relatively wide range of molecules (95).  LTA 
is also a pathogen-associated molecular pattern (PAMP) recognized by toll-like receptors 
of the innate immune response (3). 
 
MSCRAMMs 
GAS encodes numerous surface-associated adhesin molecules that allow for 
attachment and adherence to structures on the eukaryotic cell surface or with components 
of the intercellular matrix.  These proteins, known as MSCRAMMs, for microbial surface 
component recognizing adhesive matrix molecules, include the fibronectin-binding 
proteins, protein F (prtF) (93), SfbII (128), protein F2 (prtF2) (108), Sfbx (109), Pfbp 
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(212), FbaA (250), FbaB (251), and Fbp54 (52).  Other proteins such as the 
aforementioned M-protein and serum opacity factor (SOF) (53) can bind fibronectin as 
well.  The multitude and extensive array of fibronectin-binding proteins illustrates how 
important this function is to GAS during human host infection.  
In addition, multiple collagen-binding MSCRAMMs have been identified in 
GAS.  One of these proteins, Cpa, is expressed in at least 28 serotypes of GAS and has 
been found to bind to type 1 collagen (127).  Cpa is thought to have a role in attachment 
and internalization of GAS in tissues containing type 1 collagen, as a cpa mutant showed 
decrease internalization into epithelial cells (127).  A second 57 kDa collagen-binding 
protein has been identified in GAS, which uses collagen on the host eukaryotic cell as its 
receptor (264).  However, no evidence for the role of this protein in GAS virulence has 
been discovered.   
 
Streptococcal collagen-like surface protein 
 The group A streptococci produce the streptococcal collagen-like protein, SclA, 
and as its name implies, SclA is similar to collagen in structure.  SclA has been found to 
be important in adhesion, as it can bind to both fibroblasts (200), lung epithelial cells 
(147), and respiratory epithelial cells (47).   Additionally, sclA is up-regulated by Mga 
(202), the transcriptional regulator of the core virulence genes, suggesting an important 
role for the protein in bacterial virulence.  Furthermore, studies involving mutants in sclA 
have shown attenuation in virulence following a subcutaneous injection and a decrease in 
epithelial cell adherence, highlighting the importance of this adhesin to GAS 
pathogenesis.  Recently, it has been shown that SclA can bind the human complement 
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regulatory protein, factor H, to inhibit the alternative complement pathway (39).  In 
addition, SclA is capable of binding a fibrinolysis inhibitor, TAFI, and through its 
recruitment of plasmin to the surface of the GAS cell (189), can modulate the 
inflammatory reactions of the host.   
 
C5a peptidase 
 C5a peptidase, encoded by the scpA gene, is a surface-associated and anchored 
endopeptidase that specifically cleaves and inactivates the C5a chemotaxin of the 
complement system (49).  The peptidase acts on the cell’s binding site for PMNs, 
inhibiting the recruitment of phagocytic cells to the site of infection, and potentially 
enabling GAS’s evasion of the immune system (111).    Numerous studies have shown 
the importance of the C5a peptidase to the virulence of GAS.  Not only is the scpA gene 
part of the Mga core-virulence regulon, it has also been demonstrated to be important in 
the intranasal and subcutaneous models of GAS infection (110, 111).   
 
Capsule 
 The hyaluronic acid capsule of GAS is encoded by the has operon, which is 
negatively regulated by the CovRS two-component system (21, 97, 139), and is activated 
under conditions associated with infection (86).  The capsule is chemically identical to 
that found in human connective tissue.  Because of this, GAS capsule can bind to CD44, 
the receptor for human hyaluronic acid, and evade the host response through molecular 
mimicry, to mediate attachment to the epithelial cells (216).  Additionally, capsule has 
been found to be an important virulence factor of GAS, as acapsular strains fall victim to 
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phagocytosis and have complete avirulence in the pharyngeal model of infection (270).  
Likewise, in a skin infection model, acapsular mutants could not produce the local 
necrosis and systemic infection of the wild type strain (217), suggesting a role for the 
hyaluronic acid capsule in soft tissue invasion.   
 
Serum opacity factor 
 The serum opacity factor (SOF), only produced by Class II serotypes, is an 
important adhesin of GAS as it helps to bind streptococcal cells to high-density 
lipoproteins through a fibronectin-mediated process (54, 185).  SOF is not only bound to 
the cell surface, but can also be found as a released protein by the cell (89, 272).  Bound 
SOF appears to have two distinct activities, having roles in both serum opacification and 
fibronectin/fibrinogen binding, as mentioned previously (53, 114, 125, 198).  Although 
its direct role in virulence has been difficult to discern because of its bifunctional nature, 
studies have shown that inactivation of sof resulted in a reduction of virulence in an IP 
mouse model of infection (53).  
 
Streptolysin S 
 Streptolysin S (SLS) is an oxygen stable, non-immunogenic toxin that is released 
from the cell only in the presence of a carrier molecule (1, 26).  For this reason, SLS is 
primarily surface-bound, associated with the LTA.  This protein has the ability to lyse 
and damage the membranes of many cell types, including erythrocytes, lymphocytes, 
neutrophils, platelets, and even some subcellular organelles (80).   Lysis of these cells is 
mediated by insertion of a lysin complex into the membrane, leading to formation of 
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transmembrane pores and damage of the cell’s integrity(38).  SLS mutants have been 
shown in vivo to have impaired lesion formation and decreased pathogenesis within a 
subcutaneous skin infection model (59).  Additionally, SLS has been shown to impair 
phagocytic clearance, promote epithelial cell cytotoxicity (59)and mediate the cytocidal 
effect of GAS on neutrophils (173), demonstrating SLS as a potent virulence factor used 
by GAS for host immune evasion.      
 
Protein G-related α2-macroglobulin-binding protein (GRAB) 
 The Protein G-related α2-macroglobulin-binding protein (GRAB) is a cell-surface 
associated protein that enables GAS to protect its own surface-associated virulence 
factors by regulating proteolytic activity at the streptococcal surface (201).  As an 
inhibitor of both GAS and human proteases, GRAB has been shown to be an important 
virulence factor, as studies involving grab mutants showed an attenuation in virulence in 
both a localized subcutaneous skin infection model and a systemic infection model within 
mice (201, 255). 
 
S. pyogenes cell envelope protease (SpyCEP) 
 The S. pyogenes cell envelope serine protease (SpyCEP, scpC) was recently 
described as a widely-expressed (257) CovR-regulated protease capable of cleaving the 
neutrophil-recruiting chemokines, IL-1, IL-2, IL-6, and IL-8 (66, 257).  Additionally, it 
has been shown to cleave the granulocyte chemotactic protein 2 (GCP-2) and growth-
related oncogene alpha (GROα), two potent chemokines rich in the human tonsils (66).  
In vivo, a knockout mutant lacking SpyCEP was shown to be attenuated for virulence in a 
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subcutaneous mouse skin lesion model (275).  Furthermore, in a mouse upper respiratory 
tract infection model, SpyCEP was shown to enhance bacterial dissemination from the 
nasopharynx to the lungs (257). Thus, SpyCEP has shown to be necessary for bacterial 
dissemination, as it is involved in interfering with the innate immune response by 






 Streptolysin O (SLO) is an oxygen-labile, thiol activated hemolysin that interacts 
with membrane cholesterol and aggregates to form pores in the membranes of host cells 
(219).  Like SLS, SLO can target numerous cell types, including erythrocytes, 
macrophages, leukocytes, and platelets.   SLO has been shown to be important for 
invasive disease in a mouse skin infection model (141).  However, the exact role of SLO 
is still unknown, as it does not appear to be involved in the formation of necrotic lesions 
or bacterial dissemination for GAS (141).  Recently, it was discovered that SLO is 
involved in cytolysin-mediated translocation (CMT), a pore-forming process that 
mediates translocation of an effector molecule (S. pyogenes NAD-dehydrogenase/Spn) 
into the cytoplasm of the eukaryotic host cell (170).  It was found that SLO not only acts 
as a hemolysin to form the pore necessary for translocation, but that it plays a more 
active, presently unknown role in the process, beyond just forming the pore (153).  
Additionally, new evidence suggests that SLO interferes with the internalization of GAS, 
 24 
through local perturbation of the keratinocyte cell membrane, and disruption of a 
clathrin-dependent uptake pathway (142). 
 
Streptococcal pyrogenic exotoxin B  
 SpeB is a cysteine protease, one of the many proteolytic enzymes of GAS.  
Although its role in GAS is somewhat ambiguous, some studies have shown that a speB 
mutant decreased mouse lethality (148), resistance to phagocytosis (146), and even 
eliminated fibrinogen cleavage (163).  Other studies, however, have shown no significant 
effect on virulence (9, 10).  Additionally, SpeB has been shown to cleave and degrade 
streptococcal IgG-binding proteins.  For this reason it is thought to promote prevention of 
complement activation at the bacterial surface, thereby preventing antibody-mediated 
phagocytosis, leading to the survival of GAS (50, 67).  Furthermore, SpeB was shown to 
be involved in the spread of GAS, as it can cleave surface-attached fibrinogen-binding 
proteins (Protein F, Fba), releasing GAS from attachment to host cells, and thus 
facilitating bacterial spread (199, 269). 
 
Streptococcal inhibitor of complement  
 The secreted inhibitor of complement-mediated lysis, encoded by sic, 
incorporates into the membrane attack complex of complement to inhibit complement-
mediated lysis (71).   It has also been shown to inactivate two antibacterial peptides of the 
innate immune response, LL37 and human neutrophil alpha-defensin (74).  Additionally, 
Sic aids in bacterial survival at mucosal surfaces (99) and has been shown to bind and 
alter the activities of lysozyme and the secretory leukocyte proteinase inhibitor (70).  Due 
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to the various roles of Sic, it can be said to be a multifunctional virulence factor, able to 
interact with various host cell proteins and members of the immune system.   
 
Streptokinase 
 Streptokinase (Ska) has been considered a virulence factor of streptococci, as far 
back as the 1930’s, because of its ability to lyse fibrin clots (253) and subsequently, to 
spread the GAS infection.  The protein acts as an activator, as it forms a complex with 
plasminogen to convert the plasminogen to its active proteolytic form plasmin (143).  
GAS streptokinase is specific for human plasminogen (244), as it exhibits little or no 
activity against other mammalian species.  Studies using a transgenic mouse expressing 
human plasminogen increased mortality in mice.  This response was dependent on the 
expression of streptokinase (244).  Streptokinase has also been implicated in the 
development of acute post-streptococcal glomerulonephritis, as it has been shown to be 
deposited in renal glomeruli, resulting in local activation of the complement cascade, and 
ultimately nephritis (182).   
 
S. pyogenes NAD-glycohydrolase 
 Along with SLO, S. pyogenes NAD-glycohydrolase (NADase/Spn) is involved in 
CMT, where SLO forms the pores necessary to deliver NADase to the cytoplasm of the 
host epithelial cell.  The GAS NADase has been found not only to cleave NAD to 
produce nicotinamide and ADP-ribose, but also to produce cyclic ADP-ribose (112).  In 
vivo mouse models of invasive soft-tissue infection and septicemia showed that mutants 
lacking NADase activity were significantly attenuated for virulence (30), suggesting an 
 26 
important role of NADase to streptococcal infection.  Additionally, it has been discovered 
that NADase is involved in numerous host cell changes that enhance GAS pathogenicity, 
including actin rearrangement to inhibit bacterial internalization, augmentation of SLO-
mediated cytotoxicity, and induction of keratinocyte apoptosis (31). 
 
Immunoglobulin G-degrading enzyme 
 IdeS (immunoglobulin G-degrading enzyme of S. pyogenes/MAC) was identified 
based upon its similarity to the human leukocyte adhesion receptor, Mac-1 (265).  As an 
extracellular proteinase, IdeS has been shown to cleave the opsonizing IgG antibody at 
the hinge region to produce two Fab fragments and the Fc portion (265).  This cleavage 
results in inhibition of opsonophagocytosis and production of reactive oxygen species, 
allowing GAS to avoid killing by PMNs (137), thus, enhancing its survival within the 
host.   
 
Superantigens (pyrogenic exotoxins) 
 Streptococcal pyrogenic exotoxins were originally named based upon their 
presumed role in the development of scarlet fever.  There exist numerous exotoxins 
within GAS, including (although not limited to): SpeA, SpeC, SpeF (79), SpeJ (166), 
SMEZ (176), SpeL and SpeM (230).  Not all exotoxins are present in all strains, due to 
the fact that some are phage-encoded.  Additionally, based upon sequenced genomes, 
some exotoxins are shown to have more than one allele, suggesting varied functions.  
Although no clear role of these toxins/superantigens in the disease process has been 
established, as superantigens, these proteins are believed to bind nonspecifically to the T-
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cell receptor and class II MHC.  This results in the release of numerous interleukins and 
cytokines, leading to shock in STSS (122). 
 
DNases 
 Although GAS encode four antigenically distinct DNases (A, B, C, and D) 
capable of degrading DNA, it is unknown whether any of them is an important virulence 
factor.  However, recent studies in two murine models of infection and in cynomolgus 
macaques have shown that a GAS strain lacking DNase production exhibits a decrease in 
virulence (241).  Additionally, it is believed that the DNases degrade neutrophil 
extracellular traps, or NETS, and aid in evasion of the innate immune response (33, 241).  
Moreover, the Sda1 DNase has been shown to be involved in the switch to invasive GAS 




 In order to cause such a wide range of diseases, GAS has evolved numerous 
mechanisms to regulate its virulence genes.  Unlike other prokaryotes, GAS has not been 
shown to utilize alternative sigma factors to control virulence gene expression.  
Alternatively, the majority of regulation for GAS is controlled by transcriptional 
regulators and signal transduction networks.  These virulence regulators include classical 




Two component systems (TCS) 
 Two component systems (TCS) are one of the best-characterized signal 
transduction systems within bacteria.  A classical TCS consists of two proteins.  The first 
of the two proteins, the histidine kinase (HK), typically exists in the membrane of the cell 
and it generally receives signals front the external environmental, causing 
autophosphorylation.  The second protein, the response regulator (RR), resides inside the 
cell and upon transfer of a phosphate from the histidine kinase, produces an internal 
effect, typically through transcriptional regulation.  GAS contains 13 TCSs, and those 
that have been connected to virulence are described below.  A more extensive, in-depth 
review of the bacterial TCS follows this section.   
 
CovRS 
 The most studied, and best-described TCS of GAS is the CovRS system (TCS 2), 
named for its control of virulence in GAS.  Originally named CsrRS for its role in capsule 
synthesis regulation, the TCS was later renamed to emphasize its more widespread role in 
virulence regulation (69).  Believed to respond to environmental stresses such as changes 
in pH, temperature, and osmolarity (58), CovRS has been shown to directly or indirectly 
influence expression of approximately 15% of the GAS genome (81), with the majority 
of the genes being repressed.  This has led to CovR being considered the major negative 
global regulator of virulence genes within GAS.  Numerous studies have elucidated the 
significance of CovR to expression of virulence factors within a host.  In the mouse soft 
tissue model of infection, CovRS was shown to be repressed, leading to an increase in 
virulence factor production (83).  In a longitudinal macaque pharyngitis model, 
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expression of CovRS varied, but correlated with the course of colonization and infection 
(263).  Additionally, exposing GAS to human blood resulted in global changes to allow 
for bacterial survival and adaptation to the protein-rich conditions (82).   
Increasing evidence also suggests that spontaneous mutations in CovRS allow 
GAS to become more invasive (14, 58, 243, 268).  These GAS strains containing 
mutations also appear to become more dominant within the population.  Recent data have 
shown that a pharyngeal isolate and blood isolate from the same individual, isolated 13 
days apart, were genetically similar, but differed by the presence of an 11 bp insert within 
covS leading to a truncated mutant version of CovS (78).  Additionally, to determine the 
in vivo impact of a covS mutation, a murine subcutaneous chamber model was employed, 
comparing a wild type M1 strain to a previously isolated animal-passaged covS mutant.  
Bacteria were collected 24 hours post inoculation, allowing ample time for the bacteria to 
sense their environments, yet not long enough to allow for restructuring of the bacterial 
community and selection of mutants.  Differences in gene expression dynamics were 
observed between a wild type and animal-passaged covS mutant, indicative of 
transcriptional changes within gene sets associated with GAS invasion, immune evasion, 
tissue-dissemination, and metabolic reprogramming (13).  Thus, the overwhelming 
amount of in vivo data suggests that CovRS has an important and extremely significant 
role in modulating gene expression during GAS infection. 
 
FasBCAX 
 The FasBCAX system (TCS 1), which exhibits homology to the quorum-sensing 
TCS of S. aureus (Agr) and S. pneumoniae (Com) (124), is unlike other conventional 
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TCSs.  The operon consists of two genes encoding histidine kinases (fasB and fasC), one 
gene encoding a response regulator (fasA), and a fourth gene encoding the effector of the 
operon, a small monocistronic RNA transcript (fasX).  Named for its ability to regulate 
fibronectin /fibrinogen binding, hemolytic activity, and streptokinase transcription (124), 
the TCS regulates genes in a growth-phase dependent manner.  FasBCAX down-
regulates genes encoding GAS adhesins (fbp54, mrp) and activates genes encoding 
secreted aggressins (sagA, ska) and cytotoxins at the end of exponential growth (124).  It 
is thought that the TCS may be involved in local tissue destruction because of its strong 
cytotoxic and apoptotic phenotype (121). 
 
Ihk/Irr 
 The Ihk/Irr TCS (TCS 13) is named for its proximity to isp, a gene encoding an 
immunogenic secreted protein: isp-adjacent histidine kinase and isp-adjacent response 
regulator, respectively.  It has been shown to be important in GAS as it is involved in the 
evasion of polymorphonuclear leukocyte (PMN)-mediated killing during exposure to the 
innate immune response.   More specifically, using phagocytosis assays, Ihk/Irr was 
shown to enhance GAS survival by controlling expression of genes critical for GAS 
survival after phagocytosis (267). Additionally, irr was shown to be highly expressed in 
16 patients during GAS-induced acute pharyngitis (267), suggesting that Ihk/Irr is critical 
for GAS survival and pathogenesis in humans.  Moreover, a separate study using a irr 
mutant showed attenuation of virulence in both soft tissue infection and bacteremia 
mouse models (266).  The study also suggested that ihk/irr are induced by neutrophil-
derived ROS (266), resulting in expression of genes that enable GAS to survive host cell 
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lysis, and to disseminate to cause further disease.  Thus, GAS is able to detect and evade 
the human innate immune system through the aid of the Ihk/Irr TCS.   
 
SptRS 
 The SptRS TCS (TCS 4) links metabolism and virulence factor production to 
bacterial persistence in saliva.  Named for its involvement in saliva persistence, the 
SptRS TCS has been shown to regulate multiple genes encoding proteins involved in 
acquisition and processing of complex carbohydrates (222), including amyA, malE, araD, 
and asaD.  Additionally, a study of GAS gene expression over a period of 86 days in the 
monkey oropharynx confirmed a role for SptRS in GAS pathogenesis of the upper 
respiratory tract (263).  Furthermore, an in vivo study using a subcutaneous mouse 
infection model determined that a mutation in M5005_Spy_0680 (SptR) caused a 
significantly larger skin lesion than its wild type parental strain (229) and either directly 
or indirectly affected several genes involved in GAS pathogenesis (e.g. scpA, sic, prtS) 
(229).  Thus, it appears that the SptRS TCS allows GAS to alter its metabolic pathways 
upon entering the oropharynx and to aid in the production of virulence factors necessary 
for its survival.   
 
TrxSR 
 TCS 10, previously known as Spt10SR, and renamed TrxSR for two-component 
regulatory system X, is the latest GAS TCS studied to be directly linked to GAS 
virulence.  TrxSR is the homolog to a pneumococcal TCS that has been shown to be 
essential for full virulence in several models of pneumococcal infection (96, 252).  It is 
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also a homolog of a Enterococcus faecalis TCS involved in resistance to bacitracin (91).   
Based upon its homology to known virulent TCSs, a preliminary study was undertaken to 
determine if TrxR played a role in streptococcal infection.  Using an in vivo murine 
model of GAS soft tissue infection, a trxR mutant was found to be attenuated for 
virulence (135).  Additionally, trxSR was shown to be directly repressed by CovR (135).  
Thus, the data suggest that TrxSR is involved in GAS virulence, although its mechanism 
of action has yet to be determined.   
 
Other GAS TCS 
 Of the 13 conserved TCSs of GAS, only five have been studied in detail, with 
little information known about the remaining systems in relation to a role or involvement 
in virulence.  Recently, a study assessed the role of three previously uncharacterized 
TCSs by expression microarray analysis (229). Although they did not appear to have 
direct roles in virulence, putative roles can be inferred for the TCSs based upon the genes 
that they regulate.  TCS 5 (M5005_Spy_0784/0785) is believed to directly activate a 
nearby mannose/fructose-PTS system, while TCS 7 (M5005_Spy_0832/0833) is thought 
to be involved in malate metabolism due to its activation of a malate-sodium symporter 
homolog (229).  A role for the third TCS in the study, TCS 9 (M5005_Spy_1280/1281), 
could not be determined based upon its regulon, although it appears to function as a 
switch for the cell late in growth, as it has a regulon roughly 30 times bigger in stationary 





 In addition to the aforementioned TCSs involved in virulence regulation, GAS 
encode for almost 30 stand-alone transcriptional regulators.  These proteins have no 
known or identified sensor component and typically exist as regulators within existing 
signal transductions networks, or on their own as ‘one-component’ systems.  In this type 
of system, the regulators interact with or respond directly to signals, to alter their activity 
within the cell.    Those stand-alone regulators that have been characterized and shown to 
be involved in virulence regulation are detailed below.   
 
Mga 
 Mga, or the multiple gene regulator of GAS, was the first virulence regulator 
found in S. pyogenes.  Originally called mry to reflect its regulation of the M-protein 
(194), another study identified the same region upstream of emm to regulate ScpA and 
termed the gene virR (46).  Later, mry and virR were found to be the same gene and it 
was renamed mga to indicate that it was a multi-virulence factor regulator (218).  To 
date, mga has been found in all sequenced GAS strains (24) as two divergent alleles (88).  
Additionally, several homologs of Mga exist in other pathogenic streptococci and Gram-
positive pathogens.  They have been shown to be essential for infection, suggesting that 
Mga belongs to a common family of virulence regulators.   
Mga is activated by both growth phase and environmental conditions, as it 
responds to varying environmental signals such as elevated CO2, increased iron levels, 
temperature, and sugar availability (35, 167).  Several studies have shown that Mga 
regulates many genes important for the early stages of infection, a time at which GAS 
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would encounter such conditions within the human body, as listed above.   These Mga-
regulated virulence genes include sof, sic, sclA, fba, and the aforementioned emm and 
scpA (46, 169).  They have been shown to be very highly activated by Mga and have 
collectively become known as the ‘core’ Mga regulon.  Additionally, Mga was found to 
influence the expression of several metabolic operons and genes important in the 
transport and utilization of sugar, albeit at low-levels (207).   
 Numerous studies have shown the in vivo relevance of Mga in a variety of animal 
models of GAS disease.  Initial studies using a mouse model of infection demonstrated 
that the loss of mga caused attenuation of virulence (118).  More recently, experiments 
using a large-scale signature-tagged mutagenesis screen in zebrafish established that Mga 
is important in vivo for disease pathogenesis and that a mga mutant exhibited attenuated 
virulence (120).  To gain an understanding of Mga during the course of an infection, 
several studies have looked at the growth of GAS in both ex vivo and in vivo 
environments.  During growth in whole human blood, maximal levels of mga transcript 
were found 30 minutes post blood exposure (82), correlating with data that suggest 
maximal expression of the Mga regulon occurs in vitro during exponential growth (169, 
260).  Additionally, a cynomolgus macaque pharyngeal model was used to demonstrate 
that the Mga regulon is maximally expressed during the acute phase of pharyngitis 
infection (263).  Taken together, these data prove that Mga is indispensable for GAS, as it 






 Rgg, also known as RopB for regulation of proteinase, is homologous to other 
Gram-positive transcriptional regulators that have been shown to regulate expression of 
extracellular products during the stationary phase of growth (151).  In the M49 strain, 
Rgg is involved in production of SpeB (43).  Additionally, it has been shown to regulate 
the expression of other virulence factors and even transcriptional regulators, like Mga.  
This suggests that some of Rgg’s affect may be indirect (45).  Furthermore, Rgg activates 
several amino acid catabolism operons (44) and contributes to utilization of alternative 
sugars associated with secondary metabolism and thermal stress responses (42), making it 
a global regulatory factor of not only virulence, but of genes involved in secondary 
metabolism and stress as well.  Recently, a new role for Rgg has emerged, as it has been 
proposed that Rgg may be involved in quorum-sensing, by regulating competence of 
GAS through binding of small pheromone peptides(162). 
 
RofA 
 RofA was first identified in an M6 strain as a positive transcriptional activator of 
its own transcription, and of prtF, a gene encoding for a fibronectin-binding protein (72).  
It has since been shown to also repress important virulence genes, including mga, sagA, 
and speB (19), also in an M6 strain.  Additionally, the same study showed that a rofA 
mutant exhibited reduced eukaryotic cell internalization rates in combination with 
decreased host cell viability (19).  However, it was later shown that there appeared to be 
strain-specific variation in RofA-regulation, whereas a rofA mutant in an M2 strain 
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showed significantly increased affinity for adherence to the host cells with no change in 
bacterial internalization rates (123).   
Since the discovery of RofA in GAS, three other homologs of RofA have been 
described, and designated as members of the RALP (Rof-A like protein) family.  These 
regulators act at the transition from exponential growth to stationary phase and most 
often serve as negative regulators of virulence.  The three other members of the RALP 
family are described below.    
 
Nra 
 Nra, the second member of the RALP family, is predominately found in opacity 
factor (OF)-negative serotypes (123) and is encoded within the FCT genomic region 
(197).  Nra shares homology with RofA.  However, it is a negative regulator of genes in 
the M49 serotype, unlike the activator RofA, and regulates its own expression and such 
adhesin genes as Cpa (collagen-binding protein) and PrtF2, a fibronectin-binding protein 
(197).  Like RofA, Nra regulates not only Mga, but other virulence genes such as SpeA, 
SpeB, and SLS that are involved in host cell damage (174).  Furthermore, a transcriptome 
study on an M49 strain showed that Nra also repressed transcript levels of pilus and 
capsule synthesis operons, as well as two important GAS regulator systems, Rgg and the 
Ihk/Irr TCS (126).  In addition to repressing, Nra was found to induce expression of 
metabolic enzymes and several stress response-associated proteins (126).  In contrast to 
the findings from the M49 serotype, recent data suggest an opposing effect in the M53 
serotype, as Nra appears to function as a positive regulator of pilus gene transcription and 
inactivation of nra leads to loss of virulence in a mouse model of superficial skin 
infection (149).  Thus, while it appears that the regulatory effects between the two 
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serotypes are polar opposites, there is a conservation of Nra’s regulation of pilus gene 
transcription, suggesting a role for Nra in virulence gene expression. 
 
RALP3 
 RALP3, also a member of the RofA-like family, has been shown to negatively 
control hyaluronic acid capsule and cysteine protease expression (130).  Its presence is 
currently limited to only a few of the sequenced serotypes (M1, M4, M12, M28, and 
M49) and seems to have varied affects in different strains.  In an M1T1 strain, the ralp3 
mutant exhibited greater survival in human whole blood and serum.   This behavior also 
correlated with reduced covR transcription in the ralp3 mutant, suggesting CovR as a 
potential linker between RALP3 and the hasA and speB genes (130).  Additionally, in an 
M49 strain, RALP3 was shown to repress expression of msmR, the multiple sugar 
metabolism regulator, yet to activate expression of nra (126).  It was also shown to 
regulate the ERES region of the chromosome (epf ralp3 eno sagA) (126), which contains 
important known virulence factor genes.   
 
RivR  
 RivR, ralp IV, is the fourth member of the RofA-like protein family of 
transcriptional regulators to be discovered.  RivR is directly repressed by the CovRS TCS 
(209).  It is believed that GAS requires expression of RivR for growth in situations where 
CovR is dephosphorylated (209).  It has been shown that RivR can not only activate 
expression of the Mga regulon (210) but can also act in concert with Mga to enhance its 
ability to activate transcription.  Additionally, a rivR mutant was attenuated for virulence 
in the invasive subcutaneous mouse model of infection (210). 
 38 
Other GAS Regulators 
 Along with TCSs and stand-alone regulators, there are several other factors that 
have been shown to be involved in virulence factor regulation in GAS.  These regulators 
(e.g. small RNAs, metal regulators) do not fit neatly into the aforementioned categories.  
A few of these will be discussed below.   
 
Pleiotropic effect locus 
 The pleiotropic effect locus (pel) represents a unique positive regulator in GAS 
that has an effect on the expression of multiple surface and secreted proteins involved in 
virulence (140).  Interestingly, pel is an untranslated mRNA located within the promoter 
region of sagA (157), the first gene in a nine gene operon responsible for SLS production 
and secretion (180).  Initial studies using a pel mutant in an M49 strain resulted in a loss 
of transcription for the speB and emm genes, and reduced secretion of Ska (140).  
Additionally, in vivo studies using a mouse skin air sac model showed that a pel mutant 
had reduced virulence compared to a wild type strain (65).  Furthermore, this RNA was 
shown to be regulated in a growth-phase dependent manner and is induced by 
conditioned media (157), suggesting regulation of pel by other regulatory molecules of 
GAS.  Regulation by pel appears to be serotype specific, however, as pel had no 
regulatory activity in M1T1 GAS isolates (193).   
 
MtsR 
 MtsR is a metal-dependent regulator that was found to regulate the streptococcal 
iron acquisition (sia) operon in response to iron availability (16).  As iron has been shown 
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to influence the production of various virulence factors such as the M-protein (167) and 
SLS (85), in vivo studies using an mtsR mutant in an M49 strain have shown attenuation 
for virulence in both intramuscular and intraperitoneal zebrafish infection models (16).  
Additionally, microarray studies on the mutant broaden the MtsR regulon beyond metal 
homeostasis to include essential virulence and pathogenesis genes of GAS (mga, emm49, 
ska) (256).  Moreover, in an M3 strain, MtsR was shown to be linked to necrotizing 
fasciitis in mice and non-human primates (187), implicating MtsR as an important 
regulator in GAS pathogenesis. 
 
CodY 
 CodY is a pleiotropic regulator that has been shown to be involved in the amino 
acid starvation response, in which the organism faces nutrient limitation, in several low 
G+C Gram-positive bacteria.  Numerous studies have looked at the relationship between 
the acquisition of nutrients and virulence gene expression, as it is believed that this 
process is the primary event in the establishment of infection.  One such study showed 
that CodY affects the transcription of numerous transcriptional regulators involved in 
virulence (mga, covRS, rgg/ropB), pel) when grown in complex or defined media (156).  
Additionally, it was shown that CodY contributed to virulence gene regulation in human 
blood and extended the previously found in vitro regulon (155).  Although it is not 
apparent whether CodY is exerting direct affects on its regulon, or if its regulation is 
through a secondary network, CodY represents a global regulator within GAS that is 




 Srv, the streptococcal regulator of virulence, is another transcriptional regulator of 
GAS that was identified based upon its homology to the PrfA virulence regulator of 
Listeria monocytogenes (204).  Using an intraperitoneal mouse model of infection, Srv 
was shown to be required for full virulence in an M1 strain, as loss of srv resulted in a 
significant decrease in GAS virulence (204).  Additionally, microarray studies show that 
inactivation of srv results in a reduction of Sic and in increase in SpeB (203), two widely 
known virulence factors.  Furthermore, Srv was shown to be necessary for GAS biofilm 
formation (61), as it regulates the production of SpeB, a protease involved in degradation 
of GAS and host proteins necessary for the biofilm.   After testing this in vivo using both 
a chinchilla model of otitis media and a murine model of soft tissue infection, it was 
concluded that Srv-mediated regulation of SpeB contributes to biofilm stability, as it may 
play a role in producing SpeB when dispersion and dissemination of the bacteria is 









Signal transduction systems function as intracellular information processing 
pathways that link an outside stimulus to an internal response.  They typically exist as a 
series of phosphorylation steps to move the signal into a successful effect.  As early as 
the 1980s, researchers found and named a new class of regulatory systems in bacteria as  
‘two-component system’ (TCS).  Two-component systems serve as a basic stimulus-
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response coupling mechanism that allows organisms to sense and respond to changes in 
environmental conditions.  As the name suggests, a TCS involves two proteins to elicit a 
response.  The histidine kinase is the primary connector of stimuli within the cellular 
environment.  It passes the ‘signal’ along in the form of a phosphate to a response 
regulator, which produces the adaptive response. This mechanism and its constituent 
proteins will be discussed in further detail below.  
 
System Architecture 
The majority of TCSs have a very simple design.  A transmembrane sensor kinase 
activates a cytoplasmic RR through a single phosphoryl transfer, leading the activated RR 
to elicit its adaptive response (Fig 2A).  This transfer occurs via three phosphotransfer 
reactions and two phosphorylation intermediates: 
 
1. Autophosphorylation: HK-His + ATP         HK-His~P + ADP 
2. Phosphotransfer: HK-His~P + RR-Asp        HK-His +RR-Asp~P 
3. Dephosphorylation: RR-Asp~P + H20        RR-Asp +Pi 
 
Adapted from (237) 
 
 
In the first step of autophosphorylation, the γ-phosphate of ATP is transferred to the 
conserved histidine residue within the HK.  The RR then catalyzes the transfer of the 
phosphate group from the histidine residue of the HK to its own conserved aspartate 
residue.  In the final step of the reaction, the phosphate is transferred from the aspartate 
residue of the RR to water in a hydrolysis reaction (237).  A classic example of this basic 
scheme is that of the well-studied EnvZ-OmpR osmosensing TCS of E. coli.  In this 
system, upon autophosphorylation of EnvZ, EnvZ transfers its phosphate to OmpR.  The 
activated OmpR then modulates the expression of two outer membrane porin proteins in 
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response to the osmolarity of the cellular environment (40).  In a slightly more 
complicated version of the basic TCSs, some HKs can not only phosphorylate one RR, 
but also have the ability to competitively phosphorylate another (e.g. CheA-CheB/CheY).   
More elaborate versions of the TCS are the multiple phosphotransfer pathways 
known as phosphorelays.  The basic design of a phosphorelay pathway incorporates five 
phosphoryl transfer reactions and four phosphoprotein intermediates (Fig 2B).    These 
TCSs are composed of His- and Asp-containing domains that are used as phosphotransfer 
elements in either isolated domains or as part of a hybrid kinase.  The Bacillus subtilis 
sporulation control system is an example of a phosphorelay system that contains two HKs 
and a single RR, along with additional receiver His-containing phosphotransfer protein 

















FIGURE 2.  Two-component system schematic.  A, The classical TCS pathway in 
which a HK receives a signal through its sensing domain and phosphorylates at a 
conserved histidine within its catalytic domain.  This phosphate is then transferred to the 
receiver domain (REC) and activates the RR, which allows the protein to elicit its cellular 
response.  B, A phosphorelay in which a hybrid HK involving an additional REC and 
histidine phosphotransfer (HPt) domain is used for multiple phosphotransfer events 
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TCSs are found in the three domains of life: prokaryotes, archaea, and eukaryotes.  
In prokaryotes and archaea, several hundred two-component proteins have been 
identified.  In E. coli, there are 30 HKs and 32 RRs (237).  In other sequenced organisms, 
the number of HKs and RRs differs significantly, ranging anywhere from 0 (Mycoplasma 
genitalium) to 80 (Synechocystis sp.) (237).  In contrast to the numerous two-component 
proteins found in prokaryotes, only a small number have been identified in eukaryotes.  
Those that have been described are predominantly in microorganisms, with only a few 
found in plants (e.g. Arabidopsis thaliana) and none in animals (237).  Eukaryotic TCSs 
typically have hybrid kinases that contain RR domains and do not contain DNA-binding 
domains.  Although there are differences between prokaryotic and eukaryotic TCSs, as 
will be mentioned in more detail later, the overall mechanism is still the same: to sense 
and respond to environmental changes. 
 
Phosphotransfer Chemistry  
 Histidine kinases were named for the important role that the histidine residue 
plays in the overall function of the protein.  Typically, phosphorylation occurs on the N3-
position of the imidazole ring of the histidine (246), which creates a phosphoamidate 
bond.  This bond is important because it contains a large negative free energy of 
hydrolysis, making it relatively unstable (239).  Because of this, the phospho-histidine 
residue is much more suitable as a phosphotransfer intermediate, that can drive 
phosphorylation of its cognate aspartate residue within the RR, than as a 
stoichiometrically phosphorylated site for protein interaction.  While HKs are 
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catalytically similar to Ser/Thr/Tyr protein kinases, the chemistry and catalytic 
mechanism of phosphoryl transfer differ between the two.  For Ser/Thr/Tyr kinases, 
phosphorylation results in a phosphoester bond.  This bond has a smaller free energy for 
the isolated residue than that of the protein.  Because of this, the phosphate is transferred 
from ATP directly to the protein substrate.  
 Phosphorylation of the aspartate, on the other hand, produces a high-energy acyl 
phosphate.  The best-characterized phospho-aspartate intermediate is found in the P-type 
ion-translocating ATPases (248).  In these proteins, the free-energy of the phospho-
aspartate is significantly less than measured in a small-molecule acyl phosphates.  With 
the energy, the acyl phosphate bond is able to drive a conformational change within the 
protein.  It is hypothesized that this energy is also able to cause long-range 
conformational changes, and not just local electrostatic effects, to activate the RR and 





Most prokaryotic and eukaryotic HKs contain an amino-terminal signal-sensing 
domain, a region of the protein that is connected to the cytoplasmic kinase core through a 
transmembrane helix and a cytoplasmic linker (237).  The more complicated hybrid HKs, 
which are typically found in but not limited to eukaryotes, have an additional 
phosphorylatable receiver module and/or phosphotransfer unit attached to the 
cytoplasmic transmitter core (73) (Fig 2B).  Whether the kinase is of the classical type or 
a hybrid model, the stimuli are sensed directly through these sensory domains, and/or can 
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be sensed indirectly through a protein-protein interaction with an accessory protein.  
Thus, owing to the multitude of HKs specific for distinct signals, the sensing domain of 
the HK shares very little primary sequence similarity from one protein to another, 
allowing for diverse, yet specific ligand/stimulus interaction within the organism.   
HKs are able to sense a wide variety of stimuli, including but not limited to small 
molecules, cell envelope stress, light, turgor pressure, redox potential, and 
electrochemical gradients (77).  The sensing domains of HKs can be classified into three 
major groups based upon their membrane topologies (161).  The largest group of sensory 
domains is represented by the classical HKs, where the sensory domain typically lies 
within the periplasm, between two transmembrane helices, and transduction of the signal 
occurs across the membrane.  The second group contains not two transmembrane helices, 
but several (237), with no apparent extracellular domain.  In these sensory domains, it is 
believed that these stimuli are membrane associated, such as a change in cell envelope 
integrity.  The last type of sensory domain does not lie within the membrane, rather, it 
exists in the cytoplasm for sensing diffused and internal stimuli, like the chemotaxis 
kinase CheA (236) or the nitrogen regulatory kinase NtrB (152).  These HKs take part in 
protein-protein interactions with other cytosolic components to initiate a response.   
In order to respond to such an enormous, diverse group of signals, HKs have 
evolved several mechanisms of signal perception, occurring at either their own sensor 
domain, one of their transmembrane regions, or through auxiliary proteins (i.e. three-
component system) (129).  For the most common form of signal perception, in which 
HKs sense their signal through an obligatory sensory domain, PAS domains are most 
frequently used (258).  These domains exist as an α/β fold, capable of incorporating 
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signals by many mechanisms, including direct binding to the PAS domain cavity, binding 
through a co-factor containing PAS domain, binding at the PAS domain-membrane 
interface, and signal-mediated modulation of inter-PAS domain disulfide bonds (129).  
The well characterized PhoQ HK of Salmonella typhimurium utilizes the sensor domain-
membrane interface to control inducible resistance through its signal, host antimicrobial 
peptides (15).  Here, in the absence of the antimicrobial peptides, the PhoQ sensor 
domain is attached to the membrane surface.  However, once the peptides are present, 
they have the ability to displace bound metal ions and release the sensor domain from the 
membrane, thus promoting signal transduction across the membrane to activate the HK 
(129).  Regardless of the sensing mechanism used, signal perception by the HK initiates 
its own kinase domain activation, ultimately leading to autophosphorylation and signal 
transduction.   
 
Linker domains 
 The sensor domains of membrane HKs are generally connected to their 
cytoplasmic kinase core through a linker domain.  This linker typically starts at the end of 
the last membrane-spanning region in the sensory domain and ends at the conserved 
histidine residue within the catalytic core.  These domains are of variable lengths, ranging 
from less than 40 amino acids to more than 150 (68).  Based upon computational analyses 
of sequence similarities between several linker domains, there appears to be a 50-residue 
α-helical, coiled-coil motif lying within this region (228).  Although little is known about 
the linker domain, it has been hypothesized, based upon this coiled-coil motif, that they 
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may aid in promoting intramolecular protein-protein associations and/or act in structural 
relays between the sensing and kinase domains (191).   
 
The kinase domain, the catalytic core of the HK  
The kinase domain of the histidine kinase typically lies at the carboxy-terminal 
end of the protein.  This region houses the catalytic core of the protein.  It is responsible 
not only for phosphorylation and dimerization, but also for ATP/ADP-binding and 
phosphotransfer.   This domain can typically be split into two separate regions, one for 
dimerization and an adjacent second half that comprises the nucleotide-binding pocket. 
The main body of the phosphotransfer domain is an α/β-sandwich fold consisting of a 
four-stranded antiparallel β sheet and three α helices (237, 271), reminiscent of the 
ATPase domains of such proteins as DNA gyrase and Hsp90 (25).  Due to the function of 
this domain, the catalytic core is much more conserved between HKs than the sensory 
domain.  As such, it can be identified by a set of conserved primary sequence motifs, 
which include the H, N, G1, F, and G2 boxes (211) (Fig 3).  The H box, which is 
typically found in the dimerization region of the core, contains the conserved His residue 
that is the site of phosphorylation.  It is this invariant histidine that is the site of the 
autophosphorylation reaction. The four other conserved boxes comprise the nucleotide-
binding pocket within the active site.  These residues are all located in close proximity to 
each other, as can be seen in Figure 3.  Part of this region (the “ATP lid”) is also highly 




FIGURE 3. Crystal structures of the catalytic kinase core.  A, Structure of the catalytic 
domain and nucleotide-binding pocket from E. coli PhoQ; shown with bound ATP 
analog.  B, Structure of the entire kinase core of Thermatoga maritima HK853.  Shown as 
a dimer of two monomers, the first is orange and pink (catalytic domain) and the second 






 Once the catalytic His of the HK becomes phosphorylated, it transfers the 
phosphate to a conserved Asp residue within the receiver domain of the RR.  This N-
terminal domain, also referred to as its regulatory domain, is well-conserved between 
RRs, like that of the HK’s kinase domain.  CheY, a single-domain RR involved in 
chemotaxis, serves as a representative model for the RR regulatory domains and has had 
its crystal structure determined.  Based upon its crystal structure, the receiver domain is a 
doubly wound α/β protein that has a central five-stranded parallel β sheet surrounded by 
five α helices (238).  Numerous highly conserved residues, along with the catalytic Asp, 
participate in receiving the phosphate within the active site of the domain.  The active-
site cleft is formed by loops that extend from the C-terminal ends of the β strands β1, β3 
A. B. 
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and β5 (271).  This cleft contains the site of phosphorylation, Asp57, located in the 
solvent-exposed loop between β3 and αC (215, 237).  This residue also lies adjacent to 
other acidic residues, Asp12 and Asp13, which aid in coordination of the Mg2+ that is 
required for phosphoryl transfer to the catalytic aspartate.  Additionally, residues Thr87, 
Tyr106, and Lys109 complete the active-site cleft, and have been shown to be involved in 
the phosphorylation-induced conformational change of the RR (8, 274).  Although the 
residues outlined above are those of CheY, numerous X-ray and NMR structures for 
other RR receiver domains (e.g. PhoB, FixJ) suggest an importance for the identical 
residues, albeit in slightly different locations, for those proteins.   
 
Effector domain 
 Once the Asp within the receiver domain has become phosphorylated, 
conformation changes occur within the RR to order to elicit an appropriate response.  
Members of the RR family have a diverse set of output responses, as dictated by their 
effector domains.  Although a small percentage of RRs exist as stand-alone CheY-like 
receiver domains, the majority of RRs (63%) are transcription factors, which have DNA-
binding activity to regulate gene expression (77).  These RRs can be divided into three 
major subfamilies based upon the homology of their DNA-binding domains: the 
OmpR/PhoB winged-helix domains, the NarL/FixJ four-helix domains, and the NtrC 
ATPase-coupled helical DNA binding domains (239).  These domains are well studied 
and have known three-dimensional structures that feature different variants of the helix-
turn-helix DNA-binding structural motif.  Other widespread, but far less common DNA-
binding domains include the AraC, LytR, and PrrA domains (76).  Interestingly, the LytR 
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DNA-binding domain completely lacks an HTH motif, and appears to consist mostly of  
β-strands (226). 
 Those RRs that have an RNA-binding domain, rather than DNA-binding domain, 
exist relatively rarely within RRs (1%) and commonly belong to the ANTAR family of 
regulators (77).  In transcriptional regulators of the AmiR and NasT type, these domains 
stimulate transcription by preventing transcriptional termination at rho-independent 
terminators (184, 224).  RRs that contain a enzymatic domain are found in roughly in 
13% of RRs (77).  The majority of these RRs have domains involved in the regulation of 
cyclic diguanylate (c-di-GMP) levels within cells, as they have c-di-GMP-specific 
phosphodiesterase activity (76).  The remaining enzymatic subfamilies include the 
chemotaxis methylesterase CheB domains, HK domains attached C-terminal to receiver 
domains, and protein phosphatase domains of the PP2C family (77).  Lastly, a small and 
diverse group of RRs contains output domains that have protein-binding capabilities.  
These RRs exert their effects through protein-protein interactions, and can include such 
domains as PAS, GAF, and TPR (76). 
 
Activation by phosphorylation 
 Once the receiver domain of the RR becomes phosphorylated by phosphate 
transfer from the HK, many structural changes occur within the RR to promote its 
activation.  While phosphorylation generally leads to an active protein, for some RRs, 
phosphorylation causes the protein to be in the “off” state.  For most RRs, though, when 
the protein is not phosphorylated, the effector domain is typically inhibited by the 
unphosphorylated receiver domain, which blocks the C-terminal effector region of the 
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protein from carrying out its effect.  Upon phosphate transfer, long-range structural 
perturbations within the protein occur, repositioning the N- and C-terminal domains of 
the RR.  Recently determined structures of the phosphorylated receiver domain of NtrC 
elucidated these changes.  Displacement of β4, β5, αC, and αD away from the active site 
of NtrC exposes a hydrophobic surface that is thought to allow transmission of the 
activation signal to the effector domain (117).  This slight repositioning causes dramatic 
changes to the molecular surface of NtrC and alters the protein topology to allow for 
signal transmission to its transcriptional effector domain and subsequent protein 
activation.  Additionally, the conformation of two highly conserved switch residues, 
Ser/Thr on β4 and Phe/Tyr on β5, reorient towards the active site upon phosphorylation 
to hydrogen bond with the oxygen on the phosphate (77, 94).  While these changes have 
been experimentally demonstrated for NtrC, the range and magnitude of structural 
changes upon phosphoryl activation can vary among RRs, although the general 




Regulation of HK activities 
As has been discussed in detail above, the main role of the HK is that of an 
autokinase, in which it transfers a phosphate from ATP to itself, and then this phospho-
HK serves as a phospho-donating substrate for the RR.  However, many HKs are 
bifunctional.  In addition to their autokinase activity, they possess phosphatase activity 
toward their cognate phosphorylated RRs.  Both the autokinase and phosphatase activities 
of HKs can be regulated directly or indirectly by stimuli.  Regulation of the 
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autophosphorylation can allow for optimization of signal transmission.  One example of 
this appears in the chemotaxis TCS involving the HK CheA.  For this system, CheA is 
either inhibited or stimulated by signals transmitted from its chemoreceptors, in order to 
regulate its signaling intensity (28).  Additionally, for kinases that possess phosphatase 
activity, the ability to decrease the level of RR phosphorylation provides a swift 
mechanism to essentially shut down the signaling pathway.  The phosphatase activity for 
these proteins typically involves amino acid residues located in the dimerization region of 
the kinase domain, and through interaction with the ATP-binding region, enables it to 
regulate its activity (77).  As has been demonstrated by the osmosensor HK EnvZ, the 
catalytic histidine residue is used for reverse transfer that sends the phosphoryl group 
from the RR back to the HK (64).  Together, these mechanisms allow individual TCSs to 
meet their specific needs and optimize signal transmission between the HK and RR.   
 
Regulation of RR dephosphorylation 
 Separate from the phosphatase activity of the HK, many RRs utilize their own 
autophosphatase activity in order to allow for fine-tuning of their specific systems.  Their 
ability to catalyze autodephosphorylation occurs at varying rates, as it can happen very 
quickly, within a matter of seconds, or occur more slowly, taking as long as a few hours 
(77).   Although RR dephosphorylation can be influenced by the phosphatase activities of 
the HKs, in most cases the mechanism appears to be different, as it does not involve the 
catalytic histidine of the HK’s kinase domain (106).  Additionally, for some HKs, it has 
been shown that their phosphatase activity is stimulated by ATP (116).  Moreover, 
dephosphorylation of the RRs can also be effected by auxiliary proteins.  In the B. subtilis 
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sporulation system, a set of three highly regulated phosphatases (RapA, RapB, and RapE) 
dephosphorylate Spo0F (192), while an additional phosphatase (Spo0E) 
dephosphorylates Spo0A (186).   Thus, a significant number of RR dephosphorylation 
mechanisms exist, adding to the numerous regulatory strategies employed within a TCS 
to meet the specific needs of the system.   
 
Other modes 
 In addition to regulating the HK and RR activities, certain systems employ 
additional regulatory mechanisms to control the signal output of the TCS.  Not all TCSs 
have a defined reaction to a stimulus.  Some systems can create a graded response upon 
signal activation while others may produce an all-or-nothing response.  In addition to 
altering the level of RR phosphorylation, an alternative strategy used by numerous TCSs 
is to control the level of gene expression of the RR.  In these systems, the TCS genes are 
subject to autoregulation.   Phosphorylated forms of the RR can function as an either an 
activator or repressor of their own operon (e.g. PhoPQ system of S. typhimurium (231)), 
controlling the amount of their own gene expression.  Moreover, another non-traditional 
regulatory mechanism employed by TCSs such as the E. coli chemotaxis system involves 
one HK phosphorylating more than one RR.  In these ‘branched’ systems, competition 
for phosphoryl groups can influence the activation of both RRs, creating a precise and 
defined reaction in response to potentially complex stimuli.  More elaborate forms of 
these intrinsically branched pathways can exist, with “many-to-one”, “one-to-many”, and 
“many-to-many” relationships occurring.  These added regulatory strategies allow each 
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individual TCSs to create a specific response and modulate signal transmission within its 








E. coli strains, media, and growth conditions 
 E. coli strains used in this study are listed in Table 1.  Strain DH5α was used as 
the host strain for plasmid constructions and was cultured in Luria-Bertani (LB) medium 
(EMD Biosciences).  C41 [DE3] was used for protein expression and cultured in ZYP-
5052 auto-induction media (240).  BTH101 was used for the bacterial two-hybrid studies 
and was plated at 30ºC on MacConkey agar (Difco) supplemented with 1% maltose 
(Sigma).   E. coli was grown at 37ºC with shaking under normal aerobic conditions.  
Growth was measured by a spectrophotometer (Ultraspec 10, Amersham Biosciences) at 
OD600 nm.  Antibiotics were used at the following concentrations: ampicillin 100 µg/ml; 
spectinomycin 100 µg/ml; kanamycin 50 µg/ml, and erythromycin 500 µg/ml. 
 
GAS strains, media, and growth conditions 
 GAS strains used and constructed in the study are listed in Table 1.  GAS was 
cultured in Todd-Hewitt medium supplemented with 0.2% yeast extract (THY; Difco).  
Growth was assayed by optical density with a Klett-Summerson photoelectric colorimeter 
with the A filter.  C media was prepared using a previously described method (151).  
Prior to use, magnesium sulfate (0.4 mM), potassium phosphate (10 mM), and sodium 
chloride (150 mM) were added and the pH of the media was buffered to 7.5 with HEPES 
to achieve a final concentration of 0.1 M.  Antibiotics were used at the following 
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concentrations: spectinomycin 100 µg/ml, kanamycin 300 µg/ml, and erythromycin 1 
µg/ml. 
 
Table 1. Bacterial strains 
 




















M1T1 GAS, clinical isolate, SpeB(+) SpeA(-) Sda1 (low) 
M1T1 GAS, clinical isolate, SpeB(-) SpeA(+) Sda1 (high) 
E. coli, F– cya-99 araD139 galE15 galK16 rpsL1 (StrR) 
hsdR2 mcrA1 mcrB1 
E. coli, F– ompT gal dcm hsdSB (rB- mB-) (DE3) 
E. coli, hsdR17 recA1 gyrA endA1 relA1 
M6 GAS, clinical isolate 
M6 GAS, TrxR- 
M6 GAS, TrxR+ cured strain 
M4 GAS, clinical isolate 
M4 GAS, TrxR- (insertional inactivation of trxR) 
M4 GAS, TrxR+ cured strain 
M1T1 GAS, clinical isolate, Mga- 
M1T1 GAS, clinical isolate, CovS 
M1T1 GAS, TrxR- (insertional inactivation of trxR) 
M1T1 GAS, TrxT- (∆trxT strain) 
M49 GAS 
M49 GAS, TrxR- (insertional inactivation of trxR) 
M49 GAS, TrxR+ cured strain 
   (14) 
   (14) 
  (113) 
 
  (63) 
(90) 
   (207) 
    This study 
    This study 
   (207) 
    This study 
   This study 
   (135) 
   (222) 
   (135) 
This study 
(249) 







 Plasmid DNA was isolated from E. coli by alkaline lysis using either the Wizard 
Miniprep (Promega) or the Midi/Maxi prep purification systems (Qiagen) according to 
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the manufacturer’s instructions.  DNA fragments were isolated from agarose gels using 
either the QIAquick (Qiagen) or Wizard SV (Promega) gel extraction kits. 
 
GAS Chromosomal DNA Isolation 
 GAS chromosomal DNA was isolated as previously described (11, 41).  Briefly, 
15 ml cultures were grown overnight at 37°C with 20 mM glycine and pelleted in the 
morning.  Cells were washed in 10 mM Tris, resuspended in Solution I (1 M Tris, pH 8, 
0.25 M EDTA pH 8, and 50% Sucrose) supplemented with fresh lysosome (130 mg/ml), 
and incubated for 90 minutes with rotation at 37°C.  Cells were pelleted and resuspended 
in Solution II (1 M Tris pH 8, 0.25 M EDTA pH 8, 20% SDS) and incubated at 37°C for 
15 minutes.  To the suspension, RNase A (10 mg/ml) and Proteinase K (20 mg/ml) were 
added and were placed at 55°C for 30 minutes with frequent inversion.  The cell lysate 
was then extracted once with an equal volume of TE-saturated phenol, with 1:1 phenol-
chloroform until the interface cleared, and once with 24:1 chloroform-isoamyl alcohol.  
The DNA was then ethanol precipitated overnight, pelleted, and resuspended in water.  
DNA concentrations were measured by the A260 absorbance on a spectrophotometer 
(Ultraspec 2100 pro, Amersham Biosciences). 
 
Polymerase Chain Reaction 
Polymerase chain reaction (PCR) was performed using Phusion high-fidelity 
polymerase (New England Biolabs, NEB) for cloning and Taq DNA polymerase (NEB) 
for diagnostic assays.  To use Phusion polymerase, annealing temperatures for primers 
were determined using the Finnzymes TM calculator  
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(https://www.finnzymes.fi/tm_determination.html).  Amplification was carried out by an 
initial denaturation step at 98°C for 4 minutes, followed by 35 cycles of denaturation at 
98°C for 10 seconds, a 30 second annealing step at a pre-determined temperature, and an 
extension step at 72°C for approximately 15-30 seconds per kb of DNA.   A final 
extension step for 4 minutes completed the reaction to ensure production of the full-
length product.  To use Taq polymerase, the PCR protocol was modified slightly from 
Phusion: briefly, 30 cycles were used, denaturation was performed at 95°C, and longer 
extension times were used (~1 kb/minute).  Annealing temperatures for use with Taq 
polymerase were determined through Vector NTI software (version 11.0).  PCR reactions 
were purified either by QIAquick PCR purification kit or Wizard SV PCR clean-up 
systems according to manufacturer’s instructions.  DNA sequencing was performed by 
Genewiz, Inc. 
 
PAGE oligonucleotide purification 
The oligonucleotides used in the construction of the mutated HTHs and mutated 
catalytic signaling residues for TrxS and TrxR were PAGE purified prior to annealing.  
Briefly, the lyophilized oligonucleotides pellet (Integrated DNA Technologies) were 
resuspended in 100 µl dH20 with 20 µl formamide stop solution (SequiTherm Excel II 
kit, Epicentre).  The oligonucleotides were then loaded and run on a 10% sequencing gel 
(42% (w/v) urea, 20% (v/v) 5x TBE, 25% (v/v) 40% acrylamide bis solution).  After 
running for 75 minutes, the gel was placed on an intensifying cassette and a short-wave 
UV light was used to locate the DNA bands.  The bands were then excised, crushed, and 
soaked in 10 mM Tris, pH 8.0 overnight, followed by a phenol-chloroform extraction. 
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Table 2. PCR primers 
 
































































































M1 trxR effector-nde 
M1 trxR effector-xho 
M1 trxR linker-nde 
M1 trxR linker-xho 
M1 trxR Nde-L 





















 Spt10PE CTATATAATTTCATCAGTCG (135) 















 trxR D55A R 
 
trxR D55E L 
 














 TrxR HTH-1 YL413AL-L 
 
TrxR HTH-1 YL413AL-R 
 













TrxR HTH-1 AL413AA-R 
 
TrxR HTH-2 NH461AA-L 
 
TrxR HTH-2 NH461AA-R 
 

















trxS M1 trxS Nde-L ggcgcatatgATTGACGAAGTTTATG This study 
 M1 trxS Xho-R gcgctcgagAGCATCCTTTCTAATC This study 
 T18C-trxS-trun-BamHI 
T18C-trxS-XmaI 








 trxS H383A R 
 








Lowercase letters represent additional sequence added.  Underline text denotes added restriction sites. 
 
Enzymatic DNA modifications 
 Enzymatic DNA modifications were performed using enzymes according to the 
manufacturer’s suggested conditions.  Restriction digests were performed using enzymes 
and buffers from NEB for 2 hours at their optimal temperatures.  Ligation reactions using 
T4 ligase (NEB) were performed at 16°C overnight.  T4 polynucleotide kinase (PNK, 





E. coli competent cells 
To prepare DH5α or C41 [DE3] competent cells, 500 ml of LB broth was 
inoculated with a 5 ml overnight starter culture and grown to an OD600 of around 0.6.  
Cells were placed on ice for 30 minutes in order to cool them and stop their growth 
minutes prior to centrifugation at 6,000 x g for 15 minutes at 4°C.  After the initial 
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pelleting, cells were washed three times in ice-cold sterile 10% glycerol.  After the final 
wash, cells were resuspended in 800 µl of 10% glycerol and split into 50 µl aliquots. 
Aliquots were stored at -80°C for no more than one year. 
 
GAS competent cells 
To prepare competent GAS cells for transformations, 150 ml of THY broth 
containing 20 mM glycine was inoculated with a 7.5 ml overnight starter culture and was 
incubated static at 37°C until OD600 reached between 0.2 and 0.3.  Cells were placed on 
ice for 30 minutes in order to cool them and to stop their growth prior to centrifugation at 
8,000 x g for 20 minutes at 4°C.  The pelleted cells were washed three times with 20 ml 
of cold 10% glycerol.  After the final wash, the cells were resuspended in 800 µl of 10% 




 To remove excess salts prior to electroporation of DNA into either E. coli or 
GAS, DNA was drop-dialyzed over dH20 on a 0.025 µM membrane filter (Millipore) for 
30-60 minutes.  Electroporation of both E. coli and GAS were performed using a 
GenePulser Xcell (Bio-rad).  For electroporation of E. coli, the 50 µl competent cell 
aliquot was mixed with the drop-dialyzed DNA in a pre-chilled 2 mm cuvette and 
transformed using the following settings: 2.5 kV, 200 Ω, and 25 µF.  Cells were 
immediately added to 1 ml LB broth and outgrown for 1 hour at 37°C shaking, prior to 
centrifugation at 6,000 x g.  Pelleted cells were resuspended in 100 µl saline and plated 
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on the appropriate antibiotic for selection.  For electroporation of GAS, a similar protocol 
was used with the 200 µl competent cell aliquot with the following electroporator 
settings: 1.75 kV, 400 Ω, and 25 µF.  Cells were placed in 10 ml THY broth and 
outgrown static for 2 hours at 37°C.  Cells were pelleted at 8,000 x g and resuspended in 





A. Plasmid constructions 
 
Construction of PtrxT-luc vectors, pKSM637 and pKSM670 
 Wild type PtrxT was amplified from MGAS5005 (Table 1) using primers M1 
PSpy1307-Xho-L and M1 PSpy1307-Bgl-R (Table 2).  The 620 bp promoter PCR 
fragment was BglII/XhoI digested and ligated into BglII/XhoI-digested luciferase 
plasmid pKSM720 (Table 1) to form pKSM637. 
 Truncated PtrxT was amplified from MGAS5005 (Table 1) using primers M1 
PSpy1307-Xho-L-2 and M1 PSpy1307-Bgl-R-2 (Table 2), which deleted the last 65 bp 
from the promoter region. The promoter PCR fragment was BglII/XhoI digested and 















































trxR insertional inactivation plasmid 
ColE1 ori ApR lacZα 
Gene replacement/shuttle vector for E. coli and GAS with KmR 
Replicating vector for GAS with SpR 
Replicating vector for GAS with KmR 
GAS replicating plasmid containing PrpsL 
GAS replicating plasmid PrpsL-TrxR 
∆trxT mutagenic plasmid with non-polar aad9 
GAS replicating plasmid with PtrxT-luc 
Expression vector M1 GAS His-MBP-TrxS (signaling region) 
trxT complementing vector  
Expression vector M1 GAS His-MBP-TrxS H383A 
Expression vector M1 GAS His-MBP-TrxR 
Expression vector M1 GAS His-MBP-TrxR D55A 
Expression vector M1 GAS His-MBP-TrxR D55E 
PtrxT-luc truncated  
GAS replicating plasmid PrpsL-His-MBP-TrxR 
GAS replicating plasmid PrpsL-His-MBP-TrxR D55A 
GAS replicating plasmid PrpsL-His-MBP-TrxR D55E 
GAS replicating plasmid PrpsL-His-MBP-TrxR HTH-1 mutant  
GAS replicating plasmid PrpsL-His-MBP-TrxR HTH-2 mutant  
GAS replicating plasmid PrpsL-His-MBP-TrxR HTH-1/2 mutant 
T25C-tagged TrxS (signaling region) KmR 
GAS replicating plasmid with firefly luciferase and RBS 
GAS replicating plasmid with Pmga-luc SpR 
Expression vector M1 GAS His-MBP-TrxR HTH-1/2 mutant 
Expression vector M1 GAS His-MBP-TrxR (∆effector) 
Expression vector M1 GAS His-MBP-TrxR (∆receiver) 
Expression vector M1 GAS His-MBP-TrxR (effector only) 
GAS replicating plasmid PrpsL-His-MBP-TrxR (∆effector) 
GAS replicating plasmid PrpsL-His-MBP-TrxR (∆receiver) 
GAS replicating plasmid PrpsL-His-MBP-TrxR (effector only) 
T18C-tagged TrxS (signaling region) ApR 
Replicating vector for GAS with EmR 
Vector containing non-polar aad9 gene 
T18 expressing two-hybrid vector with linker 
T25 expressing two-hybrid vector with linker 
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Gift, D. Kearns 
 




Construction of allelic exchange vector pKSM636 for creation of MGAS5005.trxT  
SOE PCR (splicing by overlap extension by the polymerase chain reaction) (98) 
was used to make a non-polar deletion of the trxT gene.  The primers Spy1307-1a/b 
(Table 2) were created to amplify a 1,060 bp upstream region from MGAS5005 (Table 1) 
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containing the first twenty nucleotides of trxT, a BglII site, and a 10 bp overlap with the 
second fragment at the 3’ end.  A second set of primers, Spy1307-2a/b (Table 2), were 
created to amplify a 1,080 bp downstream region from MGAS5005 (Table 1) containing 
the last 58 nucleotides of trxT, with a BglII site at the 5’ end.  These fragments were then 
combined as template DNA using the Spy1307-3a/b primers to generate the deletion.  
The resulting product was then blunt-end ligated into a HincII-digested pBluescript II KS 
(-) (Table 3).  The non-polar, promoterless spectinomycin resistance gene (aad9) was 
amplified from pSL60-1 (Table 3) using primers aad9-L2-bglII and aad9-R2-bglII (145) 
(Table 2), digested with BglII, and ligated into a BglII-digested pBluescript∆trxT.  The 
∆trxT-aad9 fragment from pBluescript∆trxT was then PCR amplified using Phusion HF 
DNA polymerase and ligated with the temperature-sensitive gene replacement/shuttle 
vector pCRK (Table 3), digested with BamHI, to yield the final pKSM636 ∆trxT mutant 
(Table 3). 
 
Construction of trxT complementation vector, pKSM649 
 trxT along with its native promoter was amplified from the serotype M1 strain 
MGAS5005 (Table 1) using primers Spy1307-Eco and Spy1307-Xba (Table 2).  Both the 
PCR product and pKSM201 (Table 3) were EcoRI/XbaI-digested and the two were 
ligated together to create pKSM649 (Table 3). 
 
Construction of TrxS two-hybrid plasmids, pKSM699 and pKSM741 
 The signaling domain of M1 GAS TrxS (aa 358-574) was PCR amplified from 
MGAS5005 (Table 1) using primers T18C-trxStrun-BamHI and T18C-trxS-XmaI (Table 
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2).  The product was digested with BamHI/XmaI and ligated into BamHI/XmaI-digested 
plasmids pT25C-link and pT18C-link (Table 1) to form pKSM699 and pKSM741, 
respectively.  The resulting plasmids were verified through DNA sequencing to confirm 
an ORF that would express TrxS in-frame with the adenylate cyclase fragment. 
 
Construction of recombinant GAS TrxS and TrxR expression vectors, pKSM643 
and pKSM655 
 An amino-terminal fusion of 10xHistidine-MBP to the signaling domain of M1 
GAS TrxS (aa 358-574) was constructed as described below.  A 670 bp region containing 
the signaling domain was PCR amplified from M1 MGAS5005 (Table 1) gDNA using 
the primer pair M1 TrxS Nde-L and M1 TrxS Xho-R (Table 2).  The resulting product 
was digested with NdeI/XhoI and ligated into NdeI/XhoI-digested pVL847 (Table 3) to 
produce pKSM643 (Table 3).  Following PCR verification and DNA sequence analysis, 
pKSM643 was transformed into C41 [DE3] (Table 1) for protein expression. 
 An amino-terminal fusion of 10xHistidine-MBP to full-length M1 TrxR was 
constructed by PCR amplifying a 1,497 bp region from M1 MGAS5005 (Table 1) gDNA 
using the primer pair M1 TrxR Xho-L and M1 TrxR Nde-L (Table 2).  The resulting 
product was digested with XhoI/NdeI and ligated into XhoI/NdeI-digested pVL847 
(Table 3) to produce pKSM655 (Table 3).  After PCR verification and DNA sequence 





Construction of expression plasmids containing mutated signaling residues, H383 
(TrxS) and D55 (TrxR) 
 Using pKSM643 (His-MBP-TrxS) and pKSM655 (His-MBP-TrxR) as template 
DNA (Table 3), point mutations were made in the catalytic residues using the 
Quikchange II site-directed mutagenesis kit (Stratagene).  Briefly, using either pKSM643 
or pKSM655 as the template vectors, PAGE-purified oligonucleotides containing the 
mutated residue, each complementary to opposite strands of the vector, were extended 
during 16 cycles by PfuUltra HF DNA polymerase.  For the extension time, 7.5 and 8.4 
minutes were used for His-MBP-TrxS and His-MBP-TrxR, respectively.  To create 
H383A in His-MBP-TrxS, primers TrxS H383A-L and TrxS H383A-R (Table 2) were 
used.  In a similar manner, to create D55A or D55E in His-MBP-TrxR, primers TrxR 
D55A-L and TrxR D55A-R or TrxR D55E-L and TrxR D55E-R (Table 2) were used.  
Following temperature cycling, the PCR product was DpnI treated and transformed into 
ElectroMAX DH5alpha electrocompetent cells.  Upon sequence analysis and mutation 
verification, the plasmid was digested with NdeI/XhoI and the trxS or trxR fragment was 
moved into a clean pVL847 (Table 3) plasmid cut with NdeI/XhoI in the DH5α 
background.  The resulting plasmids were named pKSM654, pKSM657, and pKSM662, 
representing His-MBP-TrxS H383A, His-MBP-TrxR D55A, and His-MBP-TrxR D55E  
(Table 3), respectively. 
 
Construction of His-MBP-TrxR complementation vectors, pKSM678, pKSM680, 
pKSM690 
 To place wild type His-MBP-TrxR under the constitutive promoter, PrpsL, His-
MBP-TrxR was amplified from pKSM655 (Table 3) using primers His-MBP-TrxR-Hind 
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and His-MBP-TrxR-Sph (Table 2).  After digestion of the PCR product with HindIII and 
SphI, it was cloned into pKSM324 also cut with HindIII and SphI.  The resulting 
pKSM678 plasmid (Table 3) was confirmed through DNA sequencing.  
 To make the mutant pKSM680 His-MBP-TrxR D55A (Table 3) under PrpsL, His-
MBP-TrxR D55A was amplified from pKSM657 (Table 3) using the same strategy as 
above.  pKSM690 (Table 3), PrpsL-His-MBP-TrxR D55E, was created in the same 
manner, amplified from pKSM662 (Table 3).   
 
Construction of TrxR HTH-1/2 mutant vector, pKSM697 
 To mutate the two amino acids in each putative helix-turn-helix (HTH) domain of 
TrxR to alanines, a 3-step approach was employed.  First, using pKSM678 (Table 3) as 
the template plasmid, two base pairs within the first amino acid of HTH-1 were mutated 
to change Tyr (TAT) to Ala (GCT) using the Quikchange II site-directed mutagenesis kit 
(Stratagene). Briefly, PAGE-purified oligonucleotides containing the mutated residue, 
each complementary to opposite strands of the vector, were extended using the primers 
TrxR HTH-1 YL413AL-L/R (Table 2) for 6.45 minutes during 18 cycles by PfuUltra HF 
DNA polymerase.  Following temperature cycling, the PCR product was DpnI treated 
and transformed into ElectroMAX DH5alpha electrocompetent cells (Invitrogen).  Upon 
sequence analysis and mutation verification, the plasmid was digested with HindIII/SphI 
and the fragment was moved into a clean pKSM324 (Table 3) plasmid cut with 
HindIII/SphI in the DH5α background. The resulting plasmid was named pKSM691 
(Table 3). 
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In the second step, four point mutations were made within HTH-2 of pKSM691 to 
change Asn (AAT) His (CAT) to Ala (GCT) Ala (GCT) in a similar manner as above 
using primers TrxR HTH-2 NH461AA-L/R (Table 2).  The sequence was verified and the 
fragment was moved into a clean plasmid background, creating pKSM694 (Table 3). 
In the final step to make PrpsL-His-MBP-TrxR HTH-1/2, two additional point 
mutations within pKSM694 were made to change the second amino acid of HTH-1 Leu 
(CTA) to Ala (GCA) with primers TrxR HTH-1 AL413AL-L/R (Table 2) using the 
Quikchange method.  The final PrpsL-His-MBP-TrxR HTH-1/2 plasmid was named 
pKSM697 (Table 3). 
 
Construction of TrxR HTH-1/2 expression plasmid, pKSM733 
 TrxR HTH-1/2 was PCR amplified from pKSM697 (PrpsL-His-MBP-TrxR HTH-
1/2) (Table 3) using the primer pair M1 TrxR Xho-L and M1 TrxR Nde-L (Table 2).  The 
resulting product was digested with XhoI/NdeI and ligated into XhoI/NdeI-digested 
pVL847 (Table 3) to produce pKSM733 (Table 3).  After PCR verification and DNA 
sequence analysis, pKSM733 was transformed into C41 [DE3] (Table 1) for protein 
expression. 
 
Construction of plasmids containing truncated forms of His-MBP-TrxR  
 To create truncated His-MBP-TrxR proteins, the designated regions of the protein 
were first cloned into pVL847 (Table 3) resulting in TrxR in-frame with His-MBP.  
Briefly, the receiver-linker, ∆effector (bp 1-1167), linker-effector, ∆receiver (bp 351-
1485), or effector alone (bp 1167-1485) were PCR amplified from the MGAS5005 
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(Table 1) chromosome with added NdeI/XhoI sites using the following primer pairs: M1 
TrxR-NdeI/M1 TrxR-linker-Xho, M1 TrxR linker-Nde/M1 TrxR effector-Xho, and M1 
TrxR effector-Nde/M1 TrxR-effector-Xho (Table 2), respectively.  The digested PCR 
fragments were cloned into NdeI/XhoI-digested pVL847 and the resulting plasmids 
(pKSM734, pKSM735, and pKSM736 (Table 3) were confirmed through DNA 
sequencing. 
To place the His-MBP-TrxR proteins under PrpsL, the entire His-MBP-TrxR 
regions were PCR amplified from pKSM734-736 (Table 3) using the following sets of 
primers with added HindIII/SphI sites: His-MBP-TrxR-Hind/His-MBP-TrxR-linker for 
His-MBP-TrxR ∆effector and His-MBP-TrxR-Hind/His-MBP-TrxR-effector for 
∆receiver and effector-alone (Table 2).  The digested PCR fragments were cloned into 
HindIII/SphI-digested pKSM324 (Table 3) and the resulting plasmids pKSM737, 
pKSM738, and pKSM739 (Table 3) were confirmed through DNA sequencing.   
 
 
B. Strain constructions 
 
Temperature-sensitive allelic exchange of pKSM636 to create MGAS5005.trxT 
 MGAS5005 (Table 1) was transformed with pKSM636 (Table 3) as previously 
described (195).  Briefly, after electroporation, cells were outgrown for four hours at 
30°C prior to plating on plates containing both kanamycin and spectinomycin selection.  
Plates were incubated at 30°C until isolated colonies appeared.  Colonies were inoculated 
into liquid cultures with kanamycin and spectinomycin selection and passaged twice 
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overnight at 30°C.  Cells were then passaged twice at 37°C with spectinomycin selection 
only and were serially diluted onto THY spectinomycin agar and incubated at 37°C.  
Mutants were screened by sensitivity to kanamycin and verified by PCR across the trxT 
gene using primers Spy1307-L/R (Table 2). 
 
Inactivation of trxR in GA40634 and NZ131 
 trxR was inactivated in M4 GA40634 and M49 NZ131 (Table 1) using the 
temperature-sensitive integration method as previously described (194).  Briefly, plasmid 
p233-10R (Table 3) was electroporated into GA40634 and NZ131, followed by passage 
twice at 30°C with erythromycin selection. To allow for integration of the plasmid, cells 
were passaged twice at 37°C under erythromycin selection.  Integrants were screened by 
PCR for junctions and absence of the wild type trxR gene using the primers Spt10R-L1 
and Spt10R-R1 (Table 2). 
 
Creation of cured GA40634.trxR and NZ131.trxR 
The strains GA40634.trxR and NZ131.trxR (Table 1) were cured of the plasmid 
inactivating trxR by passage in liquid culture five times at 30°C and one time at 37°C 
with no drug selection.  PCR was used to screen for the intact trxR gene and restoration 








RNA extraction and DNase treatment 
 RNA was isolated using a Triton X-100 method as previously described (245).  
Briefly, 10 ml of THY broth was inoculated 1:20 from an overnight culture and grown to 
the appropriate Klett unit.  Cells were then pelleted by centrifugation at 9,000 x g for 10 
minutes at 4°C.  Cells were then resuspended in TE buffer containing 0.2% Triton X-100 
(v/v) and boiled for 10 minutes.  Upon cooling, the lysate was extracted with chloroform-
isoamyl alcohol twice and ethanol precipitated at -80°C for 25 minutes.  The reaction was 
then pelleted at 10,000 x g for 10 minutes and washed with 1 ml of 70% ethanol.  The 
RNA was finally resuspended in DEPC-treated water and quantified using a 
spectrophotometer.  The RNA was assessed for quality on a formaldehyde gel (18% (v/v) 
formaldehyde, 1% (w/v) agarose, 72% (v/v) DEPC-treated water, and 10% (v/v) 10x 
MOPS. 
RNA for microarray and real-time RT-PCR analysis was treated with Turbo 
DNase (Applied Biosystems) to remove genomic DNA (gDNA) from the sample.  
Briefly, approximately 20 µg of RNA was incubated with DNase and RNase inhibitor at 
37°C for 40 minutes according to the manufacturer’s instructions followed by one 
extraction with chloroform:isoamyl-alcohol.  A PCR reaction was then performed on 0.5 
µl of the DNased RNA to verify complete degradation of the gDNA and a RNA integrity 





 RNA for RT-PCR was treated with DNase to remove residual gDNA.  cDNA was 
then generated using the SuperScript first-strand synthesis kit for RT-PCR (Invitrogen) 
according to manufacturer’s instructions. Briefly, the DNA-free RNA was denatured at 
65ºC for 5 minutes, snap cooled on ice, and incubated with dNTPs and the random 
hexamer primers for 10 minutes at 25ºC.  Reactions with and without (control) reverse 
transcriptase were then incubated at 50ºC for 50 minutes to allow for cDNA synthesis. 
The reactions were then heated to 85ºC for 5 minutes, stopping the reaction, and the 
samples were treated with RNase H for 20 minutes at 37ºC to remove original RNA 
template.  PCR reactions were then performed on the RT+ and RT- cDNA samples, as 
well as on gDNA, using Taq polymerase.  The following primer sets were used to 
amplify intragenic regions within the trxTSR operon: trxT-trxS (Spt10PE and Spy1589-
R); trxS-trxR (trxS M1 RT-L and trxR M1 RT-R); trxR-bgaA (srxR-Spy1586 RT-L and 
srxR-Spy1586 RT-R); and trxS-bgaA (Spt10R-L1 and Bgal-L). 
 
Microarray 
Microarray experiments were performed as previously described (207).  Briefly, 
total RNA from 3 biological replicates was isolated from MGAS5005 containing the 
empty vector pJRS525 and the isogenic trxR mutant strain MGAS5005.trxR containing 
the empty vector pJRS525 at late-logarithmic phase (100 Klett units) using the TritonX-
100 isolation protocol.  Both strains were grown in the presence of spectinomycin for the 
overnight seed cultures, but not during growth for RNA isolation.  DNase I-treated RNA 
samples were converted to cDNA with an amino-allyl UTP and were Cy3 and Cy5 
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labeled using the Amino Allyl cDNA Labeling Kit (Ambion) to allow for dye-swap 
experiments.  Yield and incorporation rate of the labeled cDNA was determined using a 
Nanodrop ND-1000 (Nanodrop Technologies).  Equal volumes (35.42 µl) of labeled Cy5 
cDNA and Cy3 cDNA were dried under vacuum, resuspended in 23.8 µl of dH2O and 
boiled for 5 minutes followed by cooling on ice for 5 minutes. 5x Hybridization Buffer 
(17 µl) (GE Healthcare) and formamide (27.2 µl) were added to the cDNA and applied to 
array slides under raised cover slip (Lifterslip, Inc).  Microarray slides were hybridized at 
50°C overnight in slide chambers (Array It).  Slides were washed twice for 10 minutes 
each in the following buffer concentrations and temperatures: 6X SSPE/0.01% Tween-20 
at 50°C, 0.8X SSPE/0.001% Tween-20 at 50°C, and 0.8X SSPE at RT.  Slides were 
scanned using a Genepix 4100A personal array scanner and GenePixPro 6.0 software 
(Axon Instruments). 
 Data obtained from the wild type and trxR mutant strains were compared for 2-
fold changes in expression, ≥ 2.0 or ≤ 0.50, and was analyzed using Acuity 4.0 software 
(Axon Instruments).  Using a ratio-based normalization, data was normalized by the ratio 
of the means and samples were removed when 4 out of the 6 experiments did not show 
significance.  Validation of array data was carried out by real-time RT-PCR of 12 
differentially regulated genes using primers listed in Table 4.  Correlation coefficients for 
the arrays were determined by plotting the log value of the array on the X-axis to the log 
value of the real-time RT-PCR on the Y-axis.  An equation determining the line of best 
fit was determined, and the resulting R2 value was calculated, which represented the 
fitness of the data.  
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Table 4. Real-time PCR primers 
 
Target Primer   Sequence (5’-3’) Reference 
arp arp M4 RT-L 





atpB atpB M1 RT-L 





clpL clpL M1 RT-L 





emm emm1 RT-L 
emm1 RT-R 
emm M49 RT-L 









fasB fasB M1 RT-L 





fba fba M1 RT-L 





gyrA gyrA M1 RT-L 





lacD.2 lacD.2 M1 RT-L 





lacE lacE M1 RT-L 





lacF lacF M1 RT-L 





mga mga M1 RT-L 
mga M1 RT-R 
mga M6 RT-R 









opuAA opuAA M1 RT-L 





sclA sclA M1 RT-L 





scpA scpA M1 RT-L 





sic sic M1 RT-L 





slo slo M1 RT-L 







srxR M1 RT-L1 
srxR M1 RT-R1 
trxR M1 RT-L3 









trxS trxS M1 RT-L 





trxT Spy1307 M1 RT-L4 
Spy1307 M1 RT-R4 
TGAAAAGGGCTGTTCAACTTT 
AAGGAAAGTCAGGGCAAAAA 








Briefly, 25 ng of DNase I treated total RNA was added to Sybr Green Master Mix 
(Applied Biosystems) containing 5 µg of each specific real-time primer (Table 4) and 
combined with 5.75 units of MultiScribe reverse transcriptase (Applied Biosystems) in a 
25 µl volume for one-step, real-time RT-PCR.  The reactions were run on a Lightcycler 
480 (Roche) to detect transcript levels in the relative quantification mode with reaction 
conditions of 48°C for 30 minutes, 95°C for 10 minutes, and 40 cycles of 95°C for 15 
seconds followed by 60°C for 1 minute.  Transcript levels presented represent ratios of 
wild type/experimental relative to the level of gyrA transcript.   All primers used in real-




 To identify the promoter upstream of trxT, the 5’/3’ Race Kit (Roche, 2nd 
generation) was used following the manufacturer’s protocol.  Briefly, for 1st strand cDNA 
synthesis, 2 µg of DNase-treated MGAS5005 total RNA was incubated with buffer, 
primer Spy1307 SP1, the deoxynucleotide mixture, and Transcriptor Reverse 
Transcriptase (RT) for 60 minutes at 55°C and then for 5 minutes at 85°C to heat-
inactivate the RT.  The resulting cDNA was purified using Qiagen’s QIAquick PCR 
purification kit.  The addition of a homopolymeric A-tail (dA) to the first-strand cDNA 
was accomplished through the addition of 2 mM ATP to the purified cDNA sample.  This 
was incubated for 3 minutes at 94°C, and then Terminal Transferase was added to the 
reaction and it was incubated at 37°C for 20 minutes.  The Terminal Transferase was then 
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heat-inactivated at 70°C for 10 minutes.  PCR amplification of the dA-tailed cDNA was 
achieved by a 2-step reaction procedure.  The first PCR reaction included a primer 
specific to the dA-tail accompanied by a primer for trxT (SP2, SP4, or SP6) to amplify 
the entire piece of cDNA.  A second nested PCR reaction was then used to obtain a more 
specific region within the trxT gene using primer Spy1307 SP3, SP5, or SP7.  The 
resulting dsDNA was purified using the QIAquick kit (Qiagen) and sequenced to identify 





Protein expression and purification 
 GAS His-MBP-TrxR was purified consecutively over amylose and Ni-NTA 
resins based upon manufacturer’s protocols.  Briefly, cells were grown in ZYP-5052 
auto-induction media for 20 hours at 30°C and the resulting cell pellets stored at -80°C.  
The frozen pellets were lysed in the presence of 1 mg/ml lysozyme and 1x Complete 
Protease Inhibitor (Roche) using a Branson sonicator (6 cycles of 45 second pulses at 
50% duty cycle, output of 7.5).  His-MBP-TrxR was purified from the resulting lysate 
over the amylose resin under native conditions and directly applied to the Ni-NTA resin.  
Chosen fractions were then dialyzed into 50 mM Tris-HCl, pH 7.5 overnight and glycerol 
was added to 10% prior to storage at -80°C.  A similar expression and purification 
scheme was followed for the His-MBP-TrxR D55A and His-MBP-TrxR D55E mutants. 
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 The signaling domain of GAS TrxS tagged with His-MBP was purified 
consecutively over amylose and Ni-NTA resins based upon manufacturer’s protocols.  
Briefly, cells were grown in ZYP-5052 auto-induction media for 24 hours at 30°C and 
the resulting cell pellets stored at -80°C.  The frozen pellets were lysed in the presence of 
1 mg/ml lysozyme and 1x Complete Protease Inhibitor (Roche) using a Branson sonicator 
(6 cycles of 45 sec pulses at 50% duty cycle, output of 7.5).  His-MBP-TrxS was purified 
from the resulting lysate over the amylose resin under native conditions and directly 
applied to the Ni-NTA resin.  Chosen fractions were then stored as aliquots at -80°C.  A 
similar method was used for purification of His-MBP-TrxS H383A. 
 
GAS protein extracts 
 Soluble GAS protein extractions were performed using a PlyC (courtesy of Daniel 
Nelson, IBBR) extraction method.  Briefly, GAS cells were inoculated 1:20 into 10 ml 
THY broth, grown to the appropriate Klett unit, and pelleted by centrifugation for 10 
minutes at 8,500 x g.  Pellets were resuspended in 190 µl TN buffer (10 mM Tris-HCl, 
pH 8.0, 150 mM NaCl), and 10 µl DNase and 7 µl PlyC were added. The cells were 
inverted 5-6 times and placed on ice for 20 minutes, followed by centrifugation at 13,000 
x g for 20 minutes.  Supernatants containing the soluble proteins were extracted and 
protein concentration was assayed using the Bio-Rad protein assay kit, reading the 





SDS-PAGE gel analysis 
 SDS-polyacrylamide gels (SDS-PAGE) were made as follows: a 10% resolving 
gel was mixed and poured followed by a 6% stacking gel using the reagents found in 
Table 5.  Protein samples were mixed with 5x cracking buffer, boiled at 99°C, and loaded 
into the wells.  SDS-PAGE gels were run at 180V for 50 minutes.   
 
Table 5. SDS-PAGE buffer 
10- 15% Resolving gel 6% Stacking gel 
26% (v/v) Lower gel stock 25% (v/v) Upper gel stock 
25-37.5% (v/v) 40% Acrylamide/ bis solution 15% (v/v) 40% Acrylamide/ bis solution 
0.5% (v/v) 10% ammonium persulfate 0.5% (v/v) 10% ammonium persulfate 
0.1% (v/v) tetramehylethylene diamine 0.1% (v/v) tetramehylethylene diamine 
Brought up with H2O Brought up with H2O 
  
Lower gel stock Upper gel stock 
1.5M Tris-HCl pH 8.8 0.5M Tris-HCl pH 8.8 
0.4% (w/v) SDS 0.4% (w/v) SDS 
Brought up with H2O Brought up with H2O 
SDS running buffer Coomassie blue stain 
25mM Tris 0.25% (w/v) coomassie blue 
190mM Glycine 45.4% (v/v) methanol 
0.1% (w/v) SDS 9.2% (v/v) glacial acetic acid 
Brought up with H2O Brought up with H2O 
  
Destain solution Gel drying solution 
5% (v/v) methanol 3% (v/v) glycerol 
7.5% (v/v) glacial acetic acid 20% (v/v) EtOH 
Brought up with H2O Brought up with H2O 
  
5x Cracking buffer Transfer buffer 
0.3M Tris pH 6.8 25mM Tris base 
25% (v/v) 2-mercaptoethanol 0.2M glycine 
51% (v/v) glycerol Brought up with 20% methanol 
10% (w/v) SDS PBS-Tween 
0.01% (w/v) bromophenol blue 0.01M PBS pH 7.4 
Brought up with H2O 0.5% Tween-20 





 Selected protein samples were run on a 10% SDS-PAGE gel with 6% stacking gel 
for approximately 50 minutes at 180V.  The gels were then transferred to nitrocellulose 
membranes using the Mini-Protean apparatus (Bio-Rad) in 1x transfer buffer (25 mM 
Tris base, 0.2 M glycine, brought up with 20% methanol).  Membranes were blocked 
overnight at 4°C in blocking solution (5% (w/v) dried milk in PBS-tween).  For detection 
of His-tagged proteins, blots were incubated with a 1:1,000 dilution α-His antibody 
(Novagen) for two hours, followed by a 10 minute wash in PBS-tween.  For detection of 
TrxS, blots were incubated with a 1:500 dilution α-TrxS polyclonal antibody, followed 
by the same 10 minute wash.  For detection of HSP-60, blots were incubated with a 
1:2,500 dilution α-HSP-60 antibody (Stressgen) for two hours, followed by the same 10 
minute wash.  Blots were then incubated with a 1:20,000 α-mouse-HRP antibody (His-
tagged proteins, HSP-60) or 1:20,000 α-rabbit-HRP antibody (TrxS) for one hour, 
washed 3 times in PBS-tween for 20 minutes, and visualized using SuperSignal West 
Femto Substrate (Thermo Scientific) and a LAS-3000 CCD camera (FujiFilm). 
 
Co-immunoprecipitation assay 
 A mouse α-His monoclonal antibody (Roche) was used to precipitate His-MBP-
tagged TrxR in GAS lysates.  MGAS5005.trxR strains were grown in THY under 
spectinomycin selection to late-logarithmic phase (~ Klett 105).  Cells were pelleted and 
lysed with the cell wall hydrolase PlyC (courtesy of Daniel Nelson, IBBR) (179), to 
release the soluble proteins, along with 2 units DNase I.  The collected lysate fractions 
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were diluted 1:1 in complete PBS buffer (pH 7.3, supplemented by protease inhibitors) 
and incubated with constant rocking at 4°C for 15 minutes with Protein A agarose slurry 
(Calbiochem), 50% equilibrated in 0.5% BSA (Sigma) in dH20.  The samples were 
centrifuged for 1 minute to pull down non-specific proteins bound to the agarose beads.  
The supernatant was transferred to fresh tubes containing the α-His antibody, and 
incubated at 4°C for 2 hours with rocking.  Protein A agarose slurry was added to the 
samples after the first hour of incubation to bind the protein-antibody complex to the 
beads.  After pelleting the beads, the supernatant was removed and the slurry was washed 
in the PBS buffer.  The samples were then heat denatured at 99°C for 10 minutes to 
dissociate the proteins bound to the beads.  The samples were then pelleted once again, 
collecting the supernatant samples.   
 
Bacterial two-hybrid assay 
 The selected plasmids for analysis were co-transformed (1 µl each) into BTH101, 
electroporated, and outgrown for 1 hour at 37°C.  The bacteria were plated on 
MacConkey agar supplemented with 1% maltose and placed at 30°C overnight.  
Following overnight incubation, colonies were patched onto a fresh MacConkey-maltose 
plate and placed at 30°C overnight.   
 
TrxS-TrxR in vitro phosphorelay  
 To produce phosphorylated TrxS for transfer to TrxR (TrxS~P), a 50 µl reaction 
was prepared (50 mM Tris, pH 7.5, 10 mM MgCl2, 50 mM KCl, 1 mM dithiothreitol, 
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10% glycerol, 63.4 µM TrxS or TrxS:H383A).  20 µCi of [γ-32P]ATP (Perkin Elmer) was 
added to both labeling reactions, and samples were incubated at room temperature.  At 
15, 30, 45, and/or 60 minutes after the addition of radiolabeled ATP, 5 µl samples were 
removed and mixed with 2X SDS loading buffer.  At 60 minutes, TrxR was added to 
TrxS at a concentration of 534 µM.  5 µl samples were taken 0, 0.5, 1, 5, and 10 minutes 
after the addition of TrxR to TrxS, and 1, 5, and 10 minutes after the addition of TrxR to 
TrxS:H383A. 
To produce phosphorylated TrxS for transfer to TrxR/TrxR:D55A, a 50 µl 
reaction was prepared containing 67 µM TrxS.  TrxR and TrxR:D55A were added to the 
appropriate reactions at a concentration of 674 µM.  5 µl samples were taken 1, 5, 10, or 
20 minutes after the addition of TrxR:D55A to TrxS.   
Samples were loaded onto 10% polyacrylamide gels, run at 4°C, and after SDS-
PAGE, gels were dried for 30 minutes under no heat and scanned using a FujiFilm 
FLA7000.  The resulting data was analyzed with Multigauge analysis software (FujiFilm, 
version 3.0). 
 
Electrophoretic mobility shift assay (EMSA) 
 Promoter probes were generated by PCR amplification with Phusion HF DNA 
polymerase using MGAS5005 gDNA and the relevant primer pairs (Pmga, Pemm) listed 
in Table 2.  PCR fragments were end-labeled with [γ32P]-ATP and purified over a spin-
column (Harvard Apparatus) to remove unbound [γ32P]-ATP. 
 Mobility shift assays were performed with a total volume of 50 µl.  Each reaction 
included 5x binding buffer (100 mM Tris, pH 7.5, 5 mM CaCl2, 5 mM dithiothreitol, 50 
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µg/ml poly(dI-dC), and 200 µg/ml BSA), a constant amount of labeled promoter probe 
(2-4 ng), and various concentrations of purified His-MBP-TrxR proteins.  DNA and 
proteins were incubated at either 16°C or 25°C for 20 minutes, after which 10 µl of ficoll 
loading buffer (1% v/v ficoll and 0.02% w/v bromophenol blue) and 2 µl of 80% glycerol 
were added, mixed, and immediately loaded onto a 5% polyacrylamide gel at 4°C or 
25°C, and run at 180 V. Competition experiments were performed by inclusion of cold 
probes prior to protein addition.  Gels were dried under vacuum at 80°C for 1 hour and 
exposed overnight to a phosphoimaging screen. Images were scanned using a FujiFilm 




TRANSCRIPTIONAL REPORTER ASSAY 
 
Luciferase Assay 
For strains containing the Pmga-luc construct, luciferase assays were performed 
as follows:  MGAS5005 (WT), MGAS5005.trxR (trxR mutant), and KSM165-L.5005 
(mga mutant) transformed with pKSM721 were grown static in 12.5 ml THY medium 
under spectinomycin selection at 37ºC.  Upon reaching Klett 30, 500 µl samples were 
taken every 30 minutes across growth, encompassing early-logarithmic phase to early 
stationary phase.  The samples were centrifuged and pellets were placed at -20ºC 
overnight.  The luciferase assay was performed using the Luciferase Assay system 
(Promega).  Pellets were resuspended in various amounts of 1x Lysis buffer to normalize 
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for cell unit according to the equation 4.5= (x ml)((Klett 65)/2).   The luciferase assay 
was read using a Centro XS3 LB 960 luminometer (Berthold Technologies) where 50 µl 
of Luciferin-D reagent was directly injected. 
For strains containing PtrxT-luc constructs pKSM637 or pKSM670, luciferase 
assays were performed as follows:  MGAS5005 (WT) and 5448-AN (WT) transformed 
with either pKSM637 or pKSM670 were grown static in 12.5 ml THY media or C media 
supplemented with 150 mM NaCl and buffered to 7.5 under spectinomycin selection at 
37ºC.  Samples were collected every 40 minutes across growth and analyzed in the same 





Characterization of the trxTSR operon and its role in the activation of 





 TCSs are often used by bacterial pathogens to adapt to changing host conditions 
during the course of infection and to alter their gene expression profiles.  Numerous 
studies have elucidated the importance of various GAS TCSs.  Several of these TCSs 
have been linked to GAS pathogenesis and virulence gene regulation.  Most notably, the 
CovRS TCS functions as a repressor of many known and putative virulence factors (69, 
81).  In addition, the Ihk/Irr TCS plays an important role in both detection by, and GAS 
evasion of, the innate immune system (267).  The FasBCAX system controls genes 
encoding several GAS adhesins and secreted aggressins in a growth-phase dependent 
manner (124).  Lastly, the SptRS TCS has been shown to regulate multiple genes 
encoding proteins involved in acquisition and processing of complex carbohydrates in 
human saliva (222).   
More recently, mutations in the remaining GAS TCSs were constructed to 
determine whether they played an important role during infection (206).  One of these 
TCS response regulator mutants, trxR, was chosen for further investigation because of its 
homology to virulence-related TCSs of other Gram-positive pathogens, HK/RR07 of S. 
pneumoniae and HK/RR01 of E. faecalis.  In addition, the TrxSR TCS has been shown to 
be repressed by CovRS in two different GAS serotypes (57, 81), providing additional 
support for further analysis of TrxSR.  Using a trxR mutant in the M1T1 MGAS5005 
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strain, a preliminary study using a murine model of GAS soft tissue infection was 
undertaken.  Mice infected with the trxR mutant exhibited significantly reduced lesion 
sizes compared to those infected with wild type MGAS5005 at 48 hours post infection 
(Fig 4A) (135).  Additionally, mice infected with the trxR mutant showed a significant 
increase in survival across a 7-day period compared to those mice infected with the 
parental wild type strain (Fig 4B) (135).  
Given that inactivation of trxR leads to attenuation of virulence in a subcutaneous 
model of GAS soft tissue infection, assessed by both lesion progression and lethality (Fig 
4), it was hypothesized that TrxSR positively regulates virulence in the M1 MGAS5005 
serotype.  In the present study, TrxR is shown to be a conserved activator of the Mga 
virulence regulon.  Based upon the results presented here, in addition to previously 
published data (135), TrxSR represents a newly identified regulatory pathway employed 
by GAS for regulation of its virulence genes.  Additionally, it adds to the growing 
virulence regulatory network, which along with other TCSs and stand-alone regulators, 

























FIGURE 4.  trxR mutant in a murine model of streptococcal soft tissue infection.  A, 
Photograph of representative mice infected with WT MGAS5005 (left) or the trxR mutant 
(right) forty-eight hours post infection.  B, Survival plot comparing mice infected with 
MGAS5005 (n = 10) or the trxR mutant (n = 11) over a 7-day period. A Kaplan-Meier 





Genetic organization of the trxSR locus 
 
 The M5005_Spy_1307 (trxT), trxS, trxR and bgaA genes are unidirectionally 
transcribed and the individual open reading frames are separated by no more than 3 bp 
(Fig 5A).  This arrangement suggests that these genes may form a typical prokaryotic 
operon.  Interestingly, both trxT and its location next to a TrxSR-like TCS are very well 
conserved within other Gram-positive pathogenic bacteria (Fig 5B).  
 
 






FIGURE 5.   The trxSR genomic region.  A, operon structure of the trxSR region.  B, 
alignments of Gram-positive bacteria genome regions containing homology to trxT, trxS, 
and trxR genomic region from S. pyogenes MGAS5005. 
 
 To determine the promoter of the operon, 5’ RACE was employed.  Initial 
experiments using a nested primer within trxT revealed transcripts that ended around 35-
45 bp upstream of the start of TrxT translation (Fig 6A, green line), however, there were 
no defined sequences that matched a consensus -35 and -10 of E. coli.  Upon further 
examination, it appeared that there could be potential secondary structure present with the 
5’ UTR and this could explain why initial attempts at 5’ RACE were identifying this 
region (Fig 6A, yellow).  To determine whether there was a different 5’ end to the 




defined region, 35-45 bp upstream of the start of TrxT translation.  After sequencing 
numerous transcripts, it was determined that there was in fact a 5’ end that continuously 
was identified and was located 132 bp upstream of the start of transcription of trxT. 
Additionally, putative sequences that resembled a consensus -35 and -10 of E. coli were 
present, suggesting that this was indeed the true transcriptional start of trxT (Fig 6A, pink 
line).  
  To learn about transcriptional linkage of these genes, primer pairs were used to 
amplify their intragenic regions through RT-PCR (Fig 6B).  RT-PCR analysis of cDNA 
clearly demonstrated that some transcripts include trxT, trxS, and trxR (Fig 6C).  
Although a transcript that contains trxR and bgaA could be detected by RT-PCR, we 
could not detect a transcript containing trxS, trxR and bgaA.  Furthermore, it appears that 
bgaA can be transcribed independently of trxR in M1 strain MGAS5005, as a trxR 
mutation did not confer a polar effect on bgaA transcription (Table 6).  Thus, the operon 
appears to be composed of trxT, trxS, and trxR. 
 
Expression from PtrxT varies across growth  
 In order to assess transcriptional activation of PtrxT across growth, PtrxT was 
fused to the firefly luciferase reporter gene to generate plasmid pKSM637.  This plasmid 
was initially introduced into M1 MGAS5005 and was grown in THY, with samples taken 
every 40 minutes across growth to assess luciferase activity (Fig 7A).  Unfortunately, 
expressing PtrxT-luc in MGAS5005 resulted in low levels of relative luciferase units that 
were equivalent to background (50-70 RLU), making this strain not ideal to use. 
Therefore, the plasmid was introduced into  other  M1 strains,  SF370 and  5448-AN, to                 
 89 
bgaA trxR trxS trxT B. 
trxR-bgaA 
trxT-trxS 








ACTACTCTTA GTAAAGCGGT TTCCAAAAGC CTATAAAGTG TGCTATATTA 






















FIGURE 6.  The trxSR operon.  A, Above, 5’ UTR sequence of trxT.  Shown are the 
transcriptional start (pink), region of predicted secondary structure (yellow), 
transcriptional start found from initial 5’ RACE (green), and part of the TrxT coding 
sequence (purple).   Below, promoter region of trxT with putative -10 and -35 sequences 
(solid bars) and start of transcription (black arrow) indicated.  B, Schematic of trxSR 
genomic region in M1 MGAS5005 including putative open reading frames and primer 
locations used in RT-PCR (B).  C, Reverse transcriptase PCR reactions for regions 
indicated in A: red- trxT-trxS, blue- trxS-trxR, yellow- trxR-bgaA, black- trxS-bgaA.  
Shown are reactions with RT (+), without RT (-), a genomic DNA positive control 
(gDNA), and a no DNA negative control (Ø).  
B. 
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determine if luciferase activity could be monitored within these backgrounds.  As 
luciferase activity appeared to be highest in the 5448-AN, this strain was chosen for 
further experiments.  In addition to growing the strain in THY, the strain was also grown 
in low glucose C media supplemented with 150 mM NaCl and buffered to a pH of 7.5, as 
trxT has previously been reported to be up-regulated in C media containing 150 mM 
NaCl (144).   
In accordance with this published result, greater expression (~ 4-5 fold increase) 
was seen in the 5448-AN strain grown in the C media containing 150 mM NaCl and 
buffered to pH 7.5 than in the THY media alone.  This was also seen in MGAS5005 but 
not to the same RLU levels (Fig 7B, data not shown).  Additionally, we compared the 
wild type PtrxT-luc construct with a truncated PtrxT fused to luciferase, to delete the 
predicted secondary structure in the 5’ UTR of the promoter region.  Although there 
appears to be a difference in relative luciferase units between the two constructs, it did 
not reach statistical difference compared to luciferase produced from the wild type PtrxT-
luc and truncated PtrxT-luc plasmids in 5448-AN (Fig 7C, data not shown).  As expected, 
expression from PtrxT was higher at the end of exponential growth at the point of 
transition from exponential to stationary phases of growth.  Moreover, there was a second 
peak of PtrxT expression around 90 minutes into stationary phase (Fig 7B), which may 
represent a second point within growth that TrxSR is expressed within the cell.  Thus, 
this data shows the transcriptional pattern for PtrxT and suggests that transcriptional 
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FIGURE 7.  PtrxT expression across growth.  A, The growth curve for WT PtrxT-luc in 
MGAS5005 grown in THY is shown in Klett Units by a dashed line.  The relative 
luciferase units are shown in a solid bold line.  Samples were taken every 40 minutes 
beginning around Klett 20 and continuing through stationary phase. B, The growth curve 
for WT PtrxT-luc in 5448-AN grown in THY or C media supplemented with 150 mM 
NaCl/buffered to pH 7.5 are shown in Klett Units with dashed lines.  The relative 
luciferase unit profiles for each are shown in solid bold lines. C, The growth curve for 
WT PtrxT-luc or truncated PtrxT-luc in 5448-AN grown in C media supplemented with 
150 mM NaCl/buffered to pH 7.5 are shown in Klett Units with dashed lines.  The 
relative luciferase unit profiles for each are shown in solid bold lines. For B and C, 
samples were taken every 40 minutes beginning around Klett 35 and continuing through 
stationary phase.  Dashed black lines represent background levels of relative luciferase 
units taken from luciferase resuspension buffer alone.  For all graphs, data is 





Definition of the TrxR regulon in GAS 
 To identify the genes that TrxR regulates, a transcriptome analysis of a 
MGAS5005.trxR mutant was completed.  For the global transcriptional profile, the wild 
type MGAS5005 was compared to the MGAS5005.trxR mutant grown to late-logarithmic 
phase in THY media, a point in growth at which TrxR-mediated regulation would 
expected to be the strongest based upon the level of trxR transcript (Fig 7B).  A decrease 
(TrxR activation) or increase (TrxR repression) in transcript levels in the mutant with a 
change of twofold or greater was considered significant.  A relatively small number of 
transcripts (29 in total) were affected at late logarithmic phase by inactivation of trxR 
(Table 6, top).  Transcripts that were significantly reduced in the mutant (8 in total), 
suggesting that they are TrxR activated, represent the known members of the core Mga 
virulence regulon (207).  These included emm (37-fold), sic (26-fold), fba (9.3-fold), 
scpA (6.8-fold), sclA (4.7-fold), and grm (2.9-fold).  Although the effect on mga itself 
(1.9-fold) did not reach our 2x threshold of significance, this might be due to low-steady 
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state levels of the mga transcript produced in GAS at late-logarithmic phase.  
Additionally, when Pmga was fused to the firefly luc gene, there was a significant 
decrease in luciferase activity at this time point in growth (Chapter 5, Fig 15), confirming 
low steady-state levels of the mga transcript at late-logarithmic phase.   There was no 
evidence from the array analysis that TrxR regulated its own expression in the 
experimental conditions that we tested. 
 In addition to activating the virulence genes mentioned above, TrxR also 
represses transcription of genes in GAS. There were 21 transcripts that showed a 
significant increase in the mutant, suggesting these genes are repressed by TrxR, either in 
a direct or indirect manner (Table 6, bottom).  The TrxR-repressed genes encode proteins 
involved in various processes including general metabolism, such as amino acid 
biosynthesis (aro) and DNA replication (polA), as well as in different types of stress 
response (dnaI, clpL, and the transport of the osmo-protectant glycine-betaine opu).  
Thus, TrxR appears to activate the Mga regulon as well as repress other apparently 










 Table 6. MGAS5005.trxR vs. MGAS5005 Microarray and Real-time RT PCR validation 
5005_ 
Spy# Annotation (TIGR or NCBI) Gene 
Array Mean ± 
SD a  
RT Mean ± 
SE 
Spy2018 M1 protein precursor emm1 0.027  ±  0.186 0.013  ±  0.003 
Spy2016 Sic1.225 sic 0.038  ±  0.239 0.025  ±   0.005 
Spy2009 Fibronectin- and factor H-binding protein fba 0.103  ±  0.257 nt 
 PscpA 5' probe  0.108  ±  0.262 nt 
Spy2010 c5a peptidase precursor scpA 0.148  ±  0.233 nt 
Spy1983 Collagen-like protein Scl1, SclA sclA 0.215  ±  0.379 0.190  ±  0.015 
Spy0430 Hypothetical protein  0.224  ±  0.286 nt 
Spy2036 Gene regulated by Mga   grm 0.347  ±  0.437 nt 
Spy2019 Trans-acting positive regulator of M protein mga 0.540  ±  0.275 0.590  ±  0.077 
Spy1586 Beta-galactosidase bgaA 0.926  ±  0.319 8.610  ±  2.140 
Spy0167 Streptolysin O precursor slo 1.004  ±  0.189 0.587  ±  0.092 
Spy0242 Two-component histidine kinase; TCS1S fasB 1.020  ±  0.176 1.457  ±  0.183 
Spy0755 ATP synthase subunit 6 atpB 1.222  ±  0.231 2.333  ±  0.207 
Spy1919 Tagatose 1,6-diphosphate aldolase lacD.2 1.953  ±  0.254 1.105  ±  0.295 
Spy1918 PTS system, cellobiose-specific IIA component lacF 1.972  ±  0.247 6.733  ±  0.653 
Spy1719 Ribosome-binding factor A, putative rbfA 2.020  ±  0.321 nt 
Spy1724 N utilization substance protein A nusA 2.020  ±  0.245 nt 
Spy1577 3-dehydroquinate synthase aroB 2.030  ±  0.267 nt 
Spy1805 Preprotein translocase, SecA subunit secA 2.069  ±  0.212 nt 
Spy1759 DnaJ protein dnaJ 2.086  ±  0.263 nt 
Spy0921 tRNA delta(2)-isopentenylpyrophosphate transferase miaA 2.145  ±  0.248 nt 
Spy1399 Glucosamine-6-phosphate isomerase nagB 2.235  ±  0.319 nt 
Spy1725 Unknown conserved protein  2.249  ±  0.344 nt 
Spy0726 CbbY family protein, putative  2.260  ±  0.199 nt 
Spy0806 Ribosomal protein L20 rplT 2.283  ±  0.360 nt 
Spy0185 DNA polymerase I polA 2.314  ±  0.228 nt 
Spy1917 PTS system, cellobiose-specific IIC component lacE 2.316  ±  0.299 1.700  ±  0.270 
Spy1196 integrase/recombinase XerC, putative xerC 2.353  ±  0.382 nt 
Spy0808 conserved hypothetical protein  2.430  ±  0.262 nt 
Spy1995 FlaR flaR 2.458  ±  0.247 nt 
Spy0809 3-dehydroquinate dehydratase, type I aroD 2.519  ±  0.265 nt 
Spy1277 phnA protein phnA 2.642  ±   0.405 nt 
Spy2066 Conserved hypothetical protein  2.735  ±  0.303 nt 
Spy0888 ClpE clpL 3.044  ±   0.173 nt 
Spy0183 Glycine betaine transport ATP-binding protein opuAA 3.047  ±  0.337 nt 
Spy0184 Glycine betaine-binding protein/ transport system  opuABc 3.209  ±  0.343 nt 
 
Data are sorted by Array mean value and shading indicates TrxR regulation; activation 







The microarray analysis was validated by real-time RT-PCR on 12 differentially 















FIGURE 8. Validation of microarray studies.  The log of the mean value for both WT 
vs. trxR- microarray and real-time RT-PCR data was plotted.  A line of linear regression 
was calculated to determine the correlation coefficient. 
 
 
Complementation with trxR on a plasmid restores expression of the Mga regulon 
 To assess the role of trxR in the reduced expression of the Mga-regulated genes, a 
complementation assay was performed.  The wild type trxR gene was cloned under the 
control of the constitutive GAS rpsL promoter (PrpsL) on the multi-copy, replicating 
plasmid pKSM612.  Real-time RT-PCR was performed on total RNA isolated at late-
exponential phase from MGAS5005 with an empty vector and compared to the 
MGAS5005.trxR mutant containing either an empty vector or the complementing 
pKSM612 plasmid.  The level of trxR transcript was significantly higher in the 
complemented strain (MGAS5005.trxR/pKSM612) than in the wild type MGAS5005 





Array vs. Real-time 
R2=0.892 
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copy of the trxR promoter.  For each Mga-regulated gene tested, the complementing 
plasmid restored the transcript level of the trxR mutant to wild type levels (emm, sic, fba, 
scpA, and sclA) (Fig 9).  This demonstrates that trxR alone is capable of complementing 























FIGURE 9.  Complementation with trxR restores expression of the Mga regulon. A 
complementation assay on RNA used in the MGAS5005.trxR microarray was performed, 
on Mga-regulated genes activated by TrxR in the microarray (mga, emm, sic, fba, scpA, 
and sclA).  Gene transcript levels were measured by real-time RT-PCR at late-logarithmic 
growth phase in MGAS5005.trxR mutant containing empty vector and MGAS5005.trxR 
containing the PrpsL-trxR complementing plasmid pKSM612 compared to WT 
MGAS5005 containing empty vector.  Bars indicate log2 mean relative changes in gene 
transcript levels between the two strains with error bars indicating log2 standard 
deviations.  Values above the x-axis indicate an increase in a mean change in transcript 
levels, and values below the x-axis indicate a reduction in the change in transcript levels 
relative to the WT strain MGAS5005.  Dotted lines at 0.5 and 2 represent cut-offs for the 




TrxR activates the Mga regulon in both throat and generalist strains 
 A trxR deletion in two different M1 strains, SF370 and MGAS5005, has different 
effects on mga in late exponential phase (206) (Table 6).  Interestingly, SF370 is 
genetically distinct from serotype M1 strains associated with severe human infections, 
and thus, the differences in their genetic backgrounds may play a role in the observed 
effects of TrxR on the Mga-regulated genes.  To determine whether there is a functional 
conservation of TrxR’s involvement in virulence regulation, trxR was inactivated in the 
M4 clinical strain GA40634 and in a representative M49 strain, NZ131.  Upon 
inactivation of trxR, the strains were also cured to relieve trxR of the inactivating plasmid 
to generate a negative control strain.  Real-time RT-PCR was performed on total RNA 
isolated at late exponential phase under erythromycin selection from the wild type strain 
(with an empty vector) and was compared to the trxR- mutant strain and its respective 
cured strain (with an empty vector).  Real-time RT-PCR was performed on trxR and emm 
(M49) or arp (M4), mga, and opuAA, three genes representing the trxR- phenotype in 
M1T1.  The qPCR results show that in both GA40634 (Fig 10A) and NZ131 (Fig 10B), 
TrxR has a significant effect on mga and emm/arp.  Additionally, there did not appear to 
be any affect on opuAA transcripts within either of these strains, suggesting that TrxR’s 
regulation of opuAA in MGAS5005 might be strain specific.  Thus, these results suggest 
that the influence of TrxR on mga and the Mga-regulated genes is not strain or serotype 
specific, and that its role in virulence regulation is conserved among other major 





































FIGURE 10.  Real-time RT-PCR analysis of trxR- and cured strains.  Gene transcript 
levels of trxR, emm (arp), mga, and opuAA were assessed through qPCR from the trxR- 
(purple) and cured strains (blue- GA40634.trxRc, green- NZ131.trxRc).  Results are 
shown as transcript fold-change relative to their corresponding WT transcript levels and 














Deletion of trxT resembles a trxR- phenotype, however complementation does not 
restore phenotype 
 
 Because trxT was found to be co-transcribed with trxSR (Fig 6C), it was important 
to investigate the relationship between TrxT and the TrxSR TCS.  To determine whether 
TrxT is involved in the TCS, a non-polar deletion of the trxT gene was made in 
MGAS5005.  This deletion strain, MGAS5005.trxT, was then used for real-time RT-PCR 
analysis to determine a trxT- profile.  Total RNA was isolated at late exponential phase 
(as was the RNA for the trxR- studies) from MGAS5005 with an empty vector and was 
compared to the MGAS5005.trxT mutant containing an empty vector under 
spectinomycin selection.  Transcript levels of several TrxR-regulated genes were 
assessed in both the wild type and mutant trxT- strains.  qPCR results from the trxT 
mutant compared to the wild type strain followed some of the regulatory patterns that 
were seen in the trxR- strain (e.g. the Mga-regulated gene sic was significantly down, 
opuAA levels were up) (Fig 11).  This suggests, however, only a potential involvement of 
TrxT in the TCS if any, as the absence of trxT does not completely resemble that of the 
absence of trxR in MGAS5005.  Additionally, qPCR demonstrated that in the absence of 
trxT, transcript levels of trxS and trxR significantly increase, albeit only minimally.  This 
suggests that TrxT may have some sort of auto-regulatory role for this operon.  
 To confirm that the effect that was seen in the qPCR was due to TrxT, a 
complementing plasmid expressing TrxT under its native promoter was introduced into 
MGAS5005.trxT to provide TrxT in trans.  qPCR was performed on RNA isolated from 
the MGAS5005.trxT strain containing the TrxT complementing plasmid and was 
compared to wild type MGAS5005 RNA as before.  Unexpectedly, the expression of the 
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tested genes did not return to wild type levels, as we would expect, even though trxT 
expression was more than 50-fold higher than the wild type strain (Fig 11).  Thus, a role 















FIGURE 11.  Role of TrxT in the TrxSR TCS assessed through qPCR. Gene 
transcript levels of trxT, trxS, trxR, emm, sic, mga, clpL, and opuAA were assessed 
through qPCR from the MGAS5005.trxT- (green) and complemented MGAS5005.trxT- 
(PtrxT-trxT) strains (blue).  Fold-change was determined relative to the corresponding 
WT MGAS5005 containing an empty vector with transcript levels normalized to the gyrA 





This study was initiated to assess the importance of the uncharacterized TrxSR 
TCS to streptococcal disease.  The evidence presented in this study shows that the TrxSR 




regulon.  Furthermore, this work aids in modeling the complex interactions that occur 
within GAS between different regulatory pathways to influence disease progression.  
 
trxSR is part of a tightly regulated operon 
  Inspection of the MGAS5005 genome showed four tightly linked open reading 
frames (trxT, trxS, trxR, and bgaA) separated by very little intergenic space, suggesting 
that they may be part of an operon.  RT-PCR analysis of MGAS5005 cDNA clearly 
demonstrated that some transcripts contained trxT, trxS, and trxR.  Additionally, we 
found that although a transcript that contained trxR and bgaA could be detected by RT-
PCR, the trxR mutation did not confer a polar effect on bgaA transcription (Table 6), 
suggesting that bgaA can be transcribed independently of trxR in the M1 strain 
MGAS5005.   
To learn about transcriptional regulation of the trxTSR operon, we first sought to 
determine why there appeared to be such a large distance between the promoter and the 
first codon of TrxT.  The promoter of the operon, PtrxT, was previously identified by in 
vitro transcription experiments to be 132 bp upstream of the initiation codon of TrxT 
(135).  In order to verify this location, we employed 5’RACE.  Interestingly, when an 
antisense primer was used that hybridized within trxT, the amplified transcripts all ended 
in a region roughly 50-70 bp upstream of the TrxT initiation codon.  None of these 
transcripts contained a potential promoter that was located anywhere near the identified 
start site.  However, when the nested primer was used that hybridized directly 
downstream of the previously published promoter region, the promoter was confirmed.  
Therefore, based on these experiments, we believe that there may exist some sort of RNA 
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secondary structure within the 5’ UTR, which is involved in transcriptional regulation of 
the trxTSR operon.  However, we could find no evidence for this, as secondary structure 
prediction programs such as Mfold or MacVector could not predict any obvious stem-
loop structures or rho-independent terminators within this region.  As a result, it is also 
possible that this region may contain a binding site for an unknown regulator of the 
operon, such as a regulatory RNA, which has yet to be discovered.  Nevertheless, the role 
of this defined region in transcriptional regulation of trxTSR still remains unknown, as the 
data from the PtrxT-luc experiments (Fig 7C) shows that deletion of this area does not 
significantly alter or affect expression of luciferase when fused to the truncated PtrxT 
promoter region.  
As mentioned previously, published data from two different microarray studies 
using the CovR response regulator showed that CovR could repress trxSR transcription 
(57, 81). Additionally, our in vitro transcription studies have shown that increasing 
concentrations of either CovR or phosphorylated CovR resulted in a reduction in PtrxT-
specific transcript levels (135).  These results demonstrate that CovR directly represses 
transcription initiation or elongation at PtrxT to regulate the trxTSR operon.  This CovR 
repression, along with the aforementioned predicted RNA secondary structure in the 5’ 
UTR of the promoter region, provides tight transcriptional regulation of the TrxSR TCS.  
Moreover, the luciferase data from the PtrxT-luc experiments suggest a very weak and/or 
tightly regulated promoter, as relatively low levels of RLU are produced.  Such complex 
regulation of the trxTSR operon, and the TCS in general, is consistent with other 
members of the AraC family (of which TrxR belongs), as one of the most prominent 
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features of this family is that their synthesis is tightly and often intricately regulated 
(160).   
  
Defining the TrxR regulon in GAS 
 Several GAS TCSs have functional roles in coordinating the regulation of 
virulence genes within the pathogen.  Unlike many prokaryotes, GAS does not appear to 
rely on alternative sigma factors to control gene expression, as only one has been 
identified to date (SigX), and it is not expressed under laboratory growth conditions (177, 
188).  As only four of thirteen TCSs have previously been linked to virulence (as 
discussed in detail in the Literature Review), several GAS TCSs remain uncharacterized 
and may play an important role in infection as well.   
An insertional inactivation mutant of trxR was used in a subcutaneous model of 
GAS soft tissue infection to determine whether the TrxSR TCS was involved in 
regulation of virulence.  The trxR- mutant exhibited significantly reduced lesion sizes at 
forty-eight hours post infection and increased survival over a seven day period, when 
compared to the wild type strain, suggesting a role for TrxR in virulence regulation.  
Next, to confirm this role, a DNA microarray was performed to determine the TrxR 
regulon.  A relatively small number of transcripts were affected by TrxR in late 
exponential phase by inactivation of trxR, and interestingly, those transcripts that were 
found to be activated represented known members of the Mga virulence regulon.  This 
result provided an explanation for why the MGAS5005.trxR mutant in the murine skin 
infection model had an attenuation of virulence (135).  Other genes in the TrxR regulon 
exhibit a range of different functions in GAS, including translation (rbfA and rplT), 
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transcription (nusA), replication (polA), transport (lacE, secA, and opuAA-opuABc), and 
stress (clpL).  Although the trxR mutant did not show an altered growth phenotype in rich 
THY medium in vitro, it is possible that growth in vivo would reveal an effect.   
Interestingly, in a previous study using the M1 SF370.trxR strain, trxR was not 
identified as necessary for expression of the Mga-regulated gene emm (206).  Additional 
real-time RT-PCR and Northern studies of the SF370.trxR mutant confirmed these results 
for several other Mga-regulated genes.  Although the two strains belong to the same M1 
serotype, SF370 is genetically distinct from other M1 strains associated with GAS 
infections.  SF370, representing a pre-1988 M1 strain, differs from MGAS5005 and other 
post-1988 serotype M1 strains in a 36-kb region located between genes purA and nadC in 
the genome (242).  Because two prominent extracellular toxins (SLO and NADase) are 
encoded by genes in this chromosomal segment, it has been postulated that the pre-1988 
M1 strains did not produce any NADase, although they contained an intact nga gene.  As 
a result, the post-1988 M1 serotype strains are thought to have a more invasive, virulent 
phenotype than the contemporary M1 strains due to the presence of NADase production.  
Therefore, the differences in the genetic backgrounds of SF370 and MGAS5005 may 
play a role in the observed effects of TrxR on the Mga-regulated genes.  However, our 
qPCR results on the M4 GA40634.trxR and M49 NZ131.trxR demonstrate that TrxSR 
has a conserved role in regulation of mga and virulence in a broader range of GAS strains 
currently involved in streptococcal disease.  This work, thus, adds TrxSR to the list of 
regulators that interact with the Mga regulon.  The mechanism TrxR uses to interact with 
mga will be investigated in the next chapter (Chapter 5).   
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Involvement of TrxT in the TrxSR TCS 
 The arrangement of the trxTSR operon in GAS suggests that these genes may 
encode for proteins that are functionally linked.  Although it is common for a HK and RR 
to be co-transcribed, it is less common for other genes to be co-transcribed with them.  
Typically, when an additional gene is co-transcribed with those of the TCS, they are often 
required for proper function of the TCS as an accessory protein (e.g. Agr system of S. 
aureus (183)).  Therefore, TrxT, a conserved hypothetical membrane protein of unknown 
function, may be involved in the TCS.  Potential roles for TrxT include aiding in signal 
reception with the TrxS HK and support to stabilize the TrxSR interaction during 
phosphate transfer.    
From our results, whether the TrxSR TCS and TrxT are functionally linked is 
unclear at this time.  Although it appeared that a mutation in trxT followed some of the 
same regulatory patterns of the trxR- mutant, when TrxT was over-expressed in the trxT- 
background, it did not rescue its phenotype.  There are numerous possibilities as to why 
over-expressing TrxT in our experiments may not have restored the trxT- phenotype.  One 
possible reason for this result is that the TrxT protein is not functional when expressed 
off the complementing plasmid.  Additionally, trxT may need to be co-transcribed along 
with trxSR in a complex, in order to make a functional protein.  In B. subtilis, activation 
of its σB transcription factor in response to stress requires three proteins, RsbSTU, 
transcribed from the same operon (273).  For RsbT, a positive regulator of the σB 
transcription factor, its ability to function is strongly influenced by coexpression with its 
adjoining genes (273).  Perhaps a similar coexpression with trxSR, is essential for trxT to 
allow for its proper function.  Also, over-expressing trxT, because it is a predicted 
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membrane protein, may provide stress to the cell, leading to aberrant function of TrxT 
due to higher than normal levels of the protein.  Whether any of these possible 
explanations are correct is unknown at this time, and further studies investigating TrxT 
with TrxSR need to be completed in order to provide solid evidence for or against its 









 Two-component systems function as information processing pathways to link an 
outside stimulus to an internal response.  Typically, both an HK and RR are needed to 
relay this response from the outside of the cell to within.  Upon a series of 
phosphorylation steps, the ‘signal’ is passed from one protein to another, generally 
resulting in changes to the transcriptional profile of the cell.  Much of this transcriptional 
regulation involves proteins that either activate or repress expression of particular genes.  
As the majority of RRs have DNA-binding effector domains (77), numerous subfamilies 
of RR proteins exist, identified based upon their homology to one another.   
The AraC family represents one of the smaller subfamilies of RRs containing 
DNA-binding effector domains, as it exists in approximately 1% of all RRs (76).  
Although functional activities have not been assigned to all AraC-like members, based 
upon in silico searches, these proteins primarily represent transcriptional activators that 
regulate diverse bacterial functions including sugar catabolism, responses to stress, and 
virulence (160).  Members of the AraC family span across diverse prokaryotic genera, 
although most members are γ-proteobacteria (75).  The AraC family is characterized by 
significant amino acid sequence homology extending over a 100-residue stretch at the C-
terminal end of the proteins, constituting the DNA binding domain (75).  This conserved 
region has been shown to contain seven α-helices, including two helix-turn-helix (HTH) 
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binding motifs (α2-T-α3 and α5-T-α6), connected by a linker α-helix (α4), and two 
flanking α-helices (α1 and α7) (213). 
 The first, well-characterized member of the AraC family is MarA, a 
transcriptional activator of more than a dozen genes in the multiple antibiotic resistance 
(mar) regulon of E. coli.  The crystal structure of MarA has served as a reference for how 
members of the AraC family bind DNA.  Containing two HTH domains per subunit, 
MarA inserts into two adjacent segments of the major groove (205).  These adjacent 
major groove segments are located on the same face of the DNA, but are separated by 
only 27 Å, and MarA thereby bends the DNA by approximately 35° (205).  Additionally, 
the most important determinants of MarA’s binding appear to be hydrogen bonds made 
by both HTH motifs with several bases of the DNA. 
 Another well-characterized member of the AraC family is XylS of Pseudomonas 
putida.  Extensive mutational analysis of the 100 conserved C-terminal amino acids of 
XylS has revealed defined structural requirements for how the protein interacts with the 
DNA.  Although mutations in conserved residues within the α5-helix had little effect on 
XylS transcriptional activity, it was found that the distribution of polarity in the α6-helix 
was important for its activity (158).  Surprisingly, the strongest effect of the mutations 
was not observed in the HTH binding motifs, but in the conserved residues located 
outside the DNA-binding domain.  These residues in XylS included Gly-290 located in 
the turn between the two helices α5 and α6, Pro-309 located downstream of α6, and Leu-
313 located in the small last helix α7 (158).  It is thought that these three residues play an 
important role in the activation of RNA polymerase to initiate transcription. 
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   NCBI PSI-BLAST and Pfam database searches have identified a putative AraC-
like DNA binding domain at the C-terminus of TrxR.  Since none of TrxR’s homologs 
have been studied in detail biochemically, a mode of interaction for how TrxR might 
interact with its target genes was assessed.  In this study, we first demonstrate that TrxSR 
is a functional phosphorelay system, capable of interacting to pass a signal from one 
protein to another.  Additionally, TrxR’s mechanism of action is explored, in reference to 
Pmga, and details of this interaction are determined.   
 
RESULTS 
TrxS can dimerize in vivo 
 The first step in a TCS pathway upon signal recognition is autophosphorylation of 
the HK, followed by its own dimerization with another HK monomer.  In order to 
determine if TrxS can interact with itself and dimerize in vivo, the soluble, signaling 
domain of TrxS was fused in-frame to the C-terminal side of both the T18 and T25 
catalytic domains of Bordetella pertussis adenylate cyclase (CyaA) for use in a bacterial 
two-hybrid system (113).  Initial attempts at using the full-length TrxS protein for these 
experiments failed due to solubility issues, therefore only the signaling domain was 
expressed (134).  Within this system, functional complementation of adenylate cyclase 
occurs only when the two halves of the CyaA are brought within close proximity to one 
another, as CyaA is not functional when its catalytic subunits are physically separate.   
 To determine whether TrxS can dimerize, pT18C-TrxS and pT25C-TrxS were co-
transformed into BTH101, a cya- E. coli strain.  Additionally, the empty vectors and 
pT18C-TrxS/pT25C-TrxS were co-transformed to serve as negative controls 
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(pT18C/pT25C; pT18C-TrxS/pT25C; pT18C/pT25C-TrxS).  The transformation plating 
and patching were performed on MacConkey media supplemented with maltose.  
MacConkey media is a defined media that contains bile salts and a neutral red dye, which 
is a pH indicator that is yellow above a pH of 8.0, and red below a pH of 6.8.  When the 
two halves of CyaA are brought within close proximity of one another, cAMP synthesis 
occurs.  cAMP binds to CAP, and the cAMP/CAP complex bind to the malT promoter, 
activating the transcription of malT and malEFG (115).  These proteins aid in maltose 
uptake and degradation and create a byproduct of H+ ions.  The increase of H+ ions 
causes an acidic pH, and color change from yellow to magenta.  Upon plating and 
patching of the co-transformants, the three negative controls exhibited no color change 
(yellow), while the pT18C-TrxS/pT25C-TrxS turned magenta.  This result suggested that 










FIGURE 12.  TrxS dimerizes in vivo.  Bacterial two-hybrid assay plated on MacConkey 
agar plus 1% maltose.  Shown are panels with patches from plasmid co-transformants in 
BTH101, a cya- E. coli strain: negative controls pT18C/pT25C, pT18C-TrxS/pT25C, 
pT18C/pT25C-TrxS, and experimental pT18C-TrxS/pT25C-TrxS.  Yellow color 
indicates negative reaction and magenta color indicates positive reaction.  
 
 111 
TrxS exhibits autophosphorylation activity and phosphorelay to TrxR in vitro 
 Upon receiving stimulation in the form of a signal, the histidine kinase undergoes 
trans autophosphorylation at a specific histidine residue and dimerization, to transfer this 
phosphoryl group to an aspartate residue within the receiver domain of their cognate 
response regulator, to propagate the signal.  To identify the residues involved in this 
phosphorelay, we first aligned TrxS with characterized bacterial TCS histidine kinases 
such as EnvZ.  However, because TrxS belongs to a rather unusual histidine kinase 
subclass that has an atypical H-box (32), alignment of TrxS with the characterized HKs 
was very difficult.  Within the H-box, a proline precedes the conserved histidine, while 
the proline found in most kinases located five residues downstream from the histidine, is 
missing (84).  Additionally, the H-box histidine is followed by a phenylalanine instead of 
the usual acidic residue.  Once TrxS was aligned with three other members of the HPK8 
subclass (84), LytS, YehU, and HK07 (S. pneumoniae), a conserved histidine residue 
(His-383) was readily identified in the predicted dimerization/phosphorylation domain of 
TrxS (Fig 13A).  TrxR could be aligned with known bacterial response regulators, such 
as CheY and OmpR, and a conserved aspartate residue (Asp-55) was identified in the 
predicted phosphoacceptor domain of TrxR (Fig 13B). 
FIGURE 13.  Predicted catalytic residues of TrxS and TrxR.  A, alignment of residues 
within the dimerization/autophosphorylation domain from several histidine kinases.  
Phosphorelay histidine residues are in red; the predicted phosphorelay histidine of TrxS 
(His-383) is boxed.  B, alignment of residues within the phosphoacceptor domains of 
several well-characterized response regulators. Phosphoacceptor aspartate residues are in 
red, the predicted  phosphorelay aspartate of TrxR (Asp-55) is boxed. 
 A.  B. 
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To determine whether TrxS undergoes autophosphorylation and catalyzes 
phosphorylation of TrxR, and to determine whether His-383 of TrxS and Asp-55 of TrxR 
are the signaling residues of TrxSR, in vitro phosphorelay experiments were performed.  
The signaling domain from both the wild type and mutant TrxS (TrxS and TrxS:H383A) 
along with the full-length wild type and mutant TrxR (TrxR and TrxR:D55A) proteins 
were expressed as 10xhistidine-MBP-tagged fusion proteins and were purified by affinity 
chromatography over both amylose and Ni-NTA resins (Fig 14A).  To demonstrate in 
vitro autophosphorylation of the signaling domain of TrxS, radiolabeled [γ-32P]ATP was 
added to TrxS and autophosphorylation was observed by SDS-PAGE followed by 
exposure to a phosphoimaging cassette.  Exposure of TrxS to [γ32P]-ATP resulted in 
autophosphorylation that was not observed in TrxS:H383A (Fig 14B, D), and a maximal 
level of phosphorylation was observed within 60 minutes (Fig 14B).  Addition of TrxR to 
phosphorylated TrxS resulted in rapid dephosphorylation of TrxS and phosphorylation of 
TrxR (Fig 14C, F), whereas TrxS dephosphorylation and TrxR phosphorylation were not 
observed when TrxR:D55A was added (Fig 14E).  These results suggest that TrxS and 
TrxR can form an in vitro phosphorelay in which TrxS undergoes autophosphorylation at 






































FIGURE 14.  Histidine 383 of TrxS and aspartate 55 of TrxR are essential for TrxSR 
phosphorelay. A, Coomassie blue stain of SDS-PAGE with purified His-MBP tagged 
TrxS, TrxR, TrxS:H383A, and TrxR:D55A proteins.  B, incubation of 63.4 µM TrxS with 
[γ32P]-ATP over time.  C, in vitro phosphorelay between TrxS and TrxR.  63.4 µM TrxS 
was incubated with  [γ32P]-ATP for 60 minutes and following labeling, 534 µM TrxR 
was added to the reaction (vertical arrow) and samples were taken.  Proteins were 
separated by SDS-PAGE, and gels were exposed to autoradiography.  D, incubation of 
63.4 µM TrxS:H383A and transfer to 534 µM TrxR over time.  E, incubation of 67 µM 
TrxS and transfer to 674 µM TrxR:D55A over time.  F, quantification of phosphotransfer 
in C.  Amount of radiolabeled protein is shown as a percentage of TrxS at 60 minutes.  
The x-axis represents time after the addition of TrxR to the reaction.  Phosphotransfer 
pattern is representative of three independent experiments. 
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TrxS can interact with TrxR in vivo 
 After establishing that TrxS could transphosphorylate TrxR in vitro, we next 
wanted to determine whether the two proteins could physically interact.  Initial attempts 
utilized the bacterial two-hybrid assay to look at this interaction in vivo.  The previous 
pT25C-TrxS construct was used to express soluble TrxS fused to pT25C while TrxR was 
fused to pT18C to create pT18C-TrxR.  Although we could verify expression of the full-
length TrxS fusion construct, we could not confirm that a functional full-length TrxR 
fusion product was made from the pT18C-TrxR plasmid (data not shown), preventing our 
use of the bacterial two-hybrid assay to look at the TrxS-TrxR interaction.   
Thus, we utilized a different in vivo environment, that of a native GAS cell, to 
look at this interaction.  In order to do so, His-MBP-TrxR was expressed on a plasmid 
under the PrpsL promoter in the trxR- strain, MGAS5005.trxR.  Additionally, two 
aspartate mutants, D55A and the phosphomimetic D55E, also expressed under PrpsL, 
along with an empty replicating vector pJRS525, were expressed in the same 
MGAS5005.trxR background.  These strains were grown to late-logarithmic phase and 
used in a co-immunoprecipitation (co-IP) assay with an α-His antibody to pull down 
soluble proteins that His-MBP-TrxR, or its mutants, interacted with.  The collected co-IP 
samples were run in duplicate on SDS-PAGE gels and analyzed via Western blots using 
either α-His or α-TrxS antibodies.   
Western blot analysis using the α-His antibody confirmed the presence of the His-
tagged TrxR proteins, along with equal loading of the co-IP lysates, as all three His-
MBP-TrxR proteins had comparable intensities for this TrxR band (Fig 15A).  When the 
α-TrxS antibody was used on the same co-IP lysates, there seemed to be a TrxS band 
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present in all lanes including the control, suggesting that the antibody was not clean (Fig 
15B).  However, wild type His-MBP-TrxR appeared to pull down the cytosolic portion of 
TrxS more efficiently than the other proteins, as it had a very intense, dark band.  
Additionally, the D55E phosphomimetic mutant of TrxR appeared to minimally pull 
down cytosolic TrxS (58% increase over the control), compared to the wild type lane, 
while the D55A mutant had a band comparable to that of the control lane, suggesting that 
it could not interact with TrxS at all (Fig 15C).  Thus, TrxR is capable of interacting with 















FIGURE 15.  Native TrxS is pulled down by His-MBP-TrxR.  Western blot analyses 
of control (pJRS525 empty vector), His-MBP-TrxR, His-MBP-TrxR D55A, and His-
MBP-TrxR D55E co-immunoprecipitation samples run on a 10% SDS-PAGE gel.  
Immunoblot using A, α-His monoclonal antibody and B, α-TrxS polyclonal antibody.  C, 
Quantification of α-TrxS Western in B.  Data is shown as a percentage increase over the 











TrxR activates Pmga 
 As an initial step to determine how TrxR regulates mga expression, the firefly 
luciferase reporter gene was fused to the mga promoter to generate the Pmga-luc allele.  
Luciferase activity was assayed from early logarithmic growth to early stationary phase 
in MGAS5005 (WT), KSM165-L.5005 (mga mutant), and MGAS5005.trxR containing 
the Pmga-luc plasmid (Fig 16).  At several different points in the growth cycle in the wild 
type (MGAS5005) and the trxR mutant containing Pmga-luc, the trxR mutant exhibited 
significantly reduced Pmga-luc activity compared to wild type MGAS5005, including 
mid-logarithmic (3.1 fold) and early stationary (3.4 fold) phases of growth.  Relative to 
the wild type strain, the levels of Pmga-luc activity were similar for the trxR and mga 
mutants.  Interestingly, Pmga activity dropped in the wild type strain at late logarithmic 
point, the same time point used for the microarray (Table 6 and Fig 16).  These data 
suggest that TrxR activates the Mga regulon through regulation of Pmga.  
 







FIGURE 16.  Pmga activity is regulated by TrxR.  MGAS5005 (WT), KSM165-L.5005 
(mga mutant), and MGAS5005.trxR strains containing the Pmga-luc reporter plasmid 
were grown in THY medium under spectinomycin selection.  Upon reaching 30 Klett 
units, 500 µl samples were taken every 30 minutes across growth (dashed lines) and 
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TrxR specifically binds to Pmga in vitro  
 To determine if TrxR directly interacts with the promoter region of the mga gene, 
electrophoretic mobility shift assays (EMSAs) were performed on Pmga.  A Pmga probe 
was amplified from MGAS5005 that included a 301 bp fragment encompassing both Mga 
binding sites 1 and 2, and was centered between the P1 and P2 promoters of mga.  To 
address specificity of TrxR binding, a probe consisting of the promoter region of emm 
was generated.  Assays were performed using purified His-MBP-TrxR at 25°C (see 
Materials and Methods).   
 Increasing amounts of His-MBP-TrxR (0.9-2.8 µM) resulted in a mobility shift of 
labeled Pmga, indicating DNA binding by TrxR (Fig 17A, lanes 1-4, B).  This shift of the 
TrxR-Pmga interaction appeared smeary, however, and did not resolve into a distinct 
single band, remaining rather diffuse.  The addition of 500 ng of cold Pmga was able to 
compete for the interaction, nonetheless, whereas the addition of the same amount of cold 
Pemm had no effect (Fig 17, lanes 5 and 6).  Thus, His-MBP-TrxR is able to bind 














































FIGURE 17. TrxR binds specifically to Pmga. A, EMSA using a 301 bp Pmga probe 
with His-MBP-TrxR.  A constant amount (2.75 ng) of labeled probe was incubated with 
increasing amounts (0-2.8 µM) of purified His-MBP-TrxR (lanes 1-4). Unlabeled 
competitor Pmga (500ng, lane 5) and Pemm (500ng, lane 6) were used to assess 
specificity of protein binding to Pmga.  B, Quantification of EMSA in A.  Data is shown 
as the percent of the unbound, radiolabeled Pmga probe with matching lanes to the 
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The effect of phosphorylation on TrxR’s ability to bind to DNA and regulate gene 
activation  
 In the prototypical TCS, the protein’s effector domain is typically blocked from 
access and activity until the phosphate group has been transferred from the HK.  When 
this transfer occurs, the conformation of the RR changes, and relieves the effector domain 
from obstruction.  This conformational change generally causes relaxation of the protein 
and allows the RR to continue the signal propagation to elicit its cellular response.   
 In order to determine whether a phosphorylated TrxR is necessary for its ability to 
activate the Mga regulon, His-MBP-TrxR and the D55A or D55E mutants were 
expressed in a trxR- background under PrpsL.  Western blot analysis shows 
approximately equal TrxR protein levels for the three proteins, suggesting that the 
phosphorylation state of the catalytic aspartate has no affect on expression of the protein 
(Fig 18A).  The protein’s ability to complement a trxR- phenotype was then determined.  
Real-time RT-PCR was used to measure levels of TrxR-regulated genes in a trxR- strain 
containing an empty vector, wild type His-MBP-TrxR, His-MBP-TrxR D55A, or His-
MBP-TrxR D55E.  The results from these experiments show that, as predicted, the wild 
type protein can complement a trxR- phenotype.  However, unexpectedly, both the D55A 
and D55E TrxR mutants can as well (Fig 18B).  Since it can be interpreted that both of 
these proteins are active because they could both bind to Pmga in vitro (Fig 18C), the 
phosphoacceptor residue within the receiver domain does not appear to affect TrxR’s 
activity for the genes tested.  This suggests that the phosphorylation state of TrxR has 
little significance on the protein’s function in relation to activating the Mga regulon or 



























FIGURE 18.  Effect of TrxR’s phosphorylation state on gene transcription and DNA 
binding. A, Western blot analysis to determine the amount of His-MBP-tagged TrxR 
under PrpsL for the WT, D55A, and D55E proteins in the MGAS5005.trxR background.  
Shown are blots to detect His and HSP-60 (loading control).  B, Transcript levels of emm, 
sic, and opuAA from the trxR- (blue), WT TrxR (orange), TrxR D55A (green), and TrxR 
D55E (purple) in the MGAS5005.trxR- background. Shown as transcript fold-change 
relative to their corresponding WT transcript levels and normalized to the gyrA control.  
Dotted lines at 0.5 and 2 represent cut-offs for the level of significance. C, EMSA using a 
301 bp Pmga probe with His-MBP-TrxR D55 mutants.  A constant amount (3.26 ng) of 
labeled probe was incubated with increasing amounts (1.3-2.6 µM) of purified His-MBP-
TrxR D55A (lanes 1-4) or D55E protein (lanes 5-8).  Unlabeled competitor Pmga (400ng, 
lanes 3, 7) and Pemm (400ng, lanes 4, 8) were used to assess specificity of protein 
binding to Pmga.  
2.6 2.6 1.3 1.3 C. 
Pmga 






TrxR requires its HTH domains to bind to Pmga 
 To further investigate the nature of His-MBP-TrxR binding to Pmga, we focused on 
TrxR’s two predicted HTH motifs to assess their functionality in DNA binding. The two 
HTH DNA-binding motifs were identified based upon their amino acid homology to 
AraC and numbered according to their physical position (Fig 19A, B).  Alanine 
substitutions were made in two amino acids within the ‘recognition’ helices that were 
predicted to make contact with the DNA, α3 and α6-helices (205) (Fig 19B).  To allow 
analysis of DNA-binding activity in vitro, the HTH mutations were introduced directly 
into the trxR allele within a His-MBP-TrxR fusion protein contained on the plasmid 
pKSM697.  The resulting mutant fusion protein was purified from soluble E. coli lysates, 
with no significant degradation caused by the presence of the HTH mutations (data not 
shown).  
 To assay the effect of the HTH mutations on DNA binding, the ability of the TrxR 
HTH-1/2 mutant to interact with Pmga was determined in vitro by EMSA analysis.  
Using the same Pmga probe as the previous EMSA experiment (Fig 17), increasing 
amounts of His-MBP-TrxR and the HTH-1/2 mutant (1.7-2.5 µM) were added to a 
labeled Pmga probe.  Using the wild type His-MBP-TrxR protein as a control for DNA 
binding (Fig 19C, lanes 2-5), no detectable binding of the HTH-1/2 mutant protein to the 
Pmga probe was observed (Fig 19C, lanes 6-9).  Thus, the two HTH motifs within the 
AraC-like DNA binding domain of TrxR are involved in binding to the mga promoter in 


















FIGURE 19.  TrxR requires its HTH domains to bind to Pmga.  A, schematic of the 
TrxR protein showing potential helix–turn–helix (HTH) DNA-binding motifs (red ovals) 
based on amino acid sequence homology to AraC.  B, amino acid residues composing the 
two putative HTH domains of AraC and TrxR are shown with numbers in parentheses 
referring to the corresponding amino acid location. The expected HTH secondary 
structures and their residue positions within the motif are illustrated. Amino acids within 
each ‘recognition’ helix of TrxR that were mutated to alanine residues are underlined.  C, 
EMSA using a 301 bp Pmga probe with His-MBP-TrxR and His-MBP-TrxR HTH-1/2 
mutant.  A constant amount (2-4 ng) of labeled probe was incubated with increasing 
amounts (0-2.5 µM) of purified His-MBP-TrxR (lanes 1-5) or HTH-1/2 mutant (lanes 6-
9).  Unlabeled competitor Pmga (400ng, lanes 4, 8) and Pemm (400ng, lanes 5, 9) were 
used to assess specificity of protein binding to Pmga. 
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TrxR’s HTH domains are not needed for in vivo activation of Pmga 
 As the HTH domains were shown to be required for TrxR to bind to Pmga in vitro, 
the requirement of the HTH domains for activation of the Mga regulon in vivo was next 
investigated.  The His-MBP-TrxR HTH-1/2 mutant was placed under PrpsL and was 
introduced into the MGAS5005.trxR mutant.  Real-time RT-PCR was performed on total 
RNA isolated at late-exponential phase from MGAS5005 with an empty vector and 
compared to the MGAS5005.trxR mutant containing either an empty vector or the PrpsL-
His-MBP-TrxR HTH-1/2 plasmid.  Surprisingly, transcript levels of all three TrxR-
regulated genes in the HTH-1/2 mutant returned to wild type levels (Fig 20), suggesting 
that the HTH domains of TrxR are not needed in vivo for its activation of the Mga-













FIGURE 20.  TrxR does not require its HTH domains to affect gene transcription of 
the Mga regulon.  Transcript levels of trxR, emm, sic, and opuAA from the trxR- (blue) 
and TrxR HTH-1/2 mutant in MGAS5005.trxR (magenta) are shown as transcript fold-
change relative to their corresponding WT (MGAS5005) transcript levels and normalized 
to the gyrA control.  Dotted lines at 0.5 and 2 represent cut-offs for the level of 
significance. 
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Truncating TrxR does not affect its ability to rescue a trxR- phenotype 
 Since the HTH mutations did not appear to abrogate TrxR’s ability to activate the 
Mga regulon in vivo, it was therefore important to determine if the activity of TrxR was 
due to another region of the protein.  Pfam searches of TrxR reveal that TrxR has a CheY 
like receiver domain at its N-terminus and an AraC-like DNA binding effector domain at 
its C-terminus (Fig 21A).  Between these two domains, there are roughly 300 amino acids 
with no ascribed function.  Presumably there is a flexible linker within this region, 
however its location and size currently remain unknown.  In order to ascertain whether 
this “linker” region has a separate function for the TrxR protein, three truncations of 
TrxR were made: a ∆effector consisting of the entire protein minus the predicted effector 
region (aa 1-389), a ∆receiver which removed the predicted receiver domain from TrxR 
(aa 118-494), and the effector alone (aa 390-494) (Fig 21A).  These regions were first 
cloned in-frame with His-MBP, and subsequently placed under PrpsL in the same manner 
as the other TrxR complementation constructs as previously discussed.  Each protein’s 
ability to complement a trxR- phenotype was then determined.  Real-time RT-PCR was 
performed on total RNA isolated at late-exponential phase and was used to measure 
levels of TrxR-regulated genes in a trxR- strain containing an empty vector, wild type 
His-MBP-TrxR, His-MBP-TrxR ∆effector, His-MBP-TrxR ∆receiver, and His-MBP-
TrxR effector alone.  From these experiments, the results indicate any portion of the TrxR 
protein is capable of rescuing a trxR- phenotype (Fig 21B), even only the last 104 C-














FIGURE 21.  Effect of TrxR truncations on the activity of the protein in vivo.  A, 
schematic of the WT TrxR protein showing CheY-like receiver domain and putative 
regulatory effector domain based on a Pfam domain search.  Also shown are schematics 
of the ∆effector, ∆receiver, and effector TrxR truncation proteins.  B, Transcript levels of 
emm, sic and opuAA from the trxR- (blue), WT TrxR (orange), ∆effector (green), 
∆receiver (purple), and effector alone (yellow) in the MGAS5005.trxR background.  To 
quantify the level of trxR transcript in the TrxR effector alone protein, separate primers 
were used in the 3’ end of the gene, as the main trxR primer set sits down closer to the 5’ 
end.  Shown as transcript fold-change relative to their corresponding WT transcript levels 
and normalized to the gyrA control.  Dotted lines at 0.5 and 2 represent cut-offs for the 












Receiver Domain! Putative Regulatory Domain!
390 481!
117!4!
N  C  CheY-like RD!
117!4!





















 While the interaction between TCS proteins and their mechanisms of action have 
been well studied, within GAS, the majority of this work has focused on the CovRS 
system.  This study focuses on TrxSR, the newly discovered TCS that activates virulence 
in S. pyogenes.  The evidence presented here shows that in vitro, TrxSR TCS is a 
functional phosphorelay, which requires the HTH domains of TrxR for binding to Pmga.  
However, our in vivo results suggest that neither the HTH domains of TrxR, or 
phosphorylation of the protein are necessary for activation of the Mga regulon.  While the 
exact mechanism of this interaction is not entirely fully understood, this work lays the 
groundwork for understanding how TrxR, and potentially other YesN homologs, interact 
with their target DNA to control gene expression.   
 
TrxSR is a functional phosphorelay, yet it may not be needed for TrxR’s Mga-
specific activity 
 In order for a TCS to sense a signal and create a specific internal response, a HK 
must be able to dimerize and bind ATP.  Once this has occurred, a phosphate is 
transferred from ATP to a conserved histidine residue in the catalytic domain of the HK.  
This phosphate is then subsequently transferred to a conserved aspartate residue within 
the receiver domain of the RR.  Typically, this transfer causes conformational changes to 
the protein that unblocks its effector domain, allowing the protein to perform its 
necessary effector function within the cell.  If dimerization of the HK and phosphate 
transfer between the two proteins does not occur, there usually cannot be a successful 
response created by the TCS. 
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 To ascertain whether TrxS can undergo dimerization/autophosphorylation and 
catalyze phosphorylation of TrxR, bacterial two-hybrid and phosphotransfer experiments 
were performed.  Using the soluble, signaling domain of TrxS, the experiments 
confirmed the catalytic histidine, H383, and verified that TrxS can dimerize and 
autophosphorylate within its predicted signaling domain.  Upon establishing functionality 
of the TrxS protein, it was next important to confirm that phosphotransfer from TrxS to 
TrxR could take place.  Here, we show that Asp-55 may indeed be the catalytic phospho-
accepting residue within this domain, as TrxS was capable of successfully transferring a 
radiolabeled phosphate to TrxR.  Additionally, when the aspartate was mutated to an 
uncharged alanine, this abrogated phosphotransfer, thus supporting the role of this 
aspartate in the transfer.  Although TrxS rapidly dephosphorylated upon addition of 
TrxR, there appears to be some loss of the radiolabeled ATP as only roughly 65% of the 
initial ATP from phospho-TrxS was transferred to TrxR.  Since TrxS may possess 
phosphatase activity, either against itself or TrxR, this could account for the missing 
radiolabel on either of the proteins.  Nevertheless, we have successfully reconstituted in 
vitro the TrxSR phosphorelay system.  
Given this result, the question became whether this interaction occurred within the 
GAS cell.  A co-immunoprecipitation assay using TrxR expressed in trans in the 
MGAS5005.trxR strain demonstrated that the native cytosolic portion of TrxS could be 
pulled down with the His-MBP-tagged TrxR.  In order to achieve this result, sustained 
protein-protein interactions between TrxS and TrxR must have occurred to withstand the 
centrifugation and washing steps of the procedure.  Since TrxS appears to physically 
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interact with TrxR within the GAS cell, albeit with one protein expressed off a plasmid, it 
strongly suggests that these two proteins do act like a canonical TCS in vivo.  
Interestingly, when in vivo experiments were performed to determine whether 
phosphorylation of TrxR was necessary for gene activation of mga, TrxR did not appear 
to need a phosphorylated aspartate within its active site to regulate gene expression.  Both 
the aspartate:alanine and aspartate:glutamate mutations appeared to complement and 
return gene transcript levels back to that of the wild type, suggesting that either form of 
TrxR, unphosphorylated or phosphorylated, appear to be used in regulation of gene 
expression.  Why, then, does TrxR participate in a phosphorelay with TrxS if 
phosphorylation of TrxR does not appear to correlate with its primary activity?  
Phosphorylation of TrxR must serve some purpose for the protein, as it is unlikely that it 
participates in a phosphorelay with TrxS for no additional gain.  The co-
immunoprecipitation assay also suggested that the TrxS-TrxR interaction depended on 
the phosphorylation state of TrxR, as a D55A mutant did not appear to pull-down any 
TrxS.  Therefore, it is plausible that TrxR may have one set of genes that it regulates in 
the absence of phosphorylation, and a second, potentially overlapping set that it regulates 
when phosphorylated.  Such is the case for CovR, as GAS uses both unphosphorylated 
and phosphorylated forms of the RR to regulate gene transcription (58).  In support for 
this hypothesis, our EMSA data showed that both the D55A and D55E proteins could 
bind to Pmga in vitro.  This would suggest that both forms of the protein are indeed, 
active, and may both be used in regulating gene expression.  However, what remains to 
be determined is how the roles of the two forms of the protein are actually different in 
reference to their activity.  
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One caveat of the in vivo complementation experiments, however, lies in the 
design of the plasmid from which His-MBP-TrxR is expressed.  The protein is expressed 
under PrpsL, which is a constitutive promoter that appears to be stronger than TrxR’s 
native PtrxT.  Additionally, this construct is expressed within GAS on a multi-copy 
plasmid.  Taken together, the amount of trxR transcript expressed from this plasmid is 
likely higher than native levels within the cell, when expressed from PtrxT.  As stated 
previously in Chapter 4, it appears that transcription from the PtrxT promoter is very 
tightly regulated.  This increase of trxR transcript, expressed off the plasmid from PrpsL, 
may translate into more total TrxR protein within the cell, allowing the trxR- phenotype 
to be overcome simply due to more TrxR protein around.  In order to test this 
explanation, TrxR would need to be expressed either under a weaker promoter and/or in 
single copy to reduce the amount of TrxR expressed from the plasmid.   
 
TrxR interacts with the promoter of mga 
 The results of the TrxR transcriptome analysis in MGAS5005 began our interest 
in TrxR’s relationship with Mga in GAS.  Since TrxR not only activates the Mga 
virulence regulon in MGAS5005, but in other serotypes as well, it became important to 
determine how TrxR was interacting with mga to cause this effect.  Due to the fact that 
TrxR activated the Mga regulon, our initial studies focused on using the firefly luciferase 
reporter gene fused to the promoter of mga, in order to monitor TrxR’s regulation of 
Pmga across growth.  Luciferase activity from Pmga-luc was assayed in the 
MGAS5005.trxR mutant and compared to that of the wild type and mga mutant.  Our 
results show that the trxR mutant exhibited significantly reduced Pmga-luc activity 
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compared to wild type at most time points.  Relative to the wild type strain, the levels of 
Pmga activity were similar for both the trxR and mga mutants.  Thus, from these data, it 
appeared that TrxR was activating the Mga regulon through regulation of Pmga. 
 As TrxR has a predicted AraC-like DNA binding domain at its C-terminus, our 
next investigation involved direct binding of TrxR to the promoter of mga.  In order to 
determine whether TrxR was capable of this binding, EMSAs were performed with 
purified His-MBP-TrxR and a Pmga probe that contained a large region of the 5’ UTR of 
mga.  Our results indicate that purified TrxR is able to bind specifically to the promoter 
of mga in vitro.  However, this interaction appears to be somewhat modest, resulting in a 
smear shift wherein the resulting protein-DNA interaction does not stay associated 
throughout the length of the gel.   The addition of greater amounts of TrxR protein does 
not appear to prolong or improve this interaction.  Nevertheless, TrxR does not bind to 
the promoter of emm, confirming that TrxR’s regulation of emm is not direct, and likely 
through Pmga.   
In an effort to determine whether the binding of TrxR to Pmga could be enhanced, 
experiments were run at 4°C to observe whether slowing down the interaction at a colder 
temperature could enable TrxR to bind to the DNA more tightly.  Unfortunately, it did 
not appear that we could enhance TrxR-Pmga binding in this manner.  Consequently, 
other factors within our EMSA reactions (i.e. length of probe, gel percentage, reaction 
component) could potentially be the cause of our smear, or it is possible that TrxR’s 
interaction with Pmga really may be very rapid and highly transient.  Thus the interaction 
of TrxR with the promoter of mga appears to be direct and the specificity of the 
interaction indicates that TrxR is capable of binding to the mga promoter.   
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Role of TrxR’s HTH domains 
 The HTH domains of AraC-like proteins allow the proteins to interact with the 
DNA of their respective regulated genes by inserting into two adjacent segments of the 
major groove of the DNA to bind.  These domains have been shown to be necessary for 
DNA binding for many well-characterized AraC-like proteins, such as MarA (205) and 
XylS (158).  In order to determine their importance in TrxR, two amino acids of each 
recognition helix in TrxR’s two putative HTH motifs were mutated to alanines to disrupt 
potential interactions with DNA. 
 DNA binding through TrxR’s HTH domains was assayed in vitro through EMSAs 
using a probe containing the promoter region of mga.  Using a His-MBP-tagged TrxR, 
DNA binding was assessed in both wild type and the HTH-1/2 versions of the protein.  
Although the shift created by wild type TrxR binding to Pmga was smeary and small for 
the highest amount of protein tested, almost the entirety of the unlabeled radiolabeled 
probe had shifted.  In contrast, the HTH-1/2 mutant had no visible shift when the protein 
was added, with the highest mutant TrxR concentration resembling the no protein lane.  
Since a double HTH mutant was used, whether this lack of binding is due to the 
mutations made in HTH-1 or HTH-2 cannot be determined at this time.  For other AraC-
like DNA binding proteins such as XylS, HTH-1 appears to be necessary for binding to 
the target DNA while HTH-2 is structurally, rather than functionally, required for specific 
DNA interactions (158).  Additional band-shift experiments would need to be completed 
with either single HTH mutant in order to determine whether the HTH domains of TrxR 
act in concert like those of XylS.  Nevertheless, the data presented here suggests that 
TrxR requires its HTH domains in vitro to bind to the promoter region of mga. 
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Surprisingly, when complementation experiments were performed to determine 
whether TrxR’s HTH domains were required for gene activation of mga, the HTH-1/2 
mutant was able to rescue the transcript levels of the TrxR regulated genes.  This 
suggests, potentially, that the HTH domains of TrxR are not necessary for in vivo binding 
to the mga promoter, which contradicts the in vitro data showing that the HTH mutant 
could not bind.  Although this may be a result of gene dosage as mentioned previously, 
there could also be another explanation.  For XylS of P. putida, the most important 
residues for DNA binding were not the residues within the HTH domains that were 
shown to make contact with the DNA, but rather residues that laid directly outside those 
domains that aided in its interaction with RNA polymerase (158).  Potentially, if these 
same key residues were mutated in TrxR and expressed in vivo, we might see trxR- like 
transcript levels for the HTH-1/2 mutant, as mutations of these residues may prevent 
TrxR’s interaction with RNA polymerase.  Additionally, it is plausible that TrxR may 
require interaction with RNA polymerase, and/or additional proteins at Pmga, for binding 
of TrxR to occur.    
Alternatively, TrxR may use an additional, alternative method of protein-DNA 
interaction outside of its AraC-like DNA binding domain.  While Pfam searches show 
only one putative DNA binding domain at the C-terminal end of the protein, there is a 
large region of the protein (~270 aa), assumed to be the ‘linker’ for the receiver and 
effector domains, that exhibits no functional homology to known characterized proteins 
(Fig 21A).  It is possible, then, that TrxR may have a second uncharacterized DNA 
binding domain that is not recognized or found by such programs as Pfam or Phyre2.  At 
this time, our results are not conclusive as to whether this region plays a significant role 
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in TrxR’s function.  As we attempted to make different truncations of the TrxR protein, 
in an effort to elucidate and tease out the role of this region, even the smallest truncated 
TrxR product tested was able to complement the trxR- phenotype.  We believed this 
protein, which only contains the last 104 aa of TrxR, and no receiver domain, was unable 
to complement the trxR- phenotype due to the fact that it lacked the majority of the 
protein.    
Ultimately, there are three likely explanations as to our results surrounding the 
mode of action TrxR uses.  As discussed previously, there is the issue of gene dosage, as 
all of our TrxR proteins are expressed under a constitutive promoter on a multi-copy 
plasmid.  Not until these proteins are expressed under their native promoter, in the 
chromosome, will this issue be resolved.  Additionally, TrxR may be regulated by an 
unidentified factor (e.g. protein-protein interactions) present in our in vivo, but not in 
vitro experiments.  This would allow TrxR binding to Pmga in our in vitro experiments, 
but be overlooked in our complementation experiments within GAS.  Therefore further 
experimentation is needed to elucidate if and what this additional factor may be.  And 
lastly, TrxR may participate in DNA binding through use of a second uncharacterized 
domain, in addition to the previously identified AraC-like DNA binding domain.  Despite 
not knowing which explanation(s) are correct at this time, we have mounting evidence 
surrounding the TrxR-Pmga interaction that enables us to begin to model how TrxR 





Conclusions and Recommendations 
 
 
 The Group A streptococcus (GAS) is a strict human-restricted pathogen that is 
able to cause a wide range of diseases in diverse niches within the human body.  In order 
adapt to these locations, GAS utilizes several two-component systems to regulate 
transcription of genes necessary for their survival in these environments.  In this study, 
TrxR, one of the previously uncharacterized TCSs, was chosen for further examination 
based upon its homology to known virulence TCSs.  The experiments presented aimed to 
identify the role of TrxSR to the GAS cell, as well as determine the mechanism by which 
TrxR interacts with, and regulates, its target genes.  Overall, these studies sought to shed 
light on the complex regulation networks used by this pathogen to adapt to host niches. 
 
Complex nature of the TrxR protein 
 The AraC protein family of transcriptional regulators encompasses a large breadth 
of diverse functional activities, ranging from proteins that are involved in sugar 
metabolism and the stress response, to those that are involved in the regulation of 
virulence.  TrxR represents a newly characterized AraC-like virulence regulator and joins 
previously described regulators of virulence such as AggR (178) and Rns (37) of E. coli, 
and VirF (62) of Shigella flexneri.   
Beyond its characterization as an AraC-like DNA-binding protein, TrxR also 
belongs to the YesN protein family, based upon its homology to the YesN response 
regulator of B. subtilis.  Interestingly, there is very little known about this family of 
regulators.  Previous characterizations of two-component systems found in the genomes 
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of both S. pneumoniae and E. faecalis have identified several YesN homologs.  RR07 of 
S. pneumoniae has been shown to be essential for full virulence in a pneumococcal 
mouse respiratory tract infection model (252), however no further characterization of its 
involvement in pneumococcal infection has been elucidated.  In E. faecalis, an RR01 
mutant had increased sensitivity to bacitracin, suggesting an involvement in the bacteria’s 
defense against antibiotics that target the cell-wall (92).   
Outside of these initial findings in S. pneumoniae and E. faecalis, no other 
published information exists for YesN homologs.  Intriguingly, each of the studies’ 
authors note the respective protein’s unusual domain organization, one that includes a 
predicted linker domain that is very large in comparison to other response regulators.  
Because of the length of this predicted linker, it has been postulated that this region of the 
protein might form its own entirely separate domain, apart from just serving as a flexible 
linker between the receiver and effector domains.  However, since there is no obvious 
similarity of this ‘linker’ to other protein sequences deposited in public databases, 
extrapolation of any further information becomes difficult.  Lange et al. has postulated 
that because of the large nature of this region, the YesN-like response regulator might be 
under dual control, one in which the cognate histidine kinase controls phosphorylation of 
the receiver domain, and another mechanism potentially controls the function of the 
insert region (133).  However, Hancock and Perego propose an alternative explanation.  
Due to the variability and length of the ‘linker’ region, they suggest that it may serve 
solely as a linker to tether the receiver and effector domains together (91).  Which 
author’s theory is correct still remains up for debate, as no experimental evidence 
presented here in this dissertation is concrete evidence for or against either model. 
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In support of Lange’s hypothesis, the STRING 8.3 bioinformatics program, a 
predictor of protein-protein interactions, has predicted that TrxR may have a binding 
partner in M5005_Spy_1062 (TCS5R), the 5th response regulator in the genome.  
Although many of the TCSs in GAS have been characterized, little is known about TCS5.  
An NCBI search of TCS5R predicts a role for the protein in maltodextrose utilization, 
although no direct connections between TCS5R and maltodextrin have been reported thus 
far.  Numerous studies have implicated a role of maltodextrose in GAS oropharynx 
infections (220, 221, 223), and the major virulence regulator CovR has also been shown 
to positively regulate TCS5 while negatively regulating TrxSR (81).  Is it therefore 
possible that unphosphorylated CovR activates TCS5R in response to maltodextrose, and 
leads to the binding of TCS5R to basal amounts of TrxR present in the cell, all before 
CovR becomes phosphorylated and has a chance to relieve its own repression of trxR?  
Thus, could TCS5R interact with TrxR in a separate, independent manner from either 
TrxS or CovR, and could this ‘linker’ region be an important binding domain for TCS5R 
to control TrxR’s activity?  With such a complex hypothesis, ascertaining the validity of 
this theory would begin with determining whether a separate function exists for the 
‘linker’ region of TrxR. Further experimentation aimed at understanding the overall 
domain structure and regulation of TrxR will potentially shed light on the complexities of 
this unique protein.  
 Interestingly, phosphorylation data may also indicate a multifaceted function for 
the TrxR protein within the GAS cell.  Our data suggest that phosphorylation of TrxR’s 
catalytic aspartate is not necessary for its gene activation of emm, sic or opuAA in vivo.  
Both the D55A and D55E catalytic mutants of TrxR were able to rescue a trxR- 
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phenotype, indicating that the phosphorylation status at D55 of TrxR is not critical to its 
ascribed function.  Why does TrxR participate in a phosphorelay with TrxS, then, if the 
phosphorylated form of TrxR acts no differently than its unphosphorylated counterpart to 
regulate gene expression?  Is it possible that TrxR is activated by a mechanism other than 
phosphorylation at D55?  Could there be a second site of phosphorylation in TrxR?  
Unfortunately, at the present time, answers to either of these questions remain unclear.  
If, for example, TrxR acted in a similar fashion to CheY of E. coli (7), then there may be 
a second site of possible phosphorylation at the N-terminal serine residue, Ser-54, in the 
absence of an aspartate at residue 55 in our TrxR D55A protein.  The adjacent serine 
residue may retain the ability to act as a ligand for Mg2+, due to its carbonyl residue, and 
thus could provide a second site for phosphorylation-induced activity in our TrxR D55A 
protein as it did for CheY’s D57N protein (7).  Additional experiments on such mutant 
proteins are necessary in order to assess the importance of this neighboring residue, and 
determine its significance to the in vitro phosphorylation and in vivo activity of TrxR.  
   
Global influence of TrxSR on regulation in GAS 
 GAS has the ability to cause a variety of diseases within the human host, and can 
infect different sites/tissues such as the respiratory tract, skin, and the bloodstream.  In 
order to infect such a wide range of environments, GAS coordinately regulates its factors 
for survival in these unique locations.  This study presents evidence suggesting that 
TrxSR represents a new pathway within GAS to influence disease progression.  Not only 
has it been shown that TrxSR is regulated by the CovRS TCS, but evidence presented 
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here also links TrxSR to Mga, a transcriptional regulator of the core virulence genes of 
GAS.   
 The stand-alone regulator Mga activates a defined set of “core” virulence genes 
encoding factors important for early stages of colonization and resistance to the host 
immune response (103).  Although the Mga regulon is induced by growth conditions such 
as logarithmic growth and elevated iron or CO2 levels, only a few regulatory networks 
have been linked to mga regulation.  The metal-dependent MtsR regulator can directly 
bind to Pmga and activate mga expression, suggesting a link between iron/metal 
homeostasis and the Mga regulon (256).  The stationary phase-associated stand-alone 
regulators Rgg/RopB, RofA, and Nra are known to repress mga expression, either 
directly or indirectly, providing a mechanism for shutting the Mga regulon down.  In 
addition, RivR/RALP4 appears to work with the Mga protein to directly enhance Mga 
activation of its target gene promoters, possibly through protein-protein interactions, and 
RivX, a small RNA, acts at the mga promoter to activate transcription of Mga regulon 
genes (210).  This work adds TrxSR to the list of regulators interacting with the Mga 
regulon.  Additionally, TrxSR not only represents the first TCS to regulate Mga 
expression, but it does so in a direct, activating manner.   
 We can now begin to model the complex interactions that occur between different 
regulatory pathways in GAS that influence disease progression (Fig 22).  The CovRS 
TCS plays a central role in this process by negatively regulating genes (ska, has, and sag) 
as well as several TCS regulatory loci linked to virulence, in response to stress and 
possibly other signals.  CovR also represses expression of rivR and rivX, encoding a 
stand-alone regulator and small RNA, respectively, which enhance transcriptional 
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activation by another stand-alone response regulator, Mga (Fig 22).  The newly defined 
virulence-associated TCS, TrxSR, is also able to directly activate transcription of mga 
and Mga-regulated genes in response to an as of yet unidentified in vivo signal (13).  
Therefore, there are two distinct pathways by which CovR downregulates Mga regulon 
expression and two separate opportunities for distinct signal input to control expression 
of these virulence genes.  The Mga virulence regulon is controlled by conditions 
conducive to productive growth such as CO2 levels and sugars (103).  Recent evidence 
suggests that the GAS phosphoenolpyruvate:carbohydrate phosphotransferase system and 
carbon catabolite repression through CcpA play a major role in this regulation.  Further 
identification of regulatory links between these virulence networks will help to better 
elucidate their contribution to pathogenesis and the complex interplay that occurs in vivo 








FIGURE 22.  Model for interacting virulence regulation in GAS.  Schematic 
representation of components for the CovRS TCS (green) and TrxSR TCS (blue) are 
shown.   Stand-alone regulators Mga (red) and RivR/RivX (purple) as well as CcpA 
(yellow) are shown within the context of a GAS cell.  Thin arrows show production of 
gene product(s) from the indicated promoter.  Thick arrowheads indicate activation, and 
thick flat ends reflect repression by the connected regulator.  Solid lines indicate direct 
regulation, while dashed lines indicate either indirect or unknown regulation.  Known or 
predicted external signals for the regulatory pathways are shown.     
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Interestingly, our transcriptome study that revealed these new interactions 
between the aforementioned virulence regulatory networks was completed at late 
logarithmic phase, a point in growth at which numerous transcriptional changes take 
place during the transition from exponential growth to stationary phase.  In addition to 
TrxR’s effect on mga at this growth point, TrxR also represses a small number of various 
genes involved in such processes as amino acid biosynthesis and the stress response.  In 
total, 29 gene transcripts were significantly affected.  Although this number appears low, 
it does not appear to be abnormal, as for example relatively few GAS genes (28) were 
affected by the Ihk/Irr TCS at a time period of 30 minutes post addition of the bacteria to 
PMNs (267).  However, the number of Irr-regulated genes increased at later time points 
in growth, growing the total Irr-regulon to well over 200 genes.  Additionally, as seen 
with the CovR response regulator, gene transcript levels varied widely across growth, 
with 98 and 229 gene transcripts affected in late-exponential and stationary phases of 
growth, respectively (81).  Because it appears that many RRs of GAS regulate different 
sets of genes at various points in growth, it’s possible that we may discover a larger TrxR 
regulon when transcriptome analyses at other points in growth are performed.    
As such, our PtrxT-luc experiments that assayed expression from PtrxT across 
growth (Fig 7), showed two points within growth where expression was maximal from 
this promoter.  The first point within growth, which showed high transcriptional 
expression from PtrxT, was late-logarithmic phase, the same time point chosen for the 
microarray.  Not only does this validate our reasoning for choosing this point for the 
microarray, but it also confirms our assumption that TrxR has an important role in the 
cell at this time.  The second peak seen in the PtrxT-luc expression profile appeared 
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roughly 60-90 minutes into stationary phase, and represents a point at which both CovR 
and SptR affect transcription of a wider range of genes than they do at any other period 
(81, 222).  Since we can only predict that TrxR might have a similar role in stationary 
phase, based upon its peak in transcriptional expression from the luciferase assay, it 
would be of interest to complete a transcriptome study in stationary phase to get a 
broader look at the overall TrxR regulon.   
Could TrxR be linked to such genes utilized in sugar metabolism early in 
stationary phase?  The position of trxTSR in the GAS chromosome may suggest that it 
could.  Not only is trxTSR located immediately downstream of an ABC sugar transport 
system, but trxR is located immediately upstream of and found to be sometimes co-
transcribed with β-galactosidase, an enzyme involved in the catabolism of lactose within 
the bacterial cell (Fig 5).  This central location of trxTSR between genes involved in sugar 
metabolism suggests a potential role or relationship for the TrxSR TCS with sugar 
transport and metabolism.  In fact, this entire trx region was found to be upregulated in an 
in vivo murine chamber infection model (13), suggesting that these systems may in fact 
be linked in some way during infection.  Consequently, when a second stationary-phase 
transcriptome study is complete, and a broader TrxR-regulon is described, we may begin 
to establish a link for other TrxR-regulated genes found in late-exponential phase and 
clarify the role of TrxR to the GAS cell.  
 
Summary 
 In conclusion, the results of this work have identified the role of the TrxSR TCS 
in the activation of the Mga-regulated virulence factors.  Beyond direct regulation of 
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these factors through interaction with Pmga, it was found that TrxR is a multifaceted 
protein with many complexities, including its requirement for phosphorylation.  Overall, 
the results provided within this dissertation have established TrxSR as a major 
contributor in the network of virulence regulation utilized by GAS to adapt to host 






1. Akao, T., T. Takahashi, and K. Kobashi. 1992. Purification and 
characterization of a peptide essential for formation of streptolysin S by 
Streptococcus pyogenes. Infection and Immunity 60:4777-80. 
2. Akesson, P., K. H. Schmidt, J. Cooney, and L. Bjorck. 1994. M1 protein and 
protein H: IgGFc- and albumin-binding streptococcal surface proteins encoded by 
adjacent genes. Biochemistry Journal 300 (Pt 3):877-86. 
3. Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nature Reviews 
Immunology 4:499-511. 
4. Almengor, A. C., T. L. Kinkel, S. J. Day, and K. S. McIver. 2007. The 
catabolite control protein CcpA binds to Pmga and influences expression of the 
virulence regulator Mga in the group A streptococcus. Journal of Bacteriology 
189:8405-8416. 
5. Andre, I., J. Persson, A. M. Blom, H. Nilsson, T. Drakenberg, G. Lindahl, 
and S. Linse. 2006. Streptococcal M protein: structural studies of the 
hypervariable region, free and bound to human C4BP. Biochemistry 45:4559-68. 
6. Anthony, B. F. 2000. Streptococcal pyoderma, p. 144-151. In D. L. Stevens and 
E. L. Kaplan (ed.), Streptococcal Infections: Clinical Aspects, Microbiology, and 
Molecular Pathogenesis. Oxford University Press, New York. 
7. Appleby, J. L., and R. B. Bourret. 1999. Activation of CheY mutant D57N by 
phosphorylation at an alternative site, Ser-56. Molecular Microbiology 34:915-25. 
8. Appleby, J. L., and R. B. Bourret. 1998. Proposed signal transduction role for 
conserved CheY residue Thr87, a member of the response regulator active-site 
quintet. Journal of Bacteriology 180:3563-9. 
9. Ashbaugh, C. D., H. B. Warren, V. J. Carey, and M. R. Wessels. 1998. 
Molecular analysis of the role of the group A streptococcal cysteine protease, 
hyaluronic acid capsule, and M protein in a murine model of human invasive soft-
tissue infection. Journal of Clinical Investigations 102:550-60. 
10. Ashbaugh, C. D., and M. R. Wessels. 2001. Absence of a cysteine protease 
effect on bacterial virulence in two murine models of human invasive group A 
streptococcal infection. Infection and Immunity 69:6683-8. 
11. Ausubel, F., R. Brent, R. Kingston, D. Moore, J. Seidman, J. Smith, and K. 
Struhl (ed.). 1997. Short Protocols in Molecular Biology, 3rd ed. John Wiley & 
Sons, Inc., New York. 
12. Aziz, R. K., R. A. Edwards, W. W. Taylor, D. E. Low, A. McGeer, and M. 
Kotb. 2005. Mosaic prophages with horizontally acquired genes account for the 
emergence and diversification of the globally disseminated M1T1 clone of 
Streptococcus pyogenes. Journal of Bacteriology 187:3311-8. 
13. Aziz, R. K., R. Kansal, B. J. Aronow, W. L. Taylor, S. L. Rowe, M. Kubal, G. 
S. Chhatwal, M. J. Walker, and M. Kotb. 2010. Microevolution of group A 
streptococci in vivo: capturing regulatory networks engaged in 
sociomicrobiology, niche adaptation, and hypervirulence. PLoS One 5:e9798. 
14. Aziz, R. K., M. J. Pabst, A. Jeng, R. Kansal, D. E. Low, V. Nizet, and M. 
Kotb. 2004. Invasive M1T1 group A Streptococcus undergoes a phase-shift in 
 144 
vivo to prevent proteolytic degradation of multiple virulence factors by SpeB. 
Molecular Microbiology 51:123-34. 
15. Bader, M. W., S. Sanowar, M. E. Daley, A. R. Schneider, U. Cho, W. Xu, R. 
E. Klevit, H. Le Moual, and S. I. Miller. 2005. Recognition of antimicrobial 
peptides by a bacterial sensor kinase. Cell 122:461-72. 
16. Bates, C. S., C. Toukoki, M. N. Neely, and Z. Eichenbaum. 2005. 
Characterization of MtsR, a new metal regulator in group A streptococcus, 
involved in iron acquisition and virulence. Infection and Immunity 73:5743-53. 
17. Beall, B., R. Facklam, and T. Thompson. 1996. Sequencing emm-specific PCR 
products for routine and accurate typing of group A streptococci. Journal of 
Clinical Microbiology 34:953-8. 
18. Beall, B., G. Gherardi, M. Lovgren, R. R. Facklam, B. A. Forwick, and G. J. 
Tyrrell. 2000. emm and sof gene sequence variation in relation to serological 
typing of opacity-factor-positive group A streptococci. Microbiology 146 (Pt 
5):1195-209. 
19. Beckert, S., B. Kreikemeyer, and A. Podbielski. 2001. Group A streptococcal 
rofA gene is involved in the control of several virulence genes and eukaryotic cell 
attachment and internalization. Infection and Immunity 69:534-537. 
20. Beres, S. B., E. W. Richter, M. J. Nagiec, P. Sumby, S. F. Porcella, F. R. 
DeLeo, and J. M. Musser. 2006. Molecular genetic anatomy of inter- and 
intraserotype variation in the human bacterial pathogen group A Streptococcus. 
Proceedings of the National Academy of Sciences of the United States of America 
103:7059-64. 
21. Bernish, B., and I. van de Rijn. 1999. Characterization of a two-component 
system in Streptococcus pyogenes which is involved in regulation of hyaluronic 
acid production. Journal of Biological Chemistry 274:4786-93. 
22. Bessen, D., K. F. Jones, and V. A. Fischetti. 1989. Evidence for two distinct 
classes of streptococcal M protein and their relationship to rheumatic fever. 
Journal of Experimental Medicine 169:269-283. 
23. Bessen, D. E. 2009. Population biology of the human restricted pathogen, 
Streptococcus pyogenes. Infection, Genetics, and Evolution 9:581-93. 
24. Bessen, D. E., A. Manoharan, F. Luo, J. E. Wertz, and D. A. Robinson. 2005. 
Evolution of transcription regulatory genes is linked to niche specialization in the 
bacterial pathogen Streptococcus pyogenes. Journal of Bacteriology 187:4163-72. 
25. Bilwes, A. M., L. A. Alex, B. R. Crane, and M. I. Simon. 1999. Structure of 
CheA, a signal-transducing histidine kinase. Cell 96:131-41. 
26. Bisno, A. L., M. O. Brito, and C. M. Collins. 2003. Molecular basis of group A 
streptococcal virulence. Lancet Infectious Diseases 3:191-200. 
27. Bisno, A. L., and D. L. Stevens. 1996. Streptococcal infections of skin and soft 
tissues. New England Journal of Medicine 334:240-5. 
28. Borkovich, K. A., L. A. Alex, and M. I. Simon. 1992. Attenuation of sensory 
receptor signaling by covalent modification. Proceedings of the National 
Academy of Sciences of the United States of America 89:6756-60. 
29. Boyle, M. D., R. Raeder, A. Flosdorff, and A. Podbielski. 1998. Role of emm 
and mrp genes in the virulence of group A streptococcal isolate 64/14 in a mouse 
model of skin infection. Journal of Infectious Disease 177:991-997. 
 145 
30. Bricker, A. L., V. J. Carey, and M. R. Wessels. 2005. Role of NADase in 
virulence in experimental invasive group A streptococcal infection. Infection and 
Immunity 73:6562-6. 
31. Bricker, A. L., C. Cywes, C. D. Ashbaugh, and M. R. Wessels. 2002. NAD+-
glycohydrolase acts as an intracellular toxin to enhance the extracellular survival 
of group A streptococci. Molecular Microbiology 44:257-69. 
32. Brunskill, E. W., and K. W. Bayles. 1996. Identification and molecular 
characterization of a putative regulatory locus that affects autolysis in 
Staphylococcus aureus. Journal of Bacteriology 178:611-8. 
33. Buchanan, J. T., A. J. Simpson, R. K. Aziz, G. Y. Liu, S. A. Kristian, M. 
Kotb, J. Feramisco, and V. Nizet. 2006. DNase expression allows the pathogen 
group A Streptococcus to escape killing in neutrophil extracellular traps. Current 
Biology 16:396-400. 
34. Burbulys, D., K. A. Trach, and J. A. Hoch. 1991. Initiation of sporulation in B. 
subtilis is controlled by a multicomponent phosphorelay. Cell 64:545-52. 
35. Caparon, M. G., R. T. Geist, J. Perez-Casal, and J. R. Scott. 1992. 
Environmental regulation of virulence in group A streptococci: transcription of 
the gene encoding M protein is stimulated by carbon dioxide. Journal of 
Bacteriology 174:5693-5701. 
36. Carapetis, J. R., A. C. Steer, E. K. Mulholland, and M. Weber. 2005. The 
global burden of group A streptococcal diseases. The Lancet Infectious Diseases 
5:685-94. 
37. Caron, J., L. M. Coffield, and J. R. Scott. 1989. A plasmid-encoded regulatory 
gene, rns, required for expression of the CS1 and CS2 adhesins of enterotoxigenic 
Escherichia coli. Proceedings of the National Academy of Sciences of the United 
States of America 86:963-7. 
38. Carr, A., D. D. Sledjeski, A. Podbielski, M. D. Boyle, and B. Kreikemeyer. 
2001. Similarities between complement-mediated and streptolysin S-mediated 
hemolysis. Journal of Biological Chemistry 276:41790-6. 
39. Caswell, C. C., R. Han, K. M. Hovis, P. Ciborowski, D. R. Keene, R. T. 
Marconi, and S. Lukomski. 2008. The Scl1 protein of M6-type group A 
Streptococcus binds the human complement regulatory protein, factor H, and 
inhibits the alternative pathway of complement. Molecular Microbiology 67:584-
96. 
40. Chang, C., and R. C. Stewart. 1998. The two-component system. Regulation of 
diverse signaling pathways in prokaryotes and eukaryotes. Plant Physiology 
117:723-31. 
41. Chassy, B. M. 1976. A gentle method for the lysis of oral streptococci. 
Biochemical and Biophysical Research Communication 68:603-8. 
42. Chaussee, M. A., E. A. Callegari, and M. S. Chaussee. 2004. Rgg regulates 
growth phase-dependent expression of proteins associated with secondary 
metabolism and stress in Streptococcus pyogenes. Journal of Bacteriology 
186:7091-9. 
43. Chaussee, M. S., D. Ajdic, and J. J. Ferretti. 1999. The rgg gene of 
Streptococcus pyogenes NZ131 positively influences extracellular SPE B 
production. Infection and Immunity 67:1715-22. 
 146 
44. Chaussee, M. S., G. A. Somerville, L. Reitzer, and J. M. Musser. 2003. Rgg 
coordinates virulence factor synthesis and metabolism in Streptococcus pyogenes. 
Journal of Bacteriology 185:6016-24. 
45. Chaussee, M. S., G. L. Sylva, D. E. Sturdevant, L. M. Smoot, M. R. Graham, 
R. O. Watson, and J. M. Musser. 2002. Rgg influences the expression of 
multiple regulatory loci to coregulate virulence factor expression in Streptococcus 
pyogenes. Infection and Immunity 70:762-70. 
46. Chen, C., N. Bormann, and P. P. Cleary. 1993. VirR and Mry are homologous 
trans-acting regulators of M protein and C5a peptidase expression in group A 
streptococci. Molecular and General Genetics 241:685-693. 
47. Chen, S. M., Y. S. Tsai, C. M. Wu, S. K. Liao, L. C. Wu, C. S. Chang, Y. H. 
Liu, and P. J. Tsai. 2010. Streptococcal collagen-like surface protein 1 promotes 
adhesion to the respiratory epithelial cell. BMC Microbiology 10:320. 
48. Cleary, P. P., Y. V. Matsuka, T. Huynh, H. Lam, and S. B. Olmsted. 2004. 
Immunization with C5a peptidase from either group A or B streptococci enhances 
clearance of group A streptococci from intranasally infected mice. Vaccine 
22:4332-41. 
49. Cleary, P. P., U. Prahbu, J. B. Dale, D. E. Wexler, and J. Handley. 1992. 
Streptococcal C5a peptidase is a highly specific endopeptidase. Infection and 
Immunity 60:5219-23. 
50. Collin, M., M. D. Svensson, A. G. Sjoholm, J. C. Jensenius, U. Sjobring, and 
A. Olsen. 2002. EndoS and SpeB from Streptococcus pyogenes inhibit 
immunoglobulin-mediated opsonophagocytosis. Infection and Immunity 70:6646-
51. 
51. Connolly, K. L., A. L. Roberts, R. C. Holder, and S. D. Reid. 2011. Dispersal 
of Group A Streptococcal Biofilms by the Cysteine Protease SpeB Leads to 
Increased Disease Severity in a Murine Model. PLoS One 6:e18984. 
52. Courtney, H. S., J. B. Dale, and D. I. Hasty. 1996. Differential effects of the 
streptococcal fibronectin-binding protein, FBP54, on adhesion of group A 
streptococci to human buccal cells and HEp-2 tissue culture cells. Infection and 
Immunity 64:2415-9. 
53. Courtney, H. S., D. L. Hasty, Y. Li, H. C. Chiang, J. L. Thacker, and J. B. 
Dale. 1999. Serum opacity factor is a major fibronectin-binding protein and a 
virulence determinant of M type 2 Streptococcus pyogenes. Molecular 
Microbiology 32:89-98. 
54. Courtney, H. S., Y. M. Zhang, M. W. Frank, and C. O. Rock. 2006. Serum 
opacity factor, a streptococcal virulence factor that binds to apolipoproteins A-I 
and A-II and disrupts high density lipoprotein structure. Journal of Biological 
Chemistry 281:5515-21. 
55. Cunningham, M. W. 2000. Pathogenesis of group A streptococcal infections. 
Clinical Microbiology Reviews 13:470-511. 
56. Dale, J. B., and E. H. Beachey. 1985. Epitopes of streptococcal M proteins 
shared with cardiac myosin. Journal of Experimental Medicine 162:583-91. 
57. Dalton, T. L., R. I. Hobb, and J. R. Scott. 2006. Analysis of the role of CovR 
and CovS in the dissemination of Streptococcus pyogenes in invasive skin 
disease. Microbial Pathogenesis 40:221-7. 
 147 
58. Dalton, T. L., and J. R. Scott. 2004. CovS inactivates CovR and is required for 
growth under conditions of general stress in Streptococcus pyogenes. Journal of 
Bacteriology 186:3928-37. 
59. Datta, V., S. M. Myskowski, L. A. Kwinn, D. N. Chiem, N. Varki, R. G. 
Kansal, M. Kotb, and V. Nizet. 2005. Mutational analysis of the group A 
streptococcal operon encoding streptolysin S and its virulence role in invasive 
infection. Molecular Microbiology 56:681-95. 
60. Denny, F. W., Jr. 2000. History of hemolytic streptococci and associated 
diseases, p. 1-18. In D. L. Stevens and E. L. Kaplan (ed.), Streptococcal 
Infections: Clinical Aspects, Microbiology, and Molecular Pathogenesis. Oxford 
University Press, New York. 
61. Doern, C. D., A. L. Roberts, W. Hong, J. Nelson, S. Lukomski, W. E. Swords, 
and S. D. Reid. 2009. Biofilm formation by group A Streptococcus: a role for the 
streptococcal regulator of virulence (Srv) and streptococcal cysteine protease 
(SpeB). Microbiology 155:46-52. 
62. Dorman, C. J. 1992. The VirF protein from Shigella flexneri is a member of the 
AraC transcription factor superfamily and is highly homologous to Rns, a positive 
regulator of virulence genes in enterotoxigenic Escherichia coli. Molecular 
Microbiology 6:1575-6. 
63. Dumon-Seignovert, L., G. Cariot, and L. Vuillard. 2004. The toxicity of 
recombinant proteins in Escherichia coli: a comparison of overexpression in 
BL21(DE3), C41(DE3), and C43(DE3). Protein Expression and Purification 
37:203-6. 
64. Dutta, R., and M. Inouye. 1996. Reverse phosphotransfer from OmpR to EnvZ 
in a kinase-/phosphatase+ mutant of EnvZ (EnvZ.N347D), a bifunctional signal 
transducer of Escherichia coli. Journal of Biological Chemistry 271:1424-9. 
65. Eberhard, T. H., D. D. Sledjeski, and M. D. Boyle. 2001. Mouse skin passage 
of a Streptococcus pyogenes Tn917 mutant of sagA/pel restores virulence, beta-
hemolysis and sagA/pel expression without altering the position or sequence of 
the transposon. BMC Microbiology 1:33. 
66. Edwards, R. J., G. W. Taylor, M. Ferguson, S. Murray, N. Rendell, A. 
Wrigley, Z. Bai, J. Boyle, S. J. Finney, A. Jones, H. H. Russell, C. Turner, J. 
Cohen, L. Faulkner, and S. Sriskandan. 2005. Specific C-terminal cleavage and 
inactivation of interleukin-8 by invasive disease isolates of Streptococcus 
pyogenes. Journal of Infectious Diseases 192:783-90. 
67. Eriksson, A., and M. Norgren. 2003. Cleavage of antigen-bound 
immunoglobulin G by SpeB contributes to streptococcal persistence in opsonizing 
blood. Infection and Immunity 71:211-7. 
68. Fabret, C., V. A. Feher, and J. A. Hoch. 1999. Two-component signal 
transduction in Bacillus subtilis: how one organism sees its world. Journal of 
Bacteriology 181:1975-83. 
69. Federle, M. J., K. S. McIver, and J. R. Scott. 1999. A response regulator that 
represses transcription of several virulence operons in the group A streptococcus. 
Journal of Bacteriology 181:3649-3657. 
70. Fernie-King, B. A., D. J. Seilly, A. Davies, and P. J. Lachmann. 2002. 
Streptococcal inhibitor of complement inhibits two additional components of the 
 148 
mucosal innate immune system: secretory leukocyte proteinase inhibitor and 
lysozyme. Infection and Immunity 70:4908-16. 
71. Fernie-King, B. A., D. J. Seilly, C. Willers, R. Wurzner, A. Davies, and P. J. 
Lachmann. 2001. Streptococcal inhibitor of complement (SIC) inhibits the 
membrane attack complex by preventing uptake of C567 onto cell membranes. 
Immunology 103:390-8. 
72. Fogg, G. C., C. M. Gibson, and M. G. Caparon. 1994. The identification of 
rofA, a positive-acting regulatory component of prtF expression: use of an m-
gamma-delta-based shuttle mutagenesis strategy in Streptococcus pyogenes. 
Molecular Microbiology 11:671-684. 
73. Foussard, M., S. Cabantous, J.-D. Pedelacq, V. Guillet, S. Tranier, L. 
Mourey, C. Birck, and J.-P. Samama. 2001. The Molecular Puzzle of Two-
Component Signaling Cascades. Microbes and Infection 3:417-424. 
74. Frick, I. M., P. Akesson, M. Rasmussen, A. Schmidtchen, and L. Bjorck. 
2003. SIC, a secreted protein of Streptococcus pyogenes that inactivates 
antibacterial peptides. Journal of Biological Chemistry 278:16561-6. 
75. Gallegos, M. T., R. Schleif, A. Bairoch, K. Hofmann, and J. L. Ramos. 1997. 
Arac/XylS family of transcriptional regulators. Microbiology and Molecular 
Biology Reviews 61:393-410. 
76. Galperin, M. Y. 2006. Structural classification of bacterial response regulators: 
diversity of output domains and domain combinations. Journal of Bacteriology 
188:4169-82. 
77. Gao, R., and A. M. Stock. 2009. Biological insights from structures of two-
component proteins. Annual Review of Microbiology 63:133-54. 
78. Garcia, A. F., L. M. Abe, G. Erdem, C. L. Cortez, D. Kurahara, and K. 
Yamaga. 2010. An insert in the covS gene distinguishes a pharyngeal and a blood 
isolate of Streptococcus pyogenes found in the same individual. Microbiology 
156:3085-95. 
79. Gerlach, D., K. H. Schmidt, and B. Fleischer. 2001. Basic streptococcal 
superantigens (SPEX/SMEZ or SPEC) are responsible for the mitogenic activity 
of the so-called mitogenic factor (MF). FEMS Immunology and Medical 
Microbiology 30:209-16. 
80. Ginsburg, I. 1999. Is streptolysin S of group A streptococci a virulence factor? 
Acta Pathologica, Microbiologica et Immunologica Scandinavica 107:1051-9. 
81. Graham, M. R., L. M. Smoot, C. A. Migliaccio, K. Virtaneva, D. E. 
Sturdevant, S. F. Porcella, M. J. Federle, G. J. Adams, J. R. Scott, and J. M. 
Musser. 2002. Virulence control in group A streptococcus by a two-component 
gene regulatory system: global expression profiling and in vivo infection 
modeling. Proceedings of the National Academy of Sciences of the United States 
of America 99:13855-60. 
82. Graham, M. R., K. Virtaneva, S. F. Porcella, W. T. Barry, B. B. Gowen, C. R. 
Johnson, F. A. Wright, and J. M. Musser. 2005. Group A Streptococcus 
transcriptome dynamics during growth in human blood reveals bacterial adaptive 
and survival strategies. American Journal of Pathology 166:455-65. 
83. Graham, M. R., K. Virtaneva, S. F. Porcella, D. J. Gardner, R. D. Long, D. 
M. Welty, W. T. Barry, C. A. Johnson, L. D. Parkins, F. A. Wright, and J. M. 
 149 
Musser. 2006. Analysis of the transcriptome of group A Streptococcus in mouse 
soft tissue infection. American Journal of Pathology 169:927-42. 
84. Grebe, T. W., and J. B. Stock. 1999. The histidine protein kinase superfamily. 
Advances in Microbial Physiology 41:139-227. 
85. Griffiths, B. B., and O. McClain. 1988. The role of iron in the growth and 
hemolysin (Streptolysin S) production in Streptococcus pyogenes. Journal of 
Basic Microbiology 28:427-36. 
86. Gryllos, I., J. C. Levin, and M. R. Wessels. 2003. The CsrR/CsrS two-
component system of group A streptococcus responds to environmental Mg2+. 
Proceedings of the National Academy of Sciences of the United States of America 
100:4227-32. 
87. Guzman, C. A., S. R. Talay, G. Molinari, E. Medina, and G. S. Chhatwal. 
1999. Protective immune response against Streptococcus pyogenes in mice after 
intranasal vaccination with the fibronectin-binding protein SfbI. Journal of 
Infectious Diseases 179:901-6. 
88. Haanes, E. J., D. G. Heath, and P. P. Cleary. 1992. Architecture of the vir 
regulons of group A streptococci parallels opacity factor phenotype and M protein 
class. Journal of Bacteriology 174:4967-4976. 
89. Hallas, G., and J. P. Widdowson. 1982. The opacity factor of group-A 
streptococci. Journal of Medical Microbiology 15:451-64. 
90. Hanahan, D., and M. Meselson. 1983. Plasmid screening at high colony density. 
Methods in Enzymology 100:333-42. 
91. Hancock, L., and M. Perego. 2002. Two-component signal transduction in 
Enterococcus faecalis. Journal of Bacteriology 184:5819-25. 
92. Hancock, L. E., and M. Perego. 2004. Systematic inactivation and phenotypic 
characterization of two-component signal transduction systems of Enterococcus 
faecalis V583. Journal of Bacteriology 186:7951-8. 
93. Hanski, E., and M. Caparon. 1992. Protein F, a fibronectin-binding protein, is 
an adhesin of the group A streptococcus Streptococcus pyogenes. Proceedings of 
the National Academy of Sciences of the United States of America 89:6172-6176. 
94. Hastings, C. A., S. Y. Lee, H. S. Cho, D. Yan, S. Kustu, and D. E. Wemmer. 
2003. High-resolution solution structure of the beryllofluoride-activated NtrC 
receiver domain. Biochemistry 42:9081-90. 
95. Hasty, D. L., I. Ofek, H. S. Courtney, and R. J. Doyle. 1992. Multiple adhesins 
of streptococci. Infection and Immunity 60:2147-52. 
96. Hava, D. L., and A. Camilli. 2002. Large-scale identification of serotype 4 
Streptococcus pneumoniae virulence factors. Molecular Microbiology 45:1389-
406. 
97. Heath, A., V. J. DiRita, N. L. Barg, and N. C. Engleberg. 1999. A two-
component regulatory system, CsrR-CsrS, represses expression of three 
Streptococcus pyogenes virulence factors, hyaluronic acid capsule, streptolysin S, 
and pyrogenic exotoxin B. Infection and Immunity 67:5298-5305. 
98. Ho, S. N., H. D. Hunt, R. M. Horton, J. K. Pullen, and L. R. Pease. 1989. Site-
directed mutagenesis by overlap extension using the polymerase chain reaction. 
Gene 77:51-9. 
 150 
99. Hoe, N. P., R. M. Ireland, F. R. DeLeo, B. B. Gowen, D. W. Dorward, J. M. 
Voyich, M. Liu, E. H. Burns, Jr., D. M. Culnan, A. Bretscher, and J. M. 
Musser. 2002. Insight into the molecular basis of pathogen abundance: group A 
streptococcus inhibitor of complement inhibits bacterial adherence and 
internalization into human cells. Proceedings of the National Academy of 
Sciences of the United States of America 99:7646-51. 
100. Hollingshead, S. K., V. A. Fischetti, and J. R. Scott. 1987. Size variation in 
group A streptococcal M protein is generated by homologous recombination 
between intragenic repeats. Molecular and General Genetics 207:196-203. 
101. Hollingshead, S. K., T. L. Readdy, D. L. Yung, and D. E. Bessen. 1993. 
Structural heterogeneity of the emm gene cluster in group A streptococci. 
Molecular Microbiology 8:707-17. 
102. Holm, S. E., A. Nordstrand, D. L. Stevens, and M. Norgreen. 2000. Acute 
poststreptococcal glomerulonephritis, p. 152-62. In D. L. Stevens and E. L. 
Kaplan (ed.), Streptococcal Infections: Clinical Aspects, Microbiology, and 
Molecular Pathogenesis. Oxford University Press, New York. 
103. Hondorp, E. R., and K. S. McIver. 2007. The Mga virulence regulon: infection 
where the grass is greener. Molecular Microbiology 66:1056-65. 
104. Horstmann, R. D., H. J. Sievertsen, J. Knobloch, and V. A. Fischetti. 1988. 
Antiphagocytic activity of streptococcal M protein: selective binding of 
complement control protein factor H. Proceedings of the National Academy of 
Sciences of the United States of America 85:1657-61. 
105. Horstmann, R. D., H. J. Sievertsen, M. Leippe, and V. A. Fischetti. 1992. Role 
of fibrinogen in complement inhibition by streptococcal M protein. Infection and 
Immunity 60:5036-41. 
106. Hsing, W., and T. J. Silhavy. 1997. Function of conserved histidine-243 in 
phosphatase activity of EnvZ, the sensor for porin osmoregulation in Escherichia 
coli. Journal of Bacteriology 179:3729-35. 
107. Hu, M. C., M. A. Walls, S. D. Stroop, M. A. Reddish, B. Beall, and J. B. Dale. 
2002. Immunogenicity of a 26-valent group A streptococcal vaccine. Infection 
and Immunity 70:2171-7. 
108. Jaffe, J., S. Natanson-Yaron, M. G. Caparon, and E. Hanski. 1996. Protein 
F2, a novel fibronectin-binding protein from Streptococcus pyogenes, possesses 
two binding domains. Molecular Microbiology 21:373-84. 
109. Jeng, A., V. Sakota, Z. Li, V. Datta, B. Beall, and V. Nizet. 2003. Molecular 
genetic analysis of a group A streptococcus operon encoding serum opacity factor 
and a novel fibronectin-binding protein, SfbX. Journal of Bacteriology 185:1208-
17. 
110. Ji, Y., B. Carlson, A. Kondagunta, and P. P. Cleary. 1997. Intranasal 
immunization with C5a peptidase prevents nasopharyngeal colonization of mice 
by the group A streptococcus. Infection and Immunity 65:2080-2087. 
111. Ji, Y., L. McLandsborough, A. Kondagunta, and P. P. Cleary. 1996. C5a 
peptidase alters clearance and trafficking of group A streptococci by infected 
mice. Infection and Immunity 64:503-10. 
112. Karasawa, T., S. Takasawa, K. Yamakawa, H. Yonekura, H. Okamoto, and 
S. Nakamura. 1995. NAD(+)-glycohydrolase from Streptococcus pyogenes 
 151 
shows cyclic ADP-ribose forming activity. FEMS Microbiology Letters 130:201-
4. 
113. Karimova, G., J. Pidoux, A. Ullmann, and D. Ladant. 1998. A bacterial two-
hybrid system based on a reconstituted signal transduction pathway. Proceedings 
of the National Academy of Sciences of the United States of America 95:5752-6. 
114. Katerov, V., P. E. Lindgren, A. A. Totolian, and C. Schalen. 2000. 
Streptococcal opacity factor: a family of bifunctional proteins with lipoproteinase 
and fibronectin-binding activities. Current Microbiology 40:149-56. 
115. Kawamukai, M., K. Ferguson, M. Wigler, and D. Young. 1991. Genetic and 
biochemical analysis of the adenylyl cyclase of Schizosaccharomyces pombe. 
Cell Regulation 2:155-64. 
116. Keener, J., and S. Kustu. 1988. Protein kinase and phosphoprotein phosphatase 
activities of nitrogen regulatory proteins NTRB and NTRC of enteric bacteria: 
roles of the conserved amino-terminal domain of NTRC. Proceedings of the 
National Academy of Sciences of the United States of America 85:4976-80. 
117. Kern, D., B. F. Volkman, P. Luginbuhl, M. J. Nohaile, S. Kustu, and D. E. 
Wemmer. 1999. Structure of a transiently phosphorylated switch in bacterial 
signal transduction. Nature 402:894-8. 
118. Kihlberg, B. M., J. Cooney, M. G. Caparon, A. Olsen, and L. Bjorck. 1995. 
Biological properties of a Streptococcus pyogenes mutant generated by Tn916 
insertion in mga. Microbial Pathogenesis 19:299-315. 
119. Kinkel, T. L., and K. S. McIver. 2008. CcpA-mediated repression of 
streptolysin S expression and virulence in the group A streptococcus. Infection 
and Immunity 76:3451-63. 
120. Kizy, A. E., and M. N. Neely. 2009. First Streptococcus pyogenes signature-
tagged mutagenesis screen identifies novel virulence determinants. Infection and 
Immunity 77:1854-65. 
121. Klenk, M., D. Koczan, R. Guthke, M. Nakata, H. J. Thiesen, A. Podbielski, 
and B. Kreikemeyer. 2005. Global epithelial cell transcriptional responses reveal 
Streptococcus pyogenes Fas regulator activity association with bacterial 
aggressiveness. Cellular Microbiology 7:1237-50. 
122. Kotb, M. 1995. Bacterial pyrogenic exotoxins as superantigens. Clinical 
Microbiology Reviews 8:411-426. 
123. Kreikemeyer, B., S. Beckert, A. Braun-Kiewnick, and A. Podbielski. 2002. 
Group A streptococcal RofA-type global regulators exhibit a strain-specific 
genomic presence and regulation pattern. Microbiology 148:1501-11. 
124. Kreikemeyer, B., M. D. Boyle, B. A. Buttaro, M. Heinemann, and A. 
Podbielski. 2001. Group A streptococcal growth phase-associated virulence 
factor regulation by a novel operon (Fas) with homologies to two-component-type 
regulators requires a small RNA molecule. Molecular Microbiology 39:392-406. 
125. Kreikemeyer, B., D. R. Martin, and G. S. Chhatwal. 1999. SfbII protein, a 
fibronectin binding surface protein of group A streptococci, is a serum opacity 
factor with high serotype-specific apolipoproteinase activity. FEMS Microbiology 
Letters 178:305-11. 
126. Kreikemeyer, B., M. Nakata, T. Koller, H. Hildisch, V. Kourakos, K. 
Standar, S. Kawabata, M. O. Glocker, and A. Podbielski. 2007. The 
 152 
Streptococcus pyogenes serotype M49 Nra-Ralp3 transcriptional regulatory 
network and its control of virulence factor expression from the novel eno ralp3 
epf sagA pathogenicity region. Infection and Immunity 75:5698-5710. 
127. Kreikemeyer, B., M. Nakata, S. Oehmcke, C. Gschwendtner, J. Normann, 
and A. Podbielski. 2005. Streptococcus pyogenes collagen type I-binding Cpa 
surface protein. Expression profile, binding characteristics, biological functions, 
and potential clinical impact. Journal of Biological Chemistry 280:33228-39. 
128. Kreikemeyer, B., S. R. Talay, and G. S. Chhatwal. 1995. Characterization of a 
novel fibronectin-binding surface protein in group A streptococci. Molecular 
Microbiology 17:137-45. 
129. Krell, T., J. Lacal, A. Busch, H. Silva-Jimenez, M. E. Guazzaroni, and J. L. 
Ramos. 2010. Bacterial sensor kinases: diversity in the recognition of 
environmental signals. Annual Review of Microbiology 64:539-59. 
130. Kwinn, L. A., A. Khosravi, R. K. Aziz, A. M. Timmer, K. S. Doran, M. Kotb, 
and V. Nizet. 2007. Genetic characterization and virulence role of the 
RALP3/LSA locus upstream of the streptolysin s operon in invasive M1T1 Group 
A Streptococcus. Journal of Bacteriology 189:1322-9. 
131. Lancefield, R. C. 1933. A serological differentiation of human and other groups 
of hemolytic streptococci. Journal of Experimental Medicine 57:571-95. 
132. Lancefield, R. C. 1962. Current knowledge of type-specific M antigens of group 
A streptococci. Journal of Immunology 89:307-313. 
133. Lange, R., C. Wagner, A. de Saizieu, N. Flint, J. Molnos, M. Stieger, P. 
Caspers, M. Kamber, W. Keck, and K. E. Amrein. 1999. Domain organization 
and molecular characterization of 13 two-component systems identified by 
genome sequencing of Streptococcus pneumoniae. Gene 237:223-34. 
134. Laub, M. T., E. G. Biondi, and J. M. Skerker. 2007. Phosphotransfer profiling: 
systematic mapping of two-component signal transduction pathways and 
phosphorelays. Methods in Enzymology 423:531-48. 
135. Leday, T. V., K. M. Gold, T. L. Kinkel, S. A. Roberts, J. R. Scott, and K. S. 
McIver. 2008. TrxR, a new CovR-repressed response regulator that activates the 
Mga virulence regulon in the Group A Streptococcus. Infect Immunity 76:4659-
68. 
136. Lee, V. T., J. M. Matewish, J. L. Kessler, M. Hyodo, Y. Hayakawa, and S. 
Lory. 2007. A cyclic-di-GMP receptor required for bacterial exopolysaccharide 
production. Molecular Microbiology 65:1474-84. 
137. Lei, B., F. R. DeLeo, N. P. Hoe, M. R. Graham, S. M. Mackie, R. L. Cole, M. 
Liu, H. R. Hill, D. E. Low, M. J. Federle, J. R. Scott, and J. M. Musser. 2001. 
Evasion of human innate and acquired immunity by a bacterial homolog of 
CD11b that inhibits opsonophagocytosis. Nature Medicine 7:1298-305. 
138. Lertcanawanichakul, M. 2007. Construction of plasmid vector for expression of 
bacteriocin N15-encoding gene and effect of engineered bacteria on Enterococcus 
faecalis. Current Microbiology 54:108-12. 
139. Levin, J. C., and M. R. Wessels. 1998. Identification of csrR/csrS, a genetic 
locus that regulates hyaluronic acid capsule synthesis in group A streptococcus. 
Molecular Microbiology 30:209-219. 
 153 
140. Li, Z., D. D. Sledjeski, B. Kreikemeyer, A. Podbielski, and M. D. Boyle. 1999. 
Identification of pel, a Streptococcus pyogenes locus that affects both surface and 
secreted proteins. Journal of Bacteriology 181:6019-6027. 
141. Limbago, B., V. Penumalli, B. Weinrick, and J. R. Scott. 2000. Role of 
streptolysin O in a mouse model of invasive group A streptococcal disease. 
Infection and Immunity 68:6384-90. 
142. Logsdon, L. K., A. P. Hakansson, G. Cortes, and M. R. Wessels. 2011. 
Streptolysin o inhibits clathrin-dependent internalization of group a streptococcus. 
MBio 2:00332-10. 
143. Lottenberg, R., D. Minning-Wenz, and M. D. Boyle. 1994. Capturing host 
plasmin(ogen): a common mechanism for invasive pathogens? Trends in 
Microbiology 2:20-4. 
144. Loughman, J. A., and M. Caparon. 2006. Regulation of SpeB in Streptococcus 
pyogenes by pH and NaCl: a model for in vivo gene expression. Journal of 
Bacteriology 188:399-408. 
145. Lukomski, S., N. P. Hoe, I. Abdi, J. Rurangirwa, P. Kordari, M. Liu, S. J. 
Dou, G. G. Adams, and J. M. Musser. 2000. Nonpolar inactivation of the 
hypervariable streptococcal inhibitor of complement gene (sic) in serotype M1 
Streptococcus pyogenes significantly decreases mouse mucosal colonization. 
Infection and Immunity 68:535-42. 
146. Lukomski, S., C. A. Montgomery, J. Rurangirwa, R. S. Geske, J. P. Barrish, 
G. J. Adams, and J. M. Musser. 1999. Extracellular cysteine protease produced 
by Streptococcus pyogenes participates in the pathogenesis of invasive skin 
infection and dissemination in mice. Infection and Immunity 67:1779-88. 
147. Lukomski, S., K. Nakashima, I. Abdi, V. J. Cipriano, R. M. Ireland, S. D. 
Reid, G. G. Adams, and J. M. Musser. 2000. Identification and characterization 
of the scl gene encoding a group A streptococcus extracellular protein virulence 
factor with similarity to human collagen. Infection and Immunity 68:6542-6553. 
148. Lukomski, S., S. Sreevatsan, C. Amberg, W. Reichardt, M. Woischnik, A. 
Podbielski, and J. M. Musser. 1997. Inactivation of Streptococcus pyogenes 
extracellular cysteine protease significantly decreases mouse lethality of serotype 
M3 and M49 strains. Journal of Clinical Investigations 99:2574-80. 
149. Luo, F., S. Lizano, and D. E. Bessen. 2008. Heterogeneity in the Polarity of Nra 
Regulatory Effects on Streptococcal Pilus Gene Transcription and Virulence. 
Infection and Immunity 76:2490-7. 
150. Lynskey, N. N., R. A. Lawrenson, and S. Sriskandan. 2011. New 
understandings in Streptococcus pyogenes. Current Opinion in Infectious 
Diseases 24:196-202. 
151. Lyon, W. R., C. M. Gibson, and M. G. Caparon. 1998. A role for trigger factor 
and an rgg-like regulator in the transcription, secretion and processing of the 
cysteine proteinase of Streptococcus pyogenes. EMBO Journal 17:6263-6275. 
152. MacFarlane, S. A., and M. Merrick. 1985. The nucleotide sequence of the 
nitrogen regulation gene ntrB and the glnA-ntrBC intergenic region of Klebsiella 
pneumoniae. Nucleic Acids Research 13:7591-606. 
 154 
153. Magassa, N., S. Chandrasekaran, and M. G. Caparon. 2010. Streptococcus 
pyogenes cytolysin-mediated translocation does not require pore formation by 
streptolysin O. EMBO Reports 11:400-5. 
154. Magner, L. N. 1992. A History of Medicine. New York Marcel Dekker, Inc. 
155. Malke, H., and J. J. Ferretti. 2007. CodY-affected transcriptional gene 
expression of Streptococcus pyogenes during growth in human blood. Journal of 
Medical Microbiology 56:707-14. 
156. Malke, H., K. Steiner, W. M. McShan, and J. J. Ferretti. 2006. Linking the 
nutritional status of Streptococcus pyogenes to alteration of transcriptional gene 
expression: the action of CodY and RelA. International Journal of Medical 
Microbiology 296:259-75. 
157. Mangold, M., M. Siller, B. Roppenser, B. J. Vlaminckx, T. A. Penfound, R. 
Klein, R. Novak, R. P. Novick, and E. Charpentier. 2004. Synthesis of group A 
streptococcal virulence factors is controlled by a regulatory RNA molecule. 
Molecular Microbiology 53:1515-27. 
158. Manzanera, M., S. Marques, and J. L. Ramos. 2000. Mutational analysis of the 
highly conserved C-terminal residues of the XylS protein, a member of the AraC 
family of transcriptional regulators. FEBS Letters 476:312-7. 
159. Markowitz, M., and E. L. Kaplan. 2000. Rheumatic Fever, p. 133-151. In D. L. 
Stevens and E. L. Kaplan (ed.), Streptococcal Infections: Clinical Aspects, 
Microbiology, and Molecular Pathogenesis. Oxford University Press, New York. 
160. Martin, R. G., and J. L. Rosner. 2001. The AraC transcriptional activators. 
Current Opinions in Microbiology 4:132-7. 
161. Mascher, T., J. D. Helmann, and G. Unden. 2006. Stimulus perception in 
bacterial signal-transducing histidine kinases. Microbiology and Molecular 
Biology Review 70:910-38. 
162. Mashburn-Warren, L., D. A. Morrison, and M. J. Federle. 2010. A novel 
double-tryptophan peptide pheromone controls competence in Streptococcus spp. 
via an Rgg regulator. Molecular Microbiology 78:589-606. 
163. Matsuka, Y. V., S. Pillai, S. Gubba, J. M. Musser, and S. B. Olmsted. 1999. 
Fibrinogen cleavage by the Streptococcus pyogenes extracellular cysteine 
protease and generation of antibodies that inhibit enzyme proteolytic activity. 
Infection and Immunity 67:4326-33. 
164. McArthur, J., E. Medina, A. Mueller, J. Chin, B. J. Currie, K. S. Sriprakash, 
S. R. Talay, G. S. Chhatwal, and M. J. Walker. 2004. Intranasal vaccination 
with streptococcal fibronectin binding protein Sfb1 fails to prevent growth and 
dissemination of Streptococcus pyogenes in a murine skin infection model. 
Infection and Immunity 72:7342-5. 
165. McArthur, J. D., and M. J. Walker. 2006. Domains of group A streptococcal M 
protein that confer resistance to phagocytosis, opsonization and protection: 
implications for vaccine development. Molecular Microbiology 59:1-4. 
166. McCormick, J. K., A. A. Pragman, J. C. Stolpa, D. Y. Leung, and P. M. 
Schlievert. 2001. Functional characterization of streptococcal pyrogenic exotoxin 
J, a novel superantigen. Infection and Immunity 69:1381-8. 
167. McIver, K. S., A. S. Heath, and J. R. Scott. 1995. Regulation of virulence by 
environmental signals in group A streptococci: influence of osmolarity, 
 155 
temperature, gas exchange, and iron limitation on emm transcription. Infection 
and Immunity 63:4540-4542. 
168. McIver, K. S., and R. L. Myles. 2002. Two DNA-binding domains of Mga are 
required for virulence gene activation in the group A streptococcus. Molecular 
Microbiology 43:1591-1602. 
169. McIver, K. S., and J. R. Scott. 1997. Role of mga in growth phase regulation of 
virulence genes of the group A streptococcus. Journal of Bacteriology 179:5178-
5187. 
170. Meehl, M. A., and M. G. Caparon. 2004. Specificity of streptolysin O in 
cytolysin-mediated translocation. Molecular Microbiology 52:1665-76. 
171. Metzgar, D., D. Baynes, C. J. Hansen, E. A. McDonough, D. R. Cabrera, M. 
M. Ellorin, P. J. Blair, K. L. Russell, and D. J. Faix. 2009. Inference of 
antibiotic resistance and virulence among diverse group A Streptococcus strains 
using emm sequencing and multilocus genotyping methods. PLoS One 4:e6897. 
172. Mitchell, T. J. 2003. The pathogenesis of streptococcal infections: from tooth 
decay to meningitis. Nature Reviews. Microbiology 1:219-30. 
173. Miyoshi-Akiyama, T., D. Takamatsu, M. Koyanagi, J. Zhao, K. Imanishi, 
and T. Uchiyama. 2005. Cytocidal effect of Streptococcus pyogenes on mouse 
neutrophils in vivo and the critical role of streptolysin S. Journal of Infectious 
Disease 192:107-16. 
174. Molinari, G., M. Rohde, S. R. Talay, G. S. Chhatwal, S. Beckert, and A. 
Podbielski. 2001. The role played by the group A streptococcal negative 
regulator Nra on bacterial interactions with epithelial cells. Molecular 
Microbiology 40:99-114. 
175. Mora, M., G. Bensi, S. Capo, F. Falugi, C. Zingaretti, A. G. Manetti, T. 
Maggi, A. R. Taddei, G. Grandi, and J. L. Telford. 2005. Group A 
streptococcus produce pilus-like structures containing protective antigens and 
Lancefield T antigens. Proceedings of the National Academy of Sciences of the 
United States of America 102:15641-6. 
176. Muller-Alouf, H., T. Proft, T. M. Zollner, D. Gerlach, E. Champagne, P. 
Desreumaux, C. Fitting, C. Geoffroy-Fauvet, J. E. Alouf, and J. M. 
Cavaillon. 2001. Pyrogenicity and cytokine-inducing properties of Streptococcus 
pyogenes superantigens: comparative study of streptococcal mitogenic exotoxin Z 
and pyrogenic exotoxin A. Infection and Immunity 69:4141-5. 
177. Musser, J. M., and F. R. DeLeo. 2005. Toward a genome-wide systems biology 
analysis of host-pathogen interactions in group A Streptococcus. American 
Journal of Pathology 167:1461-72. 
178. Nataro, J. P., D. Yikang, D. Yingkang, and K. Walker. 1994. AggR, a 
transcriptional activator of aggregative adherence fimbria I expression in 
enteroaggregative Escherichia coli. J Bacteriol 176:4691-9. 
179. Nelson, D., R. Schuch, P. Chahales, S. Zhu, and V. A. Fischetti. 2006. PlyC: a 
multimeric bacteriophage lysin. Proceedings of the  National Academy of 
Sciences of the United States of America 103:10765-70. 
180. Nizet, V., B. Beall, D. J. Bast, V. Datta, L. Kilburn, D. E. Low, and J. C. De 
Azavedo. 2000. Genetic locus for streptolysin S production by group A 
streptococcus. Infection & Immunity 68:4245-4254. 
 156 
181. Nobbs, A. H., R. J. Lamont, and H. F. Jenkinson. 2009. Streptococcus 
adherence and colonization. Microbiol Mol Biol Rev 73:407-50. 
182. Nordstrand, A., M. Norgren, J. J. Ferretti, and S. E. Holm. 1998. 
Streptokinase as a mediator of acute post-streptococcal glomerulonephritis in an 
experimental mouse model. Infection and Immunity 66:315-21. 
183. Novick, R. P. 2003. Autoinduction and signal transduction in the regulation of 
staphylococcal virulence. Molecular Microbiology 48:1429-49. 
184. O'Hara, B. P., R. A. Norman, P. T. Wan, S. M. Roe, T. E. Barrett, R. E. 
Drew, and L. H. Pearl. 1999. Crystal structure and induction mechanism of 
AmiC-AmiR: a ligand-regulated transcription antitermination complex. EMBO 
Journal 18:5175-86. 
185. Oehmcke, S., A. Podbielski, and B. Kreikemeyer. 2004. Function of the 
fibronectin-binding serum opacity factor of Streptococcus pyogenes in adherence 
to epithelial cells. Infection and Immunity 72:4302-8. 
186. Ohlsen, K. L., J. K. Grimsley, and J. A. Hoch. 1994. Deactivation of the 
sporulation transcription factor Spo0A by the Spo0E protein phosphatase. 
Proceedings of the  National Academy of Sciences of the United States of 
America 91:1756-60. 
187. Olsen, R. J., I. Sitkiewicz, A. A. Ayeras, V. E. Gonulal, C. Cantu, S. B. Beres, 
N. M. Green, B. Lei, T. Humbird, J. Greaver, E. Chang, W. P. Ragasa, C. A. 
Montgomery, J. Cartwright, Jr., A. McGeer, D. E. Low, A. R. Whitney, P. T. 
Cagle, T. L. Blasdel, F. R. DeLeo, and J. M. Musser. 2010. Decreased 
necrotizing fasciitis capacity caused by a single nucleotide mutation that alters a 
multiple gene virulence axis. Proceedings of the  National Academy of Sciences 
of the United States of America 107:888-93. 
188. Opdyke, J. A., J. R. Scott, and C. P. Moran. 2001. A secondary RNA 
polymerase sigma factor from Streptococcus pyogenes. Molecular Microbiology 
42:495-502. 
189. Pahlman, L. I., P. F. Marx, M. Morgelin, S. Lukomski, J. C. Meijers, and H. 
Herwald. 2007. Thrombin-activatable fibrinolysis inhibitor binds to 
Streptococcus pyogenes by interacting with collagen-like proteins A and B. 
Journal of Biological Chemistry 282:24873-81. 
190. Pahlman, L. I., A. I. Olin, J. Darenberg, M. Morgelin, M. Kotb, H. Herwald, 
and A. Norrby-Teglund. 2008. Soluble M1 protein of Streptococcus pyogenes 
triggers potent T cell activation. Cellular Microbiology 10:404-14. 
191. Park, H., and M. Inouye. 1997. Mutational analysis of the linker region of EnvZ, 
an osmosensor in Escherichia coli. Journal of Bacteriology 179:4382-90. 
192. Perego, M., C. Hanstein, K. M. Welsh, T. Djavakhishvili, P. Glaser, and J. A. 
Hoch. 1994. Multiple protein-aspartate phosphatases provide a mechanism for the 
integration of diverse signals in the control of development in B. subtilis. Cell 
79:1047-55. 
193. Perez, N., J. Trevino, Z. Liu, S. C. Ho, P. Babitzke, and P. Sumby. 2009. A 
genome-wide analysis of small regulatory RNAs in the human pathogen group A 
Streptococcus. PLoS One 4:e7668. 
194. Perez-Casal, J., M. G. Caparon, and J. R. Scott. 1991. Mry, a trans-acting 
positive regulator of the M protein gene of Streptococcus pyogenes with similarity 
 157 
to the receptor proteins of two-component regulatory systems. Journal of 
Bacteriology 173:2617-2624. 
195. Perez-Casal, J., J. A. Price, E. Maguin, and J. R. Scott. 1993. An M protein 
with a single C repeat prevents phagocytosis of Streptococcus pyogenes: use of a 
temperature-sensitive shuttle vector to deliver homologous sequences to the 
chromosome of S. pyogenes. Molecular Microbiology 8:809-819. 
196. Phillips, G. N., Jr., P. F. Flicker, C. Cohen, B. N. Manjula, and V. A. 
Fischetti. 1981. Streptococcal M protein: alpha-helical coiled-coil structure and 
arrangement on the cell surface. Proceedings of the National Academy of 
Sciences of the United States of America 78:4689-93. 
197. Podbielski, A., M. Woischnik, B. A. Leonard, and K. H. Schmidt. 1999. 
Characterization of nra, a global negative regulator gene in group A streptococci. 
Molecular Microbiology 31:1051-64. 
198. Rakonjac, J. V., J. C. Robbins, and V. A. Fischetti. 1995. DNA sequence of the 
serum opacity factor of group A streptococci: identification of a fibronectin-
binding repeat domain. Infection and Immunity 63:622-31. 
199. Rasmussen, M., and L. Bjorck. 2002. Proteolysis and its regulation at the 
surface of Streptococcus pyogenes. Molecular Microbiology 43:537-544. 
200. Rasmussen, M., and L. Bjorck. 2001. Unique regulation of SclB - a novel 
collagen-like surface protein of Streptococcus pyogenes. Molecular Microbiology 
40:1427-38. 
201. Rasmussen, M., H. P. Muller, and L. Bjorck. 1999. Protein GRAB of 
Streptococcus pyogenes regulates proteolysis at the bacterial surface by binding 
a2-macroglobulin. Journal of Biological Chemistry 274:15336-44. 
202. Rasmussen, R., A. Eden, and L. Bjorck. 2000. SclA, a novel collagen-like 
surface protein of Streptococcus pyogenes. Infection and Immunity 68:6370-
6377. 
203. Reid, S. D., M. S. Chaussee, C. D. Doern, M. A. Chaussee, A. G. 
Montgomery, D. E. Sturdevant, and J. M. Musser. 2006. Inactivation of the 
group A Streptococcus regulator srv results in chromosome wide reduction of 
transcript levels, and changes in extracellular levels of Sic and SpeB. FEMS 
Immunology and Medical Microbiology 48:283-92. 
204. Reid, S. D., A. G. Montgomery, and J. M. Musser. 2004. Identification of srv, a 
PrfA-like regulator of group A streptococcus that influences virulence. Infection 
and Immunity 72:1799-803. 
205. Rhee, S., R. G. Martin, J. L. Rosner, and D. R. Davies. 1998. A novel DNA-
binding motif in MarA: the first structure for an AraC family transcriptional 
activator. Proceedings of the National Academy of Sciences of the United States 
of America 95:10413-8. 
206. Ribardo, D. A., T. J. Lambert, and K. S. McIver. 2004. Role of Streptococcus 
pyogenes two-component response regulators in the temporal control of Mga and 
the Mga-regulated virulence gene emm. Infection and Immunity 72:3668-73. 
207. Ribardo, D. A., and K. S. McIver. 2006. Defining the Mga regulon: comparative 
transcriptome analysis reveals both direct and indirect regulation by Mga in the 
group A streptococcus. Molecular Microbiology 62:491-508. 
 158 
208. Roberts, A. L., K. L. Connolly, C. D. Doern, R. C. Holder, and S. D. Reid. 
2010. Loss of the group A Streptococcus regulator Srv decreases biofilm 
formation in vivo in an otitis media model of infection. Infection and Immunity 
78:4800-8. 
209. Roberts, S. A., G. G. Churchward, and J. R. Scott. 2007. Unraveling the 
regulatory network in Streptococcus pyogenes: the global response regulator 
CovR represses rivR directly. Journal of Bacteriology 189:1459-63. 
210. Roberts, S. A., and J. R. Scott. 2007. RivR and the small RNA RivX: the 
missing links between the CovR regulatory cascade and the Mga regulon. 
Molecular Microbiology 66:1506-22. 
211. Robinson, V., D. Buckler, and A. Stock. 2000. A Tale of Two Components: A 
Novel Kinase and Regulatory Switch. Nature Structural Biology 7:626-633. 
212. Rocha, C. L., and V. A. Fischetti. 1999. Identification and characterization of a 
novel fibronectin-binding protein on the surface of group A streptococci. 
Infection and Immunity 67:2720-8. 
213. Rodgers, M. E., and R. Schleif. 2009. Solution structure of the DNA binding 
domain of AraC protein. Proteins 77:202-8. 
214. Sabharwal, H., F. Michon, D. Nelson, W. Dong, K. Fuchs, R. C. Manjarrez, 
A. Sarkar, C. Uitz, A. Viteri-Jackson, R. S. Suarez, M. Blake, and J. B. 
Zabriskie. 2006. Group A streptococcus (GAS) carbohydrate as an immunogen 
for protection against GAS infection. Journal of Infectious Diseases 193:129-35. 
215. Sanders, D. A., B. L. Gillece-Castro, A. M. Stock, A. L. Burlingame, and D. 
E. Koshland, Jr. 1989. Identification of the site of phosphorylation of the 
chemotaxis response regulator protein, CheY. Journal of Biological Chemistry 
264:21770-8. 
216. Schrager, H. M., S. Alberti, C. Cywes, G. J. Dougherty, and M. R. Wessels. 
1998. Hyaluronic acid capsule modulates M protein-mediated adherence and acts 
as a ligand for attachment of group A streptococcus to CD44 on human 
keratinocytes. Journal of Clinical Investigation 101:1708-16. 
217. Schrager, H. M., J. G. Rheinwald, and M. R. Wessels. 1996. Hyaluronic acid 
capsule and the role of streptococcal entry into keratinocytes in invasive skin 
infection. Journal of Clinical Investigation 98:1954-1958. 
218. Scott, J. R., P. Cleary, M. G. Caparon, M. Kehoe, L. Heden, J. M. Musser, S. 
Hollingshead, and A. Podbielski. 1995. New name for the positive regulator of 
the M protein of group A streptococcus. Molecular Microbiology 17:799. 
219. Shatursky, O., A. P. Heuck, L. A. Shepard, J. Rossjohn, M. W. Parker, A. E. 
Johnson, and R. K. Tweten. 1999. The mechanism of membrane insertion for a 
cholesterol-dependent cytolysin: a novel paradigm for pore-forming toxins. Cell 
99:293-9. 
220. Shelburne, S. A., 3rd, D. Keith, N. Horstmann, P. Sumby, M. T. Davenport, 
E. A. Graviss, R. G. Brennan, and J. M. Musser. 2008. A direct link between 
carbohydrate utilization and virulence in the major human pathogen group A 
Streptococcus. Proceedings of the National Academy of Sciences of the United 
States of America 105:1698-703. 
221. Shelburne, S. A., 3rd, D. B. Keith, M. T. Davenport, N. Horstmann, R. G. 
Brennan, and J. M. Musser. 2008. Molecular characterization of group A 
 159 
Streptococcus maltodextrin catabolism and its role in pharyngitis. Molecular 
Microbiology 69:436-52. 
222. Shelburne, S. A., 3rd, P. Sumby, I. Sitkiewicz, C. Granville, F. R. DeLeo, and 
J. M. Musser. 2005. Central role of a bacterial two-component gene regulatory 
system of previously unknown function in pathogen persistence in human saliva. 
Proceedings of the National Academy of Sciences of the United States of America 
102:16037-42. 
223. Shelburne, S. A., M. T. Davenport, D. B. Keith, and J. M. Musser. 2008. The 
role of complex carbohydrate catabolism in the pathogenesis of invasive 
streptococci. Trends in Microbiology 16:318-25. 
224. Shu, C. J., and I. B. Zhulin. 2002. ANTAR: an RNA-binding domain in 
transcription antitermination regulatory proteins. Trends in Biochemical Sciences 
27:3-5. 
225. Shulman, S. T., R. R. Tanz, and M. A. Gerber. 2000. Streptococcal 
Pharyngitis, p. 76-101. In D. L. Stevens and E. L. Kaplan (ed.), Streptococcal 
Infections: Clinical Aspects, Microbiology, and Molecular Pathogenesis. Oxford 
University Press, New York. 
226. Sidote, D. J., C. M. Barbieri, T. Wu, and A. M. Stock. 2008. Structure of the 
Staphylococcus aureus AgrA LytTR domain bound to DNA reveals a beta fold 
with an unusual mode of binding. Structure 16:727-35. 
227. Simpson, W. A., and E. H. Beachey. 1983. Adherence of group A streptococci 
to fibronectin on oral epithelial cells. Infection and Immunity 39:275-9. 
228. Singh, M., B. Berger, P. S. Kim, J. M. Berger, and A. G. Cochran. 1998. 
Computational learning reveals coiled coil-like motifs in histidine kinase linker 
domains. Proceedings of the National Academy of Sciences of the United States 
of America 95:2738-43. 
229. Sitkiewicz, I., and J. M. Musser. 2006. Expression microarray and mouse 
virulence analysis of four conserved two-component gene regulatory systems in 
group a streptococcus. Infection and Immunity 74:1339-51. 
230. Smoot, L. M., J. K. McCormick, J. C. Smoot, N. P. Hoe, I. Strickland, R. L. 
Cole, K. D. Barbian, C. A. Earhart, D. H. Ohlendorf, L. G. Veasy, H. R. Hill, 
D. Y. Leung, P. M. Schlievert, and J. M. Musser. 2002. Characterization of two 
novel pyrogenic toxin superantigens made by an acute rheumatic fever clone of 
Streptococcus pyogenes associated with multiple disease outbreaks. Infection and 
Immunity 70:7095-104. 
231. Soncini, F. C., E. G. Vescovi, and E. A. Groisman. 1995. Transcriptional 
autoregulation of the Salmonella typhimurium phoPQ operon. Journal of 
Bacteriology 177:4364-71. 
232. Steer, A. C., M. R. Batzloff, K. Mulholland, and J. R. Carapetis. 2009. Group 
A streptococcal vaccines: facts versus fantasy. Curr Opin Infect Dis 22:544-52. 
233. Stevens, D. L. 2000. Group A beta-hemolytic streptococci: virulence factors, 
pathogenesis, and spectrum of clinical infections, p. 37-56. In D. L. Stevens and 
E. L. Kaplan (ed.), Streptococcal Infections: Clinical Aspects, Microbiology, and 
Molecular Pathogenesis. Oxford University Press, New York. 
234. Stevens, D. L. 1992. Invasive group A streptococcus infections. Clinical 
Infectious Diseases 14:2-11. 
 160 
235. Stevens, D. L. 2000. Life-threatening streptococcal infections: scarlet fever, 
necrotizing fasciitis, myositis, bacteremia, and streptococcal toxic shock 
syndrome, p. 163-79. In D. L. Stevens and E. L. Kaplan (ed.), Streptococcal 
Infections: Clinical Aspects, Microbiology, and Molecular Pathogenesis. Oxford 
University Press, New York. 
236. Stock, A., T. Chen, D. Welsh, and J. Stock. 1988. CheA protein, a central 
regulator of bacterial chemotaxis, belongs to a family of proteins that control gene 
expression in response to changing environmental conditions. Proceedings of the 
National Academy of Sciences of the United States of America 85:1403-7. 
237. Stock, A., V. Robinson, and G. P. 2000. Two-Component Signal Transduction. 
Annual Review of Biochemistry 69:183-215. 
238. Stock, A. M., J. M. Mottonen, J. B. Stock, and C. E. Schutt. 1989. Three-
dimensional structure of CheY, the response regulator of bacterial chemotaxis. 
Nature 337:745-9. 
239. Stock, J. B., A. M. Stock, and J. M. Mottonen. 1990. Signal transduction in 
bacteria. Nature 344:395-400. 
240. Studier, F. W. 2005. Protein production by auto-induction in high density 
shaking cultures. Protein Expression and Purification 41:207-34. 
241. Sumby, P., K. D. Barbian, D. J. Gardner, A. R. Whitney, D. M. Welty, R. D. 
Long, J. R. Bailey, M. J. Parnell, N. P. Hoe, G. G. Adams, F. R. Deleo, and J. 
M. Musser. 2005. Extracellular deoxyribonuclease made by group A 
streptococcus assists pathogenesis by enhancing evasion of the innate immune 
response. Proceedings of the National Academy of Sciences of the United States 
of America 102:1679-84. 
242. Sumby, P., S. F. Porcella, A. G. Madrigal, K. D. Barbian, K. Virtaneva, S. M. 
Ricklefs, D. E. Sturdevant, M. R. Graham, J. Vuopio-Varkila, N. P. Hoe, and 
J. M. Musser. 2005. Evolutionary origin and emergence of a highly successful 
clone of serotype M1 group A streptococcus involved multiple horizontal gene 
transfer events. Journal of Infectious Diseases 192:771-82. 
243. Sumby, P., A. R. Whitney, E. A. Graviss, F. R. DeLeo, and J. M. Musser. 
2006. Genome-wide analysis of group a streptococci reveals a mutation that 
modulates global phenotype and disease specificity. PLoS Pathogens 2:e5. 
244. Sun, H., U. Ringdahl, J. W. Homeister, W. P. Fay, N. C. Engleberg, A. Y. 
Yang, L. S. Rozek, X. Wang, U. Sjobring, and D. Ginsburg. 2004. 
Plasminogen is a critical host pathogenicity factor for group A streptococcal 
infection. Science 305:1283-6. 
245. Sung, K., S. A. Khan, M. S. Nawaz, and A. A. Khan. 2003. A simple and 
efficient Triton X-100 boiling and chloroform extraction method of RNA 
isolation from Gram-positive and Gram-negative bacteria. FEMS Microbiology 
Letters 229:97-101. 
246. Surette, M. G., M. Levit, Y. Liu, G. Lukat, E. G. Ninfa, A. Ninfa, and J. B. 
Stock. 1996. Dimerization is required for the activity of the protein histidine 
kinase CheA that mediates signal transduction in bacterial chemotaxis. Journal of 
Biological Chemistry 271:939-45. 
 161 
247. Swift, H. F., A. T. Wilson, and R. C. Lancefield. 1943. Typing group A 
hemolytic streptococci by M precipitin reactions in capillary pipettes. Journal of 
Experimental Medicine 78:127-33. 
248. Tanford, C. 1984. Twenty questions concerning the reaction cycle of the 
sarcoplasmic reticulum calcium pump. CRC Critical Reviews in Biochemistry 
17:123-51. 
249. Tao, L., S. K. Hollingshead, A. N. Suvorov, J. J. Ferretti, and W. M. McShan. 
1995. Construction of a Streptococcus pyogenes recA mutant via insertional 
inactivation, and cloning and sequencing of the complete recA gene. Gene 
162:59-62. 
250. Terao, Y., S. Kawabata, E. Kunitomo, J. Murakami, I. Nakagawa, and S. 
Hamada. 2001. Fba, a novel fibronectin-binding protein from Streptococcus 
pyogenes, promotes bacterial entry into epithelial cells, and the fba gene is 
positively transcribed under the Mga regulator. Molecular Microbiology 42:75-
86. 
251. Terao, Y., S. Kawabata, M. Nakata, I. Nakagawa, and S. Hamada. 2002. 
Molecular characterization of a novel fibronectin-binding protein of 
Streptococcus pyogenes strains isolated from toxic shock-like syndrome patients. 
Journal of Biological Chemistry 277:47428-35. 
252. Throup, J. P., K. K. Koretke, A. P. Bryant, K. A. Ingraham, A. F. Chalker, 
Y. Ge, A. Marra, N. G. Wallis, J. R. Brown, D. J. Holmes, M. Rosenberg, and 
M. K. Burnham. 2000. A genomic analysis of two-component signal 
transduction in Streptococcus pneumoniae. Molecular Microbiology 35:566-76. 
253. Tillett, W. S., and R. L. Garner. 1933. The fibrinolytic activity of hemolytic 
streptococci. Journal of Experimental Medicine 58:485-502. 
254. Todd, E. W., and L. F. Hewitt. 1932. A new culture medium for the production 
of antigenic streptococcal haemolysin. Journal of Pathology and Bacteriology 
35:973. 
255. Toppel, A. W., M. Rasmussen, M. Rohde, E. Medina, and G. S. Chhatwal. 
2003. Contribution of protein G-related a2-macroglobulin-binding protein to 
bacterial virulence in a mouse skin model of group A streptococcal infection. 
Journal of Infectious Diseases 187:1694-703. 
256. Toukoki, C., K. M. Gold, K. S. McIver, and Z. Eichenbaum. 2010. MtsR is a 
dual regulator that controls virulence genes and metabolic functions in addition to 
metal homeostasis in the group A streptococcus. Molecular Microbiology 76:971-
89. 
257. Turner, C. E., P. Kurupati, M. D. Jones, R. J. Edwards, and S. Sriskandan. 
2009. Emerging role of the interleukin-8 cleaving enzyme SpyCEP in clinical 
Streptococcus pyogenes infection. Journal of Infectious Diseases 200:555-63. 
258. Ulrich, L. E., E. V. Koonin, and I. B. Zhulin. 2005. One-component systems 
dominate signal transduction in prokaryotes. Trends in Microbiology 13:52-6. 
259. Ulrich, R. G. 2008. Vaccine based on a ubiquitous cysteinyl protease and 
streptococcal pyrogenic exotoxin A protects against Streptococcus pyogenes 
sepsis and toxic shock. Journal of Immune Based Therapies and Vaccines 6:8. 
 162 
260. Unnikrishnan, M., J. Cohen, and S. Sriskandan. 1999. Growth-phase-
dependent expression of virulence factors in an M1T1 clinical isolate of 
Streptococcus pyogenes. Infection and Immunity 67:5495-9. 
261. Vahling, C. M., and K. S. McIver. 2005. Identification of residues responsible 
for the defective virulence gene regulator Mga produced by a natural mutant of 
Streptococcus pyogenes. Journal of Bacteriology 187. 
262. Vincent, W. F., and K. J. Lisiewski. 1969. Improved growth medium for group 
A streptococci. Applied Microbiology 18:954-5. 
263. Virtaneva, K., S. F. Porcella, M. R. Graham, R. M. Ireland, C. A. Johnson, S. 
M. Ricklefs, I. Babar, L. D. Parkins, R. A. Romero, G. J. Corn, D. J. 
Gardner, J. R. Bailey, M. J. Parnell, and J. M. Musser. 2005. Longitudinal 
analysis of the group A streptococcus transcriptome in experimental pharyngitis 
in cynomolgus macaques. Proceedings of the National Academy of Sciences of 
the United States of America 102:9014-9. 
264. Visai, L., S. Bozzini, G. Raucci, A. Toniolo, and P. Speziale. 1995. Isolation 
and characterization of a novel collagen-binding protein from Streptococcus 
pyogenes strain 6414. Journal of Biological Chemistry 270:347-53. 
265. von Pawel-Rammingen, U., B. P. Johansson, and L. Bjorck. 2002. IdeS, a 
novel streptococcal cysteine proteinase with unique specificity for 
immunoglobulin G. The EMBO Journal 21:1607-15. 
266. Voyich, J. M., K. R. Braughton, D. E. Sturdevant, C. Vuong, S. D. 
Kobayashi, S. F. Porcella, M. Otto, J. M. Musser, and F. R. DeLeo. 2004. 
Engagement of the pathogen survival response used by group A streptococcus to 
avert destruction by innate host defense. Journal of Immunology 173:1194-201. 
267. Voyich, J. M., D. E. Sturdevant, K. R. Braughton, S. D. Kobayashi, B. Lei, K. 
Virtaneva, D. W. Dorward, J. M. Musser, and F. R. DeLeo. 2003. Genome-
wide protective response used by group A streptococcus to evade destruction by 
human polymorphonuclear leukocytes. Proceedings of the National Academy of 
Sciences of the United States of America 100:1996-2001. 
268. Walker, M. J., A. Hollands, M. L. Sanderson-Smith, J. N. Cole, J. K. Kirk, A. 
Henningham, J. D. McArthur, K. Dinkla, R. K. Aziz, R. G. Kansal, A. J. 
Simpson, J. T. Buchanan, G. S. Chhatwal, M. Kotb, and V. Nizet. 2007. 
DNase Sda1 provides selection pressure for a switch to invasive group A 
streptococcal infection. Nature Medicine 13:981-5. 
269. Wei, L., V. Pandiripally, E. Gregory, M. Clymer, and D. Cue. 2005. Impact of 
the SpeB protease on binding of the complement regulatory proteins factor H and 
factor H-like protein 1 by Streptococcus pyogenes. Infection and Immunity 
73:2040-50. 
270. Wessels, M. R., and M. S. Bronze. 1994. Critical role of the group A 
streptococcal capsule in pharyngeal colonization and infection in mice. 
Proceedings of the National Academy of Sciences of the United States of America 
91:12238-42. 
271. West, A., and A. Stock. 2001. Histidine Kinases and Response Regulator 
Proteins in Two-Component Signaling Systems. Trends in Biochemical Sciences 
26:369-376. 
 163 
272. Widdowson, J. P., W. R. Maxted, and D. L. Grant. 1970. The production of 
opacity in serum by group A streptococci and its relationship with the presence of 
M antigen. The Journal of General Microbiology 61:343-53. 
273. Zhang, S., A. Reeves, R. L. Woodbury, and W. G. Haldenwang. 2005. 
Coexpression patterns of sigma(B) regulators in Bacillus subtilis affect sigma(B) 
inducibility. J Bacteriol 187:8520-5. 
274. Zhu, X., J. Rebello, P. Matsumura, and K. Volz. 1997. Crystal structures of 
CheY mutants Y106W and T87I/Y106W. CheY activation correlates with 
movement of residue 106. J Biol Chem 272:5000-6. 
275. Zinkernagel, A. S., A. M. Timmer, M. A. Pence, J. B. Locke, J. T. Buchanan, 
C. E. Turner, I. Mishalian, S. Sriskandan, E. Hanski, and V. Nizet. 2008. The 
IL-8 protease SpyCEP/ScpC of group A Streptococcus promotes resistance to 
neutrophil killing. Cell Host Microbe 4:170-8. 
 
 
